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SUMMARY
Parenteral Nutrition (PN) provides nutrition to patients through the intravenous 
route, and is comprised of carbohydrates, fats, proteins, vitamins, trace 
elements, electrolytes and fluids. The vitamins are a major limiting factor in the 
shelf life determination of a PN formulation and are generally added just before 
administration. This thesis reports on some stability studies of a multivitamin 
infusion for the possible development of a minibag which may be stored before 
administration to PN patients.
The physicochemical stability of the water-soluble vitamins contained in 
Solivito® N Adult Injection (Fresenius Kabi), the fat-soluble vitamins 
contained in Vitlipid® N Adult Injection (Fresenius Kabi) and the combined 
admixture of the water-soluble and fat-soluble vitamins, prepared in 100 ml 
0.9% sodium chloride in Freeflex® (Fresenius Kabi) minibags was 
investigated. Physical tests include nephelometry, pH, dissolved oxygen, 
microscopy and particle size determination by laser diffraction, while the 
chemical tests used validated stability indicating reversed phase HPLC 
methods. The vitamins investigated were pyridoxine, nicotinamide, thiamine, 
folic acid, riboflavin sodium phosphate, Vitamin A and Vitamin E.
The water-soluble vitamins and the fat-soluble vitamins were found to be 
stable, with more than 90% remaining, at 4°C for 168 hours. For samples 
stored at 25°C, they remained stable for 168 hours only if light-protected. 
During simulated clinical conditions, the water-soluble and fat-soluble 
vitamins, and the combined vitamin admixture were found to be stable for up 
to 30 days storage at 4°C, and remained stable for a further 24 hours at 25°C if 
light protected. The light protective effects of different coloured plastic covers 
to be used during delivery of the vitamin minibags were also investigated.
The stability data showed promising results with the vitamins in the minibag 
remaining stable when assessed under simulated clinical conditions and these 
longer shelf-life vitamin minibags would benefit PN patients in the hospital 
and home settings.
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CHAPTER ONE
INTRODUCTION
1.1. Parenteral Nutrition
Parenteral Nutrition (PN) is an alternative method of providing nutritional 
support for patients via the intravenous route, the other methods being by the 
oral or enteral route. This intravenous route of administering artificial nutrition 
was pioneered by Dudrick et al (1968), who demonstrated for the first time, the 
success of administering concentrated glucose, amino acids and other essential 
nutrients towards growth development in both animals and man. 
Comprehensive history and development of PN have been described by many 
researchers (Driscoll 2003; Hardy and Sizer 2004; Vinnars and Wilmore 2003; 
Wretlind 1981).
Patients selected for PN are malnourished patients or patients who have the 
potential to become malnourished. In hospital settings, malnutrition remains an 
under-recognised problem. The prevalence of malnutrition of hospital patients 
on admission was demonstrated to be up to 40% with even more becoming 
malnourished during their hospital stay (Campbell et al. 2002; McWhirter and 
Pennington 1994). Awareness of malnutrition in hospital patients is now 
increasing and recently, the National Institute for Health and Clinical 
Excellence (NICE) has issued a guideline that all hospital patients should be 
screened to identify those who are malnourished or at risk of malnutrition, and 
that nutrition support should be considered in these patients (NICE 2006a).
Therefore, evaluation of nutritional status helps to determine patients who are at 
risk of developing nutrition related complications. Nutritional assessment 
includes body mass index, clinical history, dietary and biochemical 
measurements. Many screening tools evaluating nutritional status have been
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developed to detect malnutrition, an example is the ‘malnutrition universal 
screening tool’ (‘MUST’) (Malnutrition Advisory Group 2003), developed by 
the British Association for Parenteral and Enteral Nutrition (BAPEN).
1.2. Indications for PN
PN is indicated for patients who are unable to tolerate enteral feedings, such as 
in patients with ileus or bowel obstruction, patients with non-functioning 
gastrointestinal tract, for example after massive small bowel resection, or when 
the risk of enteral nutrition related complications such as aspiration is 
unacceptably high (A.S.P.E.N. Board of Directors 1986; Hall 1983; Payne- 
Jamesetal. 1989).
Provision of PN is a component of a specialised service provided to ward 
inpatient areas. With the setting up of nutrition support teams in the hospitals 
where patient care is provided by a multidisciplinary team, the PN service has 
also expanded to outpatient settings at home, also known as home parenteral 
nutrition (HPN) (NICE 2006b).
HPN is indicated for patients with irreversible intestinal failure and those 
awaiting surgery to restore gut functionality, of which Crohn’s disease is the 
most common (Jones 2003; Mughal and Irving 1986). Long-term HPN has 
markedly improved the quality of life and the survival of these patients with 
severe intestinal obstruction or malabsorption, such as short bowel syndrome 
(Gottrand et al. 2005; Messing 1995).
1.3. Routes of Administration of PN
PN can be administered either via central or the peripheral routes (Palmer and 
MacFie 2001).
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1.3.1. Central Route
The central venous route is indicated for patients who require long-term PN, 
patients who have poor peripheral venous access or those who require high 
calories with fluid restrictions. This route is also appropriate for patients who 
already have an indwelling central venous catheter (CVC), such as patients in 
intensive care units (Palmer and MacFie 2001).
1.3.2. Peripheral Route
The peripheral route is suitable in patients who require PN for up to two weeks 
and do not require high caloric requirements (Michel et al. 1981). The use of 
peripheral PN is said to be increasing with new research developments 
favouring this route, such as the availability of iso-osmolar lipid emulsions, 
and the development of PN admixtures containing lipids. The increased use of 
the peripheral route is also due to the fact that patients actually require much 
lower energy requirements than formerly considered necessary (Palmer and 
MacFie 2001; Payne-James and Khawaja 1993).
1.3.3. Peripherally Inserted Central Catheter
Typically, a CVC is inserted into the superior vena cava via the subclavian or 
internal jugular vein. Another type of CVC which is gaining interest is the 
peripherally inserted central catheter (PICC). PICC lines are inserted via 
peripheral access into the basilic or cephalic vein in the cubital fossa, with the 
tip running up into the larger veins into the superior vena cava. PICC lines 
have the advantage of avoiding direct puncture of the central veins (Palmer and 
MacFie 2001).
1.4. Complications of Administration
Complications of administration via the central route are CVC-related, and 
include problems such as catheter insertion, catheter occlusion, inadvertent
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catheter removal, venous thrombosis and catheter-related sepsis. These 
complications could be minimised by enhancing professional skills in CVC 
placements and development of care guidelines (Grant 2002; Wolfe et al. 
1986). The main limitation with peripheral PN is the incidence of 
thrombophlebitis (Everitt and McMahon 1994).
Besides catheter-related complications, another complication of PN is 
metabolic complications, such as plasma electrolyte abnormalities, fluid 
overload and those related to glucose metabolism, which are hypoglycaemia or 
hyperglycaemia (Maroulis and Kalfarentzos 2000).
1.5. Components of PN Admixtures
The composition of a PN formulation consists of three macronutrients: 
carbohydrates in the form of glucose, proteins as amino acid solutions, and fats 
in the form of lipid emulsions. Carbohydrates and fats provide the patients 
energy requirements. Also included are the major electrolytes such as sodium, 
potassium, calcium, magnesium, chloride and phosphate. The addition of 
micronutrients, consisting of the vitamins and trace elements, make a PN 
complete. PN regimens may be compounded as either ‘two-in-one’ admixtures, 
which do not contain lipid emulsion, or ‘all-in-one’ admixtures, in which the 
lipid emulsion is included (Allwood 2001). PN administration has developed 
from separate infusions of the macronutrients in bottles to administration of an 
all-in-one bag.
1.5.1. Proteins
The amino acids provide a source of amino acids which are utilised by the 
body as proteins. Traditionally, they are classified into essential and non- 
essential amino acids. Essential amino acids in adults are leucine, isoleucine, 
lysine, methionine, phenylalanine, threonine, tryptophan and valine, whilst
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some of the non-essential amino acids are alanine, arginine, glutamate, 
glutamine, glycine, serine and taurine (Cuthbertson and Rennie 2001).
The new approach recognises the fact that the non-essential amino acids may 
become ‘indispensable’ or ‘conditionally indispensable’ based on dietary needs 
and dependent on clinical conditions. For example, in infants, histidine, 
cysteine and tyrosine are also required. Arginine may be of significance in the 
critically ill where it is thought to enhance immunity in patients suffering from 
injury, trauma or sepsis. Another example is glutamine, the most abundant 
amino acid in the body which serves as nitrogen transporter between tissues, 
and provides metabolic fuel for the cells of the gastrointestinal tract. It has 
found usefulness after major surgery, bums and infections. Until recently, 
pharmaceutical problems with glutamine were its solubility and instability to 
heat, therefore the synthetic dipeptides were developed for parenteral solutions 
(Furst et al. 2001).
1.5.2. Carbohydrates
Carbohydrates are supplied in the form of glucose solutions, the specific 
glucose solutions used depending on the patient’s fluid limitation. Adult 
glucose requirement is about 145-160 g per day (Furst et al. 2001) and should 
not exceed 7 g/kg/day (A.S.P.E.N. Board of Directors 2002a). To prevent 
metabolic complications, the optimal amount can be set at 4-5 g/kg/day 
(Sauerwein and Romijn 2001). Management of glucose abnormalities in PN 
patients have been described (Knapke et al. 1989), the two common 
abnormalities being hyperglycaemia and hypoglycaemia .
1.5.3. Lipids
Lipids serve to provide caloric requirements and have the advantage of 
providing more calories at a lower osmolarity than glucose. They also serve as 
a source of essential fatty acids, such as linoleic acid and linolenic acid, which
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are necessary for the functioning of all tissues. In addition, lipids have 
numerous roles in physiologic functions and immune status (Dupont and 
Carpentier 1999). Lipid requirement is about 1-1.5 g/kg/day (Sauerwein and 
Romijn 2001).
Conventional lipid emulsions are typically made from soybean or safflower oil. 
These are long-chain triglycerides (LCT), rich in omega-6  polyunsaturated 
fatty acids (PUFA). The excessive intake of PUFA was later associated with 
interference of immune function. New lipid emulsions from medium-chain 
triglycerides (MCT) derived from palm oil or coconut oil, and LCT 
combination mixture (MCT/LCT) were then developed to decrease the PUFA 
content. More recently, lipid emulsion development has also included olive oil, 
rich in monounsaturated fatty acids (MUFA) and fish oil, rich in omega-3 fatty 
acids, and these have been shown to have anti-inflammatory and 
immunomodulatory effects (Adolph 2001; Furst et al. 2001). Mixed lipid 
emulsions made of soybean, MCT, olive oil and fish oil have been designed to 
reduce the amount of omega-6  fatty acids and to increase the amount of 
omega-3 fatty acids (Waitzberg 2005).
1.5.4. Micronutrients
The term ‘micronutrients’ includes two main classes of nutrient substances that 
are essentially required in the diet in very small amounts. These are the 
vitamins or the essential organic micronutrients, and trace elements or the 
essential inorganic micronutrients. The essential trace elements include zinc, 
iron, copper, chromium, selenium, manganese, molybdenum, fluoride and 
iodide. There are other dietary micronutrients, such as co-enzyme Q10, lipoic 
acid and carnitine but these can be synthesised in the body, and are therefore 
not recognised as being essential (Shenkin 2001).
Generally, there are two main functions of micronutrients. They either act as 
cofactors which activate enzyme activity, or as coenzymes as part of the
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enzyme catalysed reactions. Another role they perform is to act as free-radical 
scavengers, protecting tissues from oxidative damage due to the generation of 
reactive oxygen species such as the superoxide free radicals (Shenkin 2003; 
Shenkin 2006). The micronutrients will be discussed in detail under Vitamins 
(see 1.6 ) and Trace elements (see 1.7).
1.5.5. Fluids and Electrolytes
Electrolytes are important for the body’s physiologic functions. Sodium, 
potassium, calcium, magnesium and phosphorus are some of the major 
electrolytes required. Electrolyte abnormalities are associated with many 
disease states (Driscoll 1989; Solomon and Kirby 1990), therefore routine 
monitoring is essential to prevent any biochemical abnormalities.
The standard adult and paediatric electrolytes doses are as tabulated in Table 
1. 1.
Table 1.1: Daily parenteral electrolyte requirements for adults and paediatrics
Electrolyte Units Adult (A.S.P.E.N. Board 
o f Directors 2002a)
Paediatric (A.S.P.E.N. 
Board o f Directors 
2002b)
Sodium
Potassium
Chloride
Calcium
Magnesium
Phosphorus
mmol/kg
mmol/kg
mmol/kg
mmol
mmol
mmol
1-2
1-2
as needed to maintain 
acid-base balance with 
acetate 
5-7.5
4-10
20-40
3
2
5
depends on age
Fluid requirements are individualised, for adults they are generally met with 
volumes of 30 to 40 ml/kg/day (A.S.P.E.N. Board of Directors 2002a).
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1.6. Vitamins
Vitamins differ from the other nutrients in that they do not build body tissues 
but are components of certain enzymes and hormone systems, which are 
essential for the normal life processes. Vitamins are required for growth, 
maintenance, reproduction and lactation.
Vitamins originally come from the term ‘vitamine’, coined by the Polish 
biochemist named Casimir Funk. Funk isolated the antiberi-beri factor in rice 
husks, and, having evidenced it was an amine, chose the term ‘vitamine’, from 
the words vital and amine, because it was vital to life. Four different vitamins 
were proposed by Funk in his ‘vitamine theory’, the other three vitamins were 
anti-rickets vitamine, anti-scurvy vitamine, and anti-pellagra vitamine. Since 
not all the factors later proved to be amines, the term ‘vitamine’ was changed 
to ‘vitamin’ to avoid chemical confusion (Combs Jr. 1998).
The vitamins are organic, low molecular weight substances. They are classified 
broadly according to their physical properties. Vitamins are classified into two 
groups by their solubility. The water-soluble vitamins consist of members of 
the vitamin B group and ascorbic acid or vitamin C. They generally function to 
assist the activity of important enzymes such as those involved in the 
production of energy from carbohydrates and fats, thus are often referred to as 
coenzymes. They are not stored to a great extent in the body and are excreted 
in the urine when present in excess of the body’s needs; therefore they are 
considered relatively non-toxic. The water-soluble vitamins are appreciably 
soluble in polar solvents.
The fat-soluble vitamins include vitamins A, D, E, and K, these are appreciably 
soluble in non-polar solvents. They have the potential for storage in the body, 
and therefore for toxicity.
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1.6.1. Water-soluble Vitamins
1.6.1.1. B-vitamins
The B-vitamins were grouped together in a single class, although they differ in 
chemical structure and metabolic function, because they were originally 
isolated from the same sources, liver and yeast.
The B-vitamins include thiamine (Vitamin Bi), riboflavin (Vitamin B2), niacin 
(Vitamin B3), pyridoxine (Vitamin Be), folic acid, Vitamin B12 (cobalamins), 
pantothenic acid and biotin, which will be discussed.
1.6.1.1.1. Thiamine (Vitamin Bi)
CH;
C1-, HC1OH
CH- NH
Figure 1.1: Chemical structure of thiamine hydrochloride
Thiamine, or Vitamin Bi, was the first member of the vitamin B-group to be 
identified and was originally named as aneurine, the antineuritic vitamin, 
because of its function in curing polyneuritis in deficient pigeon. Thiamine, 
which in Greek means a vitamin containing sulphur (Carpenter 2003), contains 
a pyrimidine and a thiazole nucleus linked by a methylene bridge. The free 
thiamine base is unstable and two derivatives are commonly used in food and 
pharmaceutical preparations, which are thiamine mononitrate and thiamine 
hydrochloride (Figure 1.1).
The thiamine molecule is not biologically active (Basu and Dickerson 1996), 
however thiamine functions in the body in the form of the active coenzyme 
thiamine diphosphate, also known as thiamine pyrophosphate (TPP). TPP is the 
coenzyme for the decarboxylases, the group of enzymes that remove carboxyl 
groups. One function of TPP is in the oxidative decarboxylation of pyruvate
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dehydrogenase. This is the key enzyme required for the conversion of 
pyruvate, the product of carbohydrate metabolism, to acetyl coenzyme A. 
Impaired entry of pyruvate into the citric acid cycle can lead to high 
concentrations of lactate and pyruvate, and to lactic acidosis.
Thiamine deficiency can result in chronic peripheral neuritis called beri-beri, 
characterised by anorexia, cardiac enlargement and neurologic involvement, 
which can be associated with heart failure and oedema. Deficiency also can 
result in Wemicke-Korsakoff syndrome, a condition affecting the central rather 
than the peripheral nervous system (Combs Jr. 1998; Indraccolo et al. 2005). 
Cases of lactic acidosis have been reported in patients given PN therapy, which 
were traced to thiamine deficiency (Madl et al. 1993; MMWR 1997; Nakasaki 
et al. 1997).
Thiamine is degraded by heat and by ultraviolet irradiation (Basu and 
Dickerson 1996). It is incompatible when mixed with reducing agents such as 
sulphites, in particular by sodium metabisulphite, used as an antioxidant in 
some amino acids infusions, where the thiamine molecule is cleaved into 
pyrimidine and thiazole moieties (Allwood and Kearney 1998). The 
degradation pathway is shown in Figure 1.2.
Cl'
N H ,
-OH
Thiamine Hydrochloride
SOT
H 4
'S 0 3‘H+
HC1
4-am ino-2-m ethylpyram idine-5-m ethylsulphonic acid 4-m ethyl-5-(2-hydroxyethyl) thiazole 
Figure 1.2: Thiamine degradation pathway (Allwood and Kearney 1998)
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1.6.1.1.2. Riboflavin
CHjOH
HO-
HO-
HO-
NH
Figure 1.3: Chemical structure of riboflavin
Riboflavin, or Vitamin B2, consists of an isoalloxazine derivative with a sugar 
alcohol ribityl side chain (Figure 1.3). Riboflavin is converted to two main 
coenzymes, flavin mononucleotide (FMN) or riboflavin-5-phosphate and 
flavin-adenine dinucleotide (FAD). FMN and FAD function as coenzymes for 
enzymes called flavoproteins or flavoenzymes, these are oxidases that function 
aerobically, and dehydrogenases that function anaerobically. The flavin 
coenzymes act as electron carriers in a wide variety of oxidation-reduction 
reactions, including the mitochondrial electron transport chain (Hardman et al. 
1996), thus supporting energy production by aiding in the metabolism of fats, 
carbohydrates and proteins. Flavoproteins are also essential for the conversion 
of pyridoxine and folate to their respective coenzyme forms. Riboflavin is also 
required for red blood cell formation and respiration, antibody production, and 
for regulating human growth and reproduction (Basu and Dickerson 1996).
The clinical signs of riboflavin deficiency occur mostly in the mucocutaneous 
surfaces of the mouth. These include angular stomatitis (cracks at the corners 
of the mouth), cheilosis (inflammation of the lips), glossitis (inflammation of 
the tongue), magenta tongue and corneal vascularisation. Riboflavin deficiency 
often coexists with nicotinic acid deficiency and can be complicated by 
pyridoxine deficiency (Basu and Dickerson 1996).
Riboflavin is heat stable, stable in acids but not in alkaline solutions, and 
unstable to UV light with irreversible decomposition (Basu and Dickerson
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1996). Photolysis of riboflavin leads to the formation of lumiflavin (in alkaline 
solution) and lumichrome (in acidic or neutral solution) which has a greenish- 
yellow fluorescence. It is noted that exposure of milk in clear glass to sunlight 
or fluorescent light (with a peak wavelength of 400-500 nm) can result in the 
loss of significant amounts of riboflavin as a result of photolysis. The resultant 
lumiflavin and lumichrome catalyse the oxidation of vitamin C, so that even 
relatively brief exposure to light, causing little loss of riboflavin, can lead to a 
considerable loss of vitamin C. Lumiflavin and lumichrome also catalyse 
oxidation of lipids to lipid peroxides (Bender 1992).
1.6.1.1.3. Niacin
The term niacin (Vitamin B3) is the generic descriptor for nicotinic acid and 
nicotinamide (Figure 1.4) (Bender 1992). Nicotinamide is the active form 
which functions in the body as either nicotinamide adenine dinucleotide (NAD) 
or nicotinamide adenine dinucleotide phosphate (NADP). NAD and NADP 
serve as coenzymes for a wide variety of reactions in the metabolism of 
carbohydrates, fatty acids and amino acids in which there is a transfer of 
hydrogen ion (Basu and Dickerson 1996).
CONH2
Figure 1.4: Chemical structure of nicotinamide
Niacin can be obtained from the diet or synthesised from the amino acid 
tryptophan. The equivalence of dietary tryptophan and preformed niacin is 
relatively low, the generally accepted ratio being 60 mg tryptophan as 
equivalent to 1 mg of preformed niacin (Bender 1992). Although niacin is 
synthesised in the body, it is categorised as a vitamin because its precursor, 
tryptophan, is an essential amino acid, and thus the synthesis of niacin is 
dependent upon diets. The conversion of tryptophan to niacin is dependent on 
pyridoxine supplies.
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Deficiency of niacin leads to the clinical condition known as pellagra which 
involves changes in the skin (dermatitis), gastrointestinal tract (diarrhoea) and 
nervous system (dementia).
Both nicotinic acid and nicotinamide are very stable in dry form but in 
solution, nicotinamide is hydrolysed to nicotinic acid by acids and bases 
(Combs Jr. 1998).
1.6.1.1.4. Pyridoxine
OH
CH2OH
Figure 1.5: Chemical structure of pyridoxine hydrochloride
Pyridoxine (Vitamin B6) is used as a name to cover the ‘Vitamin B6 group’ or
3-hydroxy-2-methyl-pyridine derivatives (Figure 1.5). These are pyridoxine 
(new terminology pyridoxol, the alcohol), its aldehyde (pyridoxal), and its 
amine (pyridoxamine). All three forms (or vitamers) are interchangeable and 
are therefore comparably active. Plant tissues contain Vitamin B6 mostly as 
pyridoxine while animal tissues contain mostly pyridoxal and pyridoxamine. 
Pyridoxine hydrochloride is the commonly available synthetic form (Basu and 
Dickerson 1996).
The vitamers are converted in the liver mainly to pyridoxal phosphate and to 
some extent to pyridoxamine phosphate. Pyridoxal phosphate acts as a 
coenzyme, and is involved in many reactions of amino acid metabolism and 
synthesis, in glycogen phosphorylase for the utilisation of glycogen in muscle, 
and in steroid hormone action (Bender 1992). An example of amino acid 
reaction utilising pyridoxal phosphate is biosynthesis of the neurotransmitters 
(Table 1. 2), derived from decarboxylation of amino acids.
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Table 1.2: Some amines derived from amino acids under the action of vitamin 66- 
dependent decarboxylases in the body (adapted from Basu 1996)
Amino acid/derivative Amine
Histidine Histamine
5-Hydroxytryptophan 5-Hydroxytryptomine (serotonin)
Aspartic acid p  - Alanine
Glutamic acid y -  Aminobutyric acid (GABA)
Tyrosine Noradrenaline / adrenaline 
Tyramine / dopamine
Cysteic Taurine
Deficiency of Vitamin 1*6 is rare in man due to its substantial stores in the body 
and wide distribution in foods. Symptoms of Vitamin B6 deficiency include 
seborrhoea-like skin lesions about the eyes, nose and mouth accompanied by 
glossitis and stomatitis; convulsive seizures and peripheral neuritis; and rarely 
anaemia (Hardman et al. 1996).
Vitamin B6 is stable under acidic conditions but rapidly destroyed by light 
(Basu and Dickerson 1996).
I.6.I.I.5. Folic Acid
COOH
COOH
m
Pteridine
GlutamateP-aminobenzoate
Folic acid
Figure 1.6: Chemical structure of folic acid
Folic acid, also known as pteroylglutamic acid (PteGlu), consists of a pteridine 
nucleus coupled to para-aminobenzoic acid (PABA), to become pteroic acid 
molecule, and conjugated with one to seven molecules of L-glutamic acid 
(Figure 1.6). The pteridine nucleus is composed of two rings, pyrimidine and
14
pyrizine. Different substituent groups can be attached to the pyrizine ring, 
resulting in over 150 different forms existing in nature. All biologically active 
forms of folic acid are known as folacins or folates. Folates are stored in tissues 
primarily as the polyglutamates (Basu and Dickerson 1996).
Following absorption, folic acid is rapidly reduced to the active coenzyme, 
tetrahydrofolic acid (FH4). Tetrahydrofolate plays a vital role in metabolic 
reactions, both in catabolism and biosynthetic reactions such as in DNA 
synthesis and amino acid synthesis (Bender 1992).
Deficiency of folic acid affects DNA replication, notably in cells with the most 
rapid rates of multiplication. These include the gastrointestinal tract, liver and 
the bone marrow. Signs and symptoms of deficiency related to gastrointestinal 
tract include soreness of tongue, cheilosis, loss of appetite, abdominal pain and 
diarrhoea. Folate deficiency leads to macrocytic or megaloblastic anemia, with 
signs such as tiredness, breathlessness, pallor of the skin and mucous 
membranes, and systolic murmurs (Basu and Dickerson 1996; Mason 1999).
Folic acid is light sensitive, following ultraviolet (UV) exposure, folic acid is 
degraded to photoproducts, para-aminobenzoyl-L-glutamic acid and 6 - 
formylpterin (FPT). FPT is degraded further to pterin-6 -carboxylic acid upon 
continued irradiation (Off et al. 2005). The rate of degradation varies with pH, 
with a decrease in the degradation rate from acid to alkaline medium, and 
optimum stability at pH 6-7 (Akhtar et al. 1999).
Crystalline folic acid is moderately stable to heat, with significant degradation 
occurring at 200°C leading to an amorphous product. Thermal decomposition 
shows firstly, the loss of glutamic acid moiety from the folic acid structure, 
then the degradation of pterin and PABA, leaving a black carbon residue (Vora 
et al. 2 0 0 2 ).
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1.6.1.1.6. Vitamin Bn
Vitamin Bn is different from other vitamins in that it contains cobalt, which is 
a mineral. Vitamin Bn consists of a family of compounds called cobalamins 
amongst which one of the major forms is cyanocobalamin (with a cyanide 
group; Figure 1.7).
CN
Co
o=p.
HO
Figure 1.7: Chemical structure of cyanocobalamin
In the body, Vitamin Bn is mostly stored in the liver and has a half-life of 
about 400 days, and has a considerable enterohepatic circulation.
There are three vitamin B 12-dependent enzymes in the tissues, these are 
methionine synthetase, methylmalonyl-CoA mutase and leucine mutase (Basu 
and Dickerson 1996). One of the enzymes, methionine synthetase, is used to 
generate methionine from homocysteine, a reaction dependent on Vitamin B12.
CH, -  FHt + Homocysteine > FHt + Methionine
In the above reaction, both Vitamin B12 and folic acid are required for the 
conversion of homocysteine into methionine.
When the above reaction is blocked due to deficiency of Vitamin B12, the FH4 
needed for other folate requiring reactions is not formed, causing functional
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folate deficiency, thereby releasing immature red blood cells into the 
circulation resulting in pernicious anaemia. Signs and symptoms of Vitamin 
B12 deficiency are similar to folate deficiency. In addition, Vitamin B12 
deficiency may cause neurological disorders, characterised by peripheral 
neuropathy. However, Vitamin B12 deficiency is less common than folate 
deficiency because it is more stable, the body store is less easily depleted and 
excretion is reduced by enterohepatic circulation.
Vitamin B12 is stable to heat at 100°C in aqueous solutions at pH 4-7. However, 
it is very sensitive to light and alkaline, and in the presence of reducing agents 
(Basu and Dickerson 1996).
1.6.1.1.7. Pantothenic Acid
Figure 1.8: Chemical structure of pantothenic acid
Pantothenic acid is a component of a much larger coenzyme, coenzyme A 
(CoA) which is required for many acyl group transfer reaction pathways. It is 
also part of acyl carrier protein which is involved in fatty acid synthesis. Thus 
it is involved in lipid metabolism and the synthesis of cholesterols and steroids. 
As a component of acetyl CoA, it is involved in many acetylations, such as the 
conversion of choline to acetylcholine.
Pantothenic acid is widely distributed in the body. Free pantothenic acid is 
available as hygroscopic oil and is chemically unstable. It is hydrolysed in acid 
and alkaline media to pentoic acid and alanine. It is used mainly in the form of 
calcium and sodium salts which are readily soluble in water (Basu and 
Dickerson 1996).
COOH
1.6.1.1.8. Biotin
HN
H
Figure 1.9: Chemical structure of biotin
Biotin (Figure 1.9) is present in almost all foods, the best sources are from 
organ meats, egg yolks and yeast. Raw egg whites contain the glycoprotein 
avidin which can bind to biotin forming a complex that cannot be absorbed by 
the body. The complex is broken down by heat or irradiation.
Biotin-dependent enzymes are involved in gluconeogenesis, biosynthesis of 
fatty acids, propionate metabolism and catabolism of leucine. Biotin is 
sensitive to heat, especially when conditions support lipid peroxidation (Basu 
and Dickerson 1996).
I.6.I.2. Ascorbic Acid (Vitamin C)
OH
HO
OH OH
Figure 1.10: Chemical structure of ascorbic acid
Vitamin C is the generic descriptor for all compounds that exhibit the 
biological activity of ascorbic acid (Combs Jr. 1998). The chemical structure of 
ascorbic acid is shown in Figure 1.10.
Ascorbic acid or Vitamin C is isolated mostly from sources different from the 
vitamins B-complex, mainly from citrus fruits. The functions of ascorbic acid 
include synthesis of collagen, synthesis of carnitine which is required for 
transporting fatty acids into mitochondria for oxidation to provide energy for
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the cell, and metabolism of neurotransmitters such as tyrosine and the 
conversion of dopamine to noradrenaline. It is a strong reducing agent, and 
hence plays an important role as an antioxidant and free radical scavenger. It is 
also involved in the utilisation of other nutrients, such as iron, and for the 
function of the immune system (Combs Jr. 1998).
Deficiency of Vitamin C leads to a condition called scurvy, due to inhibition of 
collagen synthesis. Some of the clinical signs include swollen, bleeding and 
sensitive gums, hardening and roughness around hair follicles, and delayed 
wound healing.
The human body cannot synthesise ascorbic acid, therefore the body depends 
on dietary intake to maintain its vital biological functions. In vivo, ascorbic 
acid is metabolised by reversible oxidation to dehydroascorbic acid, which 
subsequently undergoes hydrolysis to 2,3-diketo gulonic acid. 2,3-diketo 
gulonic acid then undergoes either decarboxylation to carbon dioxide and 5-C 
fragments (xylose, xylonic acid, lyxonic acid), or oxidation to oxalic acid and
4-C fragments (e.g. threonic acid) (Combs Jr. 1992).
In PN mixtures, ascorbic acid is the least stable of all the vitamins (Allwood 
and Kearney 1998). It is degraded in the presence of oxygen, where it is 
oxidised reversibly to dehydroascorbic acid, and further degraded irreversibly 
to gulonic acid, threonic acid and oxalic acid (Figure 1.11).
THREONIC ACID + OXALIC ACID
Figure 1.11: Degradation pathway of ascorbic acid (Allwood and Kearney 1998)
ASCORBIC ACID
DEHYDRO-ASCORBIC ACID
2,3 - DIKETO - GULONIC ACID
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Degradation of ascorbic acid is enhanced by heat and catalysed by trace metals 
such as copper ions (Allwood 1982b). Degradation is also enhanced by neutral 
to alkaline pH conditions. Ascorbic acid complexes with disulfides such as 
cystine (Allwood 1984b; Allwood and Kearney 1998; Combs Jr. 1998).
1.6.2. Fat-soluble Vitamins
I.6.2.I. Vitamin A
Vitamin A refers to compounds with similar structures possessing similar 
biological activity of retinol. 0.3 micrograms all-trans-retinol is equivalent to 1 
international unit (IU) Vitamin A activity (Combs Jr. 1998).
Figure 1.12 shows the chemical structures of the vitamin A group, or the 
retinoids, which consist of three essential features. These are: (i) a beta-ionone 
ring, or the hydrophobic head; (ii) a side chain composed of two isoprenoid 
units joined together. These conjugated polyenes absorb light and are subject to 
isomerisation in the presence of light; (iii) a polar group R which determines 
the chemical reactivity. It can either be an ester as in retinol palmitate, an 
aldehyde as in retinal, or be oxidised to retinoic acid.
Substance R Molecular
formula
M
All-(£)-retinol R = H C 2 6 H 3 0 O 286.5
All-(£)-retinol acetate CO-CH3 C 2 2 H 3 2 O 2 328.5
All-(£)-retinol propionate CO-C2H5 C23H34O2 342.5
All-(£)-retinol palmitate c o - c 15h 31 C 3 6 H 6 6 O 2 524.9
Figure 1.12: Chemical structures of vitamin A groups (BP 2005)
Vitamin A is usually used in the form of esters such as the acetate, propionate 
and palmitate. In the British Pharmacopoeia (BP), the term ‘retinol’ is used for
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preparations containing synthetic esters and ‘vitamin A’ is used for 
preparations containing naturally occurring compounds. In this thesis, the 
Vitamin A ester being studied is retinol palmitate.
Vitamin A is necessary for vision, for normal differentiation of epithelial cells, 
and for reproduction. Retinol and retinal are active in maintaining normal 
vision and reproduction as well as normal growth and development, while the 
retinoic acid is active in epithelial cell differentiation for normal growth and 
development (Basu and Dickerson 1996).
Deficiency of Vitamin A can lead to night blindness and a condition called 
xerophthalmia, or dryness of the eye. Deficiency also leads to keratinisation of 
the epithelial cells, thus promoting colonisation by bacteria and infection.
Vitamin A is generally stable to heat, acid and alkali. Vitamin A is very 
sensitive to oxygen in air, especially in the presence of light and heat, although 
the retinoid esters are relatively stable. Exclusion of air can be obtained by 
sparging with an inert gas and addition of a protective antioxidant e.g. a- 
tocopherol (Combs Jr. 1998).
1.6.2.2. Vitamin D
Vitamin D refers to the group of steroids that exhibit the biological activity of 
cholecalciferol (Combs Jr. 1998). Ergocalciferol or Vitamin D2 is mainly 
present in plants and fungi while cholecalciferol or Vitamin D3 is mainly 
present in animals. Besides food sources, vitamin D is also synthesised by the 
action of sunlight on the skin. Ultraviolet B penetrates the skin and photolyses 
7-dehydrocholesterol, a provitamin D3, to form cholecalciferol or vitamin D3.
The BP specifies that if calciferol or Vitamin D is prescribed, then 
ergocalciferol (Figure 1.13) or cholecalciferol (Figure 1.14) should be 
dispensed (British Pharmacopoeia Commission 2005).
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Figure 1.13: Chemical structure of Figure 1.14: Chemical structure of
ergocalciferol cholecalciferol
Vitamin D functions mainly as a steroid hormone. To be biologically active, 
vitamin D is hydroxylated, first in the liver to form 25-hydroxy-vitamin D3, 
and then in the kidney to form the hormone, 1, 25-dihydroxyvitamin D3. 1,25- 
dihydroxyvitamin D3 regulates serum calcium and phosphorus by stimulating 
intestinal absorption and mobilising calcium stores from bone, and mobilising 
calcium reabsorption in the kidneys. The hormone is regulated by parathyroid 
hormone through a feedback mechanism.
I.6.2.3. Vitamin E
Vitamin E refers to two classes of compounds, tocopherols and tocotrienols, 
which exhibit the biological activity of a-tocopherol. There are eight possible 
stereoisomers for tocopherols. Synthetic preparations of vitamin E presently 
available are mixtures of all eight stereoisomers, which are designated with the 
prefix all-racemic-. All-racemic-alpha-tocopherol was formerly called dl-alpha- 
tocopherol and has equivalent biopotency of 1.1 IU/mg (Combs Jr. 1998).
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ch3 ch3 ch3
Figure 1.15: Chemical structure of all-racemic-alpha-tocopherol
Vitamin E is a good quencher of free radicals, thus it serves as an antioxidant. 
Vitamin E exerts its antioxidant function through its oxidation to a- 
tocopherolquinone (Basu and Dickerson 1996). Its major function is protection 
of PUFA of cell membrane phospholipids from oxidation by free radicals to 
hydroperoxides. Because of its antioxidative properties, Vitamin E is believed 
to prevent diseases that are associated with oxidative stress such as 
cardiovascular disease, cancer and neurologic disorders (Bartels et al. 2004; 
Brigelius-Flohe et al. 2002). Selenium complements Vitamin E to scavenge 
and reduce free radicals generated from PUFA.
Vitamin E is destroyed under oxidising conditions such as exposure to air and 
light, accelerated by heat and the presence of copper (Basu and Dickerson
1996).
1.6.2.4. Vitamin K
Vitamin K consists of a group of fat-soluble vitamins containing 2-methyl-1,4- 
naphthaquinone derivatives. They are phylloquinone, the naturally occurring 
vitamin synthesised from plants and designated as vitamin Ki; the 
menaquinones, which are synthesised by bacteria and designated as K2; the 
synthetic menadione or vitamin K3, and menadiol or vitamin K4 (Combs Jr.
1998). The chemical structure of phytomenadione is shown in Figure 1.16.
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Figure 1.16. Chemical structure of phytomenadione
Vitamin K plays an important role in blood coagulation. In newborn infants, 
there is a deficiency of Vitamin K and therefore it is given to the baby 
immediately after birth to prevent hemorrhagic disease of the newborn. There 
have been controversies on the use of vitamin K in newborn in that it was 
associated with incidence of leukaemia, however this risk was found to be 
unproven (American Academy of Pediatrics Vitamin K Ad Hoc Task Force 
1993).
1.7. Trace Elements
The benefits of adding trace elements to PN solutions are now widely 
recognised. They are essential for rehabilitation and maintenance of good 
nutritional status of patients (AMA Department of Foods and Nutrition 1979a). 
Trace elements either function as co-factors, activating the enzyme activity, or 
they form an essential component of the enzymes (Shenkin 2001). Many act as 
antioxidants, by protecting the tissues from oxygen free radicals (Leung 1998). 
The inorganic micronutrients considered essential include zinc, copper, 
selenium, manganese, chromium, molybdenum, iron, and iodine (Hardy and 
Reilly 1999) and will be discussed. Other trace elements considered probably 
essential are fluorine, boron, cobalt and vanadium.
Trace element contaminants such as aluminium have been detected in PN 
solutions, the potential sources of contamination coming from packaging 
materials, manufacturing methods, and raw materials for production of the 
component solutions (Borg et al. 1994; Pluhator-Murton et al. 1999).
CH;
CH.
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1.7.1. Zinc
There are over 300 zinc-containing enzymes. Zinc (Zn) is essential for the 
activity of many enzymes, such as those involved in protein synthesis, in 
protein and carbohydrate metabolism, and DNA synthesis and gene 
transcription (Scheplyagina 2005; Shenkin 2006).
Zn deficiency results in many abnormalities such as skin lesions, impaired 
immunity, and impaired wound healing. In PN therapy, acute Zn deficiency 
occurs because of increased demand for Zn as a result of increasing anabolism 
or protein synthesis (Shenkin 2006; Takagi et al. 1986).
Historically, Zn has been found as a contaminant in amino acid solutions and 
other intravenous solutions, due to Zn leaching out of the rubber stoppers used 
in glass bottles (Van Caillie et al. 1978).
Parenteral Zn for PN supplementation is available as zinc sulphate, zinc 
chloride or zinc gluconate (Hardy and Reilly 1999).
1.7.2. Copper
Copper (Cu) is a component of many enzymes, mainly oxidative enzymes, 
hydroxylases and superoxide dismutases. It is a cofactor for ceruloplasmin, 
which oxidises ferrous ion to ferric ion, therefore maintaining iron utilisation as 
well as production of haemoglobin and red blood cells. Cu deficiency therefore 
is manifested by anaemia, leucopenia and neutropenia (Hardy and Reilly 1999) 
and has been reported in patients on prolonged PN (Tokuda et al. 1986).
Parenteral Cu is available as copper sulphate, copper chloride and copper 
gluconate (Hardy and Reilly 1999).
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1.7.3. Selenium
Selenium (Se) plays a structural role as a constituent of selenoproteins, and 
enzymic role as part of many key antioxidant enzymes such as in glutathione 
peroxidase, as selenocysteine. Selenocysteine breaks down hydrogen peroxide, 
the end-product of superoxide dismutase reaction, into hydrogen and water. 
The role of Se parallels that of vitamin E, with each supporting their respective 
antioxidant functions where Se is hydrophilic while vitamin E is lipophilic. 
Known roles of selenoproteins are tabulated in Appendix 1. (Hardy and Hardy 
2003; Leung 1998; Rayman 2000).
Parenteral Se for PN supplementation is available as selenomethionine, 
selenious acid and sodium selenite (Hardy and Reilly 1999).
1.7.4. Manganese
Manganese (Mn) is involved in numerous organ functions such as for normal 
immune function, energy production and defence against free radicals. Mn is a 
co-factor in enzymatic systems such as Mn-superoxide dismutase and plays a 
role in antioxidant protection, and in pyruvate carboxylase which has a role in 
energy metabolism (Aschner and Aschner 2005).
Mn can be found as a contaminant in PN solutions. There have been reports of 
Mn toxicity where excess intake can lead to deposition of Mn in the brain 
resulting in Mn-induced neurotoxicity. Hypermanganesia can result from a 
high amount of infused Mn, causing persistent inflammation and PN-related 
cholestasis. Excess intake has also been associated with cholestatic disease and 
nervous system disorders (Aschner and Aschner 2005; Fell et al. 1996; 
Reimund et al. 2000).
For PN supplementation, Mn is available as manganese sulphate, manganese 
chloride or manganese gluconate (Hardy and Reilly 1999).
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1.7.5. Chromium
Chromium (Cr) has a major role in the maintenance of normal glucose 
metabolism, where it is a component of glucose tolerance factor, required in 
improving insulin action (Leung 1995). Cr deficiency in PN patients is rare 
because of its presence as a contaminant in amino acid solutions (Leung et al.
1995). Serum Cr has been found to be high in children on PN even though 
intake followed the recommended guideline (Moukarzel et al. 1992). However 
Cr deficiency has been reported in a patient on long-term home PN, with signs 
of increased serum glucose concentration with glycosuria (Tsuda et al. 1998).
Parenteral Cr is available in the form of chromic chloride (Hardy and Reilly 
1999).
1.7.6. Molybdenum
Molybdenum (Mo) is involved in oxidation/reduction reactions, such as in
xanthine oxidase, for metabolism of purines, and sulphite oxidase for oxidation
of sulphites formed from methionine and cysteine metabolism. Parenteral Mo 
is available as ammonium molybdate tetrahydrate (Hardy and Reilly 1999).
1.7.7. Iron
Iron (Fe) is essential for haemoglobin formation and for oxidative processes. 
The main function is to transport oxygen within the blood and muscle. In the 
body, Fe is stored in two principal forms, ferritin and haemosiderin. In aqueous
^  I
form, iron exists in two oxidation states, the ferrous form Fe , and the ferric
o  I
form Fe . This property enables Fe to act as a catalyst in redox reactions by 
accepting or donating electrons (Parfitt 1999; Yip and Dallman 1996).
Fe deficiency develops quite slowly in patients with normal Fe turnover as the 
body stores of Fe can suffice for up to one year, therefore Fe supplementation 
is not necessary during short-term PN (Leung 1995). However, patients on
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long-term PN have been shown to have Fe deficiency anaemia due to chronic 
blood loss (Khaodhiar et al. 2002).
The compatibility of Fe with PN solutions has not been established. Small 
amounts of Fe of 10 to 15 mg dose could be compatible with amino acid- 
glucose PN solutions but incompatible with All-in-One admixture, causing 
cracking and creaming of the lipid component (Khaodhiar et al. 2002).
Parenteral Fe for PN supplementation is available as ferric chloride. Other 
sources of Fe include ferrous citrate or ferrous gluconate solutions (Hardy and 
Reilly 1999).
1.7.8. Iodine
Iodine is an essential component of the thyroid hormones, thyroxine and
triiodotyronine. Iodine deficiency disorders include goitre, cretinism, impaired
mental function, increased incidence of stillbirths, and perinatal and infant 
mortality (Parfitt 1999).
Parenteral iodine can be administered as either the sodium or potassium iodide, 
which also can be found in trace element preparations (Hardy and Reilly 1999).
1.8. Micronutrient Requirements
1.8.1. Vitamin Requirements
Micronutrient requirements as recommended by the American Medical 
Association (AMA) Nutrition Advisory Group (AMA Department of Foods 
and Nutrition 1979b) are generally used at present.
Vitamin requirements are increased in patients receiving PN therapy. The daily 
parenteral vitamin requirements recommended by A.S.P.E.N are listed in Table 
1.3. Parenteral vitamin requirements differ from enteral nutrition requirements,
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where enteral nutrition requirements are designed for healthy individuals to 
prevent deficiencies and to minimise the risk from nutrition-related chronic 
disease, but dosing guidelines for parenteral vitamins on the other hand are 
approximates to the needs of patients with increased requirements in acute and 
chronic disease.
Table 1.3: Daily parenteral vitamin requirements in adults and infants (ASPEN 
2002a, ASPEN 2002b)
Vitamins Adult (A.S.P.E.N. Board 
o f Directors 2002a)
Infants (A.S.P.E.N. Board of 
Directors 2002b)
Thiamine 3 mg 1.2 mg
Riboflavin 3.6 mg 1.4 mg
Niacin 16 mg 17 mg
Folic acid 400 pg 140 pg
Pantothenic acid 5 mg 5 mg
Vitamin B6 1.7 mg 1 mg
Vitamin Bi2 1 Fg
Biotin 60 pg 20 pg
Ascorbic acid 90 mg 80 mg
Vitamin A 1000 pg 700 pg (retinol equivalent)
Vitamin D 10 pg
Vitamin E 15 mg 7 mg
Vitamin K 120 pg 200 pg
Carnitine - 2-10 mg/kg
Commercial vitamins for PN are commonly available as multivitamin 
formulations such as Solivito® N (Fresenius Kabi), Cemevit® (Baxter), 
Vitlipid® N Adult (Fresenius Kabi) and Vitlipid® N Infant (Fresenius Kabi) 
injections (Table 1.4). Commercial products for the US market have been 
summarised by Kelly (2002). Individual vitamin injections are also available 
especially of the water-soluble formulations like the B vitamins, folic acid and 
ascorbic acid where additional requirements may be required.
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Table 1.4: Vitamin content in parenteral multivitamin preparations (BNF Joint 
Formulary Committee 2006)
Vitamin Units Solivito N Cemevit Vitlipid N  
Adult
Vitlipid N  
Infant
Ascorbic acid mg 100 125 - -
Thiamine mg 2.5 3.51 - -
Riboflavin mg 3.6 4.14 - -
Pyridoxine mg 4 5.5 - -
Nicotinamide mg 40 46 - -
Vitamin Bi2 Pg 5 6 - -
Pantothenic acid mg 15 17.25 - -
Biotin Fg 60 69 - -
Folic acid Pg 400 414 - -
Vitamin A IU - 3500 3300 2300
Ergocalciferol IU - 220 200 400
a-Tocopherol mg - 11.2 10 7
Vitamin K Pg - - 150 2 0 0
1.8.2. Trace Element Requirements
The first guideline for the requirement of trace elements in PN which was 
introduced by the AMA Nutrition Advisory Group was concerned with four 
trace elements i.e. zinc, copper, chromium and manganese, where the 
committee recommended that the trace elements be made in single-entity IV 
solutions (AMA Department of Foods and Nutrition 1979a). However, 
multiple trace elements are now available in a formulation such as Additrace® 
(Fresenius Kabi) and Decan® (Baxter) for adults, and Peditrace® (Fresenius 
Kabi) for paediatrics.
1.9. Problems Associated with Micronutrients Provision
The provision of micronutrients to PN patients is complicated by many factors. 
Firstly, the majority of PN patients are supplemented with their micronutrients 
orally, which may explain why serious micronutrient deficiencies are 
uncommon. However, the proportion that is absorbed orally depends on the 
remaining absorptive capacity of the gastrointestinal tract. When given 
intravenously, the potential for micronutrients toxicity is greater as this route
30
bypasses the safe method of controlling absorption by the gastrointestinal tract. 
Therefore care has to be taken in situations where the excretory mechanism is 
not effective, such as fat-soluble vitamins, or where the therapeutic and toxicity 
margin is narrow, such as selenium (Shenkin 1986).
Secondly, a deficiency of micronutrient is difficult to determine by serum or 
laboratory values since these do not reflect tissue concentrations and body 
stores. Only extreme deficiencies that lead to clinical symptoms are recognised 
(Forbes and Forbes 1997; Gallitelli 1995; Shenkin 1997). Having said this, 
there are many studies that have been performed to determine the prevalence 
and deficiencies of micronutrients in patients, such as vitamins A, D, E and K 
deficiencies (Clark et al. 1993; DeVito et al. 1986; Jamieson et al. 1999; Pettei 
et al. 1993; Shenkin et al. 1987; Steephen et al. 1991; Vandewoude et al. 
1986), and thiamine, riboflavin and pyridoxine deficiencies (Jamieson et al.
1999).
Another problem with the provision is with respect to compatibility and 
stability in PN formulations. A formulation is regarded as unstable when the 
component drug contains less than 90% of its stated content. These physical 
chemical stability problems concerning the provision of micronutrients in PN 
formulations, with particular emphasis on the vitamins shall be discussed in 
this thesis. This thesis will not address the microbiological and sterility issues 
which are also determinants of a parenteral product’s shelf life.
1.10. Stability Issues Concerning Micronutrients in PN
Many issues concerning the stability of PN towards improving its safety and 
efficacy, and its practical considerations have been addressed (Allwood 1984a, 
1999; Allwood 2000b, 2002; Allwood and Kearney 1998; Barnett et al. 1990; 
DeRitter 1982; Manning and Washington 1992; Niemiec Jr. and Vanderveen 
1984; Rey et al. 2005). DeRitter (1982) outlined the stability characteristics of 
most vitamins, as listed in Appendix 2, and classified the labile vitamins which
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can cause problems of instability in pharmaceutical dosage forms as vitamin A, 
vitamin K, ascorbic acid, cyanocobalamin, folic acid, pantothenic acid, 
panthenol, and thiamine.
PN formulations are the most complex extemporaneous admixtures to be 
prepared, where individual patient requirements such as energy requirements, 
electrolyte requirements and clinical conditions are taken into consideration. At 
the same time, PN admixtures can consist of different proportions and types of 
glucose, amino acids, lipid emulsions and electrolytes, as well as the inclusion 
of micronutrients. Because of the many components in a PN formulation, 
pharmaceutical problems of instability and incompatibility of components 
exist, thus leading to major concerns such as reduction in potency, risk of 
precipitation and breakdown of the lipid emulsion.
Many factors can affect the physical and chemical stability of micronutrients in 
PN formulations. These include the component solutions such as the 
electrolytes, storage temperatures, the presence of oxygen, the presence of 
trace elements, and the effects of light. PN stability issues are also compounded 
by other factors such as types of containers used and sequence of mixing.
Some examples of the effects of electrolytes, oxygen and light are discussed 
under 1.10.1,1.10.2 and 1.10.3.
1.10.1. Electrolytes
Normal daily requirements of electrolytes are generally tolerated in PN 
admixtures. However, physical incompatibilities may arise when greater needs 
are required and the final PN volume is small, especially for neonates. The 
common electrolytes having problems of incompatibility are calcium and 
phosphate ions leading to calcium phosphate precipitation (see Figure 1.17).
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2 H3P04
pH < 5
2H2P04- + 2H+
pKa2 = 7.2—
2Ca2+ + 2(HP04 )2' +2H+ CaHP04.2H20  (s)J
3Ca2+ + 2P043‘ + 2H+ Ca3(P04)2 (s)J
Figure 1.17: Speciation of inorganic phosphate in PN admixture (Allwood and
Kearney 1998)
The factors influencing this solubility are the final pH of the PN admixture, the 
types of amino acids used, the types of calcium and phosphates used and 
temperature (Allwood and Kearney 1998; Poole 1983). Calcium phosphate 
precipitates were of concern when the American Food and Drug 
Administration reported two deaths in 1994, thought to be associated with 
calcium phosphate precipitates in an all-in-one PN admixture (Food and Drug 
Administration 1994).
1.10.2. Oxygen
Dissolved oxygen can originate from the component infusions, from the 
compounding process, from infusion delivery and from oxygen permeation 
through the plastic container. An example of an oxidative reaction is the
degradation of ascorbic acid. The main cause of ascorbic acid loss in PN
admixtures is due to reaction with dissolved oxygen. In the presence of 
dissolved oxygen and catalysed by copper, ascorbic acid is rapidly oxidised to 
dehydroascorbic acid (see Figure 1.11) (Allwood 1984a; Allwood et al. 1996; 
Gibbons et al. 2001).
PN admixtures can also peroxidise to potentially harmful peroxides by reaction 
with dissolved oxygen, in particular the lipid emulsions (Allwood et al. 1996; 
Helbock et al. 1993; Muhlebach and Steger 1998; Steger and Muhlebach
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1997). PUFAs in lipid emulsions react with hydroxyl radicals, autocatalyse and 
finally producing lipid hydroperoxides (Figure 1.18).
PUFA + OH0 ----------- ► PUFA0 + H20
(PUFA radical)
PUFA0 + 0 2 ----------- ► PUFA020
(PUFA peroxyl radical)
PUFA02° + PUFA------------► PUFA0 + PUFA02H
(Lipid hydroperoxide)
Figure 1.18: Lipid peroxidation (adapted from Muhlebach and Steger 1998)
Peroxides are toxic products and the maximum permissible peroxide values are 
given for some lipid emulsions by the European Pharmacopoiea. These 
peroxides diffuse into cells forming reactive species such as free radicals, 
causing tissue and cell damage. Potential toxicity of peroxides is high in 
patients with immature or compromised antioxidant system. Peroxides have 
been associated with hypoischaemic encephalopathy, bronchopulmonary 
dysplasia, retinopathy and necrotising enterocolitis in premature infants 
(Laborie et al. 1999; Pitkanen et al. 1991).
1.10.3. Light
Light is a form of electromagnetic radiation, when a molecule absorbs a photon 
in the UV-Visible spectrum, it becomes electronically excited and major 
photophysical events take place, as shown by the Jablonski diagram (Figure 
1.19). The mechanism of photodegradation involves absorption of a photon by 
the vitamin molecule that proceeds to an electronically-excited state, and 
transformation into a photodegraded product. These events have been 
described in many references on the photostability of drugs (Moore 1987; 
Tonnesen 2004).
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Figure 1.19: Jablonski diagram, adapted from Chasteen (1995)
Light exposure has also been reported to induce the generation of peroxides in 
PN admixtures (Lavoie et al. 1997; Neuzil et al. 1995; Silvers et al. 2001; 
Steger and Muhlebach 1997), the potential harm has been described previously.
It has been reported that lipid emulsions provide partial protection of vitamins 
to light, especially for Vitamin A, probably due to the opacity of the lipid 
emulsions (Shenkin 2003). Smith et al (1988) attributed the protection as being 
due to Vitamin A dissolving in the lipid emulsion.
Many micronutrients in PN are sensitive to light, the most sensitive are found 
in the vitamin group, in particular Vitamin A, Vitamin E, Vitamin K and 
riboflavin (Allwood 1982a; Allwood 2000a). These vitamins have been 
discussed individually above. Vitamin A is degraded by photolysis while 
Vitamin E is degraded by photooxidation (Allwood and Martin 2000). UV light 
has been implicated to be the main light source in the degradation of vitamin A 
(Allwood 1982a). In addition, many reviews have reported that vitamins are 
affected only by the ultraviolet component, and not by fluorescent light or 
other artificial light sources since they emit insignificant amount of UV light 
(Allwood 2000a; Allwood and Kearney 1998; Dahl et al. 1986).
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The wavelength of UVA radiation is between 320 -  380 nm. Some 
multivitamin studies in PN use phototherapy light. The wavelength of 
phototherapy light is between 420 -  470 nm of the visible spectrum (Bhatia et 
al. 1980). Therefore, it should be noted that phototherapy light studies use a 
different set of light wavelengths under examination.
1.10.4. Other Influencing Factors
Vitamin losses may depend on the chemical composition of the amino acid 
solutions. For example, thiamine is degraded by the reducing agent bisulphite, 
present in certain amino acid infusions such as Freamine® (Kearney et al. 
1995; Scheiner et al. 1981). Freamine®, however, is no longer available on the 
market.
Other factors include the type of plastic used (Balet et al. 2004; Henton and 
Merritt 1990; Lee et al. 1980) and the methods of preparation (Ball and Barnett
1996).
1.11. Problems Associated with Provision of Vitamins to PN Patients
Patients receiving PN require regular administration of vitamins and a number 
of trace elements. Once a PN is prepared it may be stored for a period of time 
before it is delivered to the patient. During storage, some vitamins are known 
to be degraded much quicker and, during PN administration, vitamins may also 
be degraded by effects of artificial light on the wards, or by sunlight, in 
particular the UV light (Allwood and Martin 2000).
Vitamins therefore are generally not considered to be stable enough for 
prolonged storage in PN solutions, and in general are advised to be added to 
PN shortly before use (Das Gupta et al. 1986).
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1.12. Aims of Project
There are differing data on the stability of vitamins in PN admixtures because 
of the wide variety of PN compositions possible and also studies that have been 
carried out have different experimental regimes. For example, thiamine in PN 
electrolyte solution was found to be stable with no significant degradation 
observed at room temperature at 24 hours (Baumgartner et al. 1997), but in 
another study (Scheiner et al. 1981) the concentration of thiamine remaining at 
24 hours was 89%.
Many vitamin stability studies carried out by other investigators looked at the 
ad-hoc stability in the recommended base regimen only, together with the other 
nutrient components, looking into factors such as the amino acid solutions 
used, as in the case for thiamine and ascorbic acid (Allwood 1982b; Kearney et 
al. 1998) and the presence of trace elements (Allwood 1982b).
In addition, generally, the water-soluble vitamins are recommended to be 
diluted in aqueous solutions while the fat-soluble vitamins are recommended to 
be diluted in lipid emulsions. So far, no studies have been conducted to look 
into the fat-soluble vitamins stability in an aqueous solution, nor the stability of 
the combined water-soluble and fat-soluble vitamins admixture in an aqueous 
solution.
In view of the above and of the fact that vitamins are recommended to be 
added shortly before use to PN, a simple minibag vitamin formulation which 
need not require reconstitution and further handling was considered for 
development. These multivitamin minibag formulations would be ready-to-use 
preparations which could be infused separately or together with the PN big 
bags containing macronutrients only, either pre-prepared from the triple 
chamber bags obtained commercially, or from those prepared centrally by the 
hospital pharmacy departments.
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Therefore, the stability of water-soluble and fat-soluble multivitamins in 100 
ml Freeflex® (Fresenius Kabi) minibags was examined. 0.9% sodium chloride 
(normal saline) was chosen as the aqueous base vehicle because it is a 
commonly used intravenous infusion with a relatively neutral pH between pH 
5.35 to pH 5.40.
The aims of this thesis were:
1. To assess the dissolved oxygen content of the base vehicle in the 
Freeflex® minibag and the permeability of the minibag plastic 
container to oxygen.
2. To look into the stability of the water-soluble B vitamins (pyridoxine, 
nicotinamide, thiamine, folic acid and riboflavin sodium phosphate) 
contained in Solivito® N Adult injection (Fresenius Kabi), and the fat- 
soluble vitamins A and E contained in Vitlipid® N Adult (Fresenius 
Kabi) injection in an aqueous normal saline minibag formulation. In 
particular, to study the losses of these vitamins over time, storage 
temperatures and upon exposure to artificial fluorescent light.
3. To study the stability of these vitamins in minibag formulation upon 
simulation of a real clinical set-up, with lighting conditions mimicking 
hospital lighting conditions and general daylight UV exposure.
4. To study the stability of the vitamins under investigation upon delivery 
conditions and upon different protective covers used.
The results of these vitamin studies would be practically useful for use by ward 
patients and by home PN patients. These results would be useful too for 
tropical countries where PN solutions would be subjected to temperatures 
much higher than room temperature.
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CHAPTER TWO
GENERAL METHODS
2.1. Introduction
This chapter describes the chemical assays of the vitamins analysed in the 
thesis project by High Performance Liquid Chromatography (HPLC). 
Nowadays, HPLC methods are increasingly used in the analysis of vitamins. 
HPLC methods have relatively high precision and accurate retention times and 
peak area measurement. Bakshi and Singh (2002) presented the steps towards 
the development of stability indicating assay methods for regulatory 
requirements and reported that 85-95% of the methods in the literature are by 
HPLC methods.
This chapter also describes the statistical analysis and the instruments used for 
the physical tests throughout the thesis.
2.2. Statistical Analysis
Microsoft Excel 2002 software for Windows® and SPSS statistical software 
for Windows® version 12 were used for data analysis. All results throughout 
the project were expressed as the mean ± standard deviation (sd) from triplicate 
samples, unless stated otherwise.
For all experimental chapters, differences between groups were analysed using 
repeated measures analysis of variances (ANOVA), and the Bonferroni test 
was used to determine where the differences lay if there was any statistical 
difference. A p  value of <0.05 was considered to be statistically significant.
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2.3. Chemical Assays by HPLC
HPLC uses the technique of separation of analytes, achieved by partitioning of 
compounds between a stationary phase and a mobile phase. The mobile phase 
acts as a carrier for the sample solution. When the sample solution is injected 
and flows through the column with the mobile phase, the solution resolves into 
its components, the degree of resolution being dependent upon the interaction 
between the component and the column and/or the stationary phase. Following 
separation, the peaks are monitored using detectors (Groves and Murty 1995; 
Snyder et al. 1997).
In developing the methods for separating these multivitamin injections into 
their component vitamins, the initial step was searching for previously 
published literature on vitamin assays by HPLC methods. Current official 
methods for vitamin assays, for example the BP and the United States 
Pharmacopoeia (USP) are for the determination of single component vitamins 
only.
Some of the literature revealed HPLC methods for determination of water- 
soluble vitamin component from plasma (Chamberlain 1985), in foods (Kail
2003), and pharmaceutical formulations (Amin and Reusch 1987; Holler et al. 
2003; Ivanovic et al. 1999; King et al. 1998; Kothari and Taylor 1982; Sadlej- 
Sosnowska et al. 1986; Williams et al. 1973). Some of the literature that 
revealed HPLC methods for determination of fat-soluble vitamin components 
included determinations in serum (Mata-Granados et al. 2004), in 
pharmaceuticals (Allwood and Martin 2000; Billion-Rey et al. 1993; Doughty 
et al. 1996; Supelco 1999), in plasma (Sau Man Po et al. 1997), and in foods 
(Rizzolo and Polesello 1992).
Several methods were initially investigated, the methods that described the 
determination of multiple component vitamins in one assay, and using a similar 
HPLC system and column available in the laboratory were carried out.
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With regards to determining the ultraviolet (UV) detection, for the water- 
soluble vitamins, the maximum ultraviolet (UV) absorbance of the individual 
vitamin standards was measured with a spectrophotometer (Model U-3300, 
Hitachi). The maximum absorbance for the vitamins was found to be in the 
ranges of 200-220 nm and 250-280 nm. The wavelength between 250-280 nm 
was preferred because most interferences will absorb much less above 240 nm 
(Snyder et al. 1997), therefore, the methods that used UV detection between 
250-280 nm were carried out.
For the water-soluble vitamins, a simple method with good separation was 
adapted from Supelco® Application Note 148 (Supelco 2000) vitamin analysis 
method, which used a C l8 column on gradient run, UV detection at 220 nm 
and using phosphate buffer 0.05 M pH7 and methanol as the mobile phase. The 
UV detection was changed to 265 nm in this method to avoid interference 
peaks.
For the fat-soluble vitamins, the UV absorbance maxima were obtained from 
referenced data. The UV absorbances found to be mostly used were 254 nm for 
vitamin K (Billion-Rey et al. 1993), 265 nm for ergocalciferol (United States 
Pharmacopeia Council of Experts 2002), 280 nm and 292 nm for vitamin E 
(Allwood and Martin 2000; Billion-Rey et al. 1993; Mata-Granados et al.
2004), and 325 nm for vitamin A (Allwood and Martin 2000). Therefore, 
different methods that use UV detection between 325nm and 265nm were 
carried out.
Modified methods performed by Allwood (1982a) and Allwood and Martin 
(2 0 0 0 ) were adapted for the determination of the fat-soluble vitamins.
The following sections describe the HPLC methods for determining the 
component vitamins of the water-soluble multivitamin injection, Solivito® N 
Adult (Fresenius Kabi) (see 2.3.3), and the fat-soluble multivitamin injection, 
Vitlipid® N Adult (Fresenius Kabi) (see 2.3.4), obtained by single runs, the
41
reasons for selecting the vitamins analysed, and their validation and stability- 
indicating tests.
2.3.1. HPLC Instrument System
The HPLC Spectra System® from Thermo Finnigan (Thermo Electron 
Corporation, San Jose, California) was used in the vitamin analysis. The 
system consisted of SCM1000 vacuum membrane degasser, P2000 high 
pressure pump, AS 1000 autosampler, UV 1000 UV detector, and 
Chromquest™ Chromatography workstation. The column used was Varian® 
C l8 stainless steel column, 150 mm x 3 mm ID, 5 um particle size, fitted with a 
ChromSep® C l8 stainless steel guard column, 10 mm x 2 mm ID.
2.3.2. General Materials for HPLC
The materials and instruments used for HPLC analysis are as listed in Table 
2 . 1.
Table 2.1: Instruments and materials used in HPLC analysis
Materials Supplier /  Manufacturer
Solivito® N Adult injections Fresenius Kabi Limited, 
Birchwood, Warrington
Vitlipid® N Adult Injections Fresenius Kabi Limited, 
Birchwood, Warrington
Water for Injections 500ml Fresenius Kabi Limited, 
Birchwood, Warrington
0.9% Sodium Chloride Intravenous infusion 
BP in Freeflex® bags, 100ml
Fresenius Kabi Limited, 
Birchwood, Warrington
Bamstead® Nanopure Ultrafiltered deionised 
water, type 1
Bamstead Thermolyne 
Corporation, Dubuque, Iowa
diPotassium hydrogen orthophosphate 
trihydrate K2HP04.3H20  (Analytical Reagent 
grade)
Fisher Scientific UK, 
Loughborough, Leicestershire
Orthophosphoric acid (Analytical Reagent 
grade)
Fisher Scientific UK, 
Loughborough, Leicestershire
Methanol (HPLC grade) Fisher Scientific UK, 
Loughborough, Leicestershire
Absolute ethanol (Analytical Reagent grade) Fisher Scientific UK, 
Loughborough, Leicestershire
Vitamins reference standards (USP and 
Analytical Reagent grades)
Sigma Chemical Co., St. 
Louis, Missouri
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Materials Supplier /  Manufacturer
Autosampler 2.0 ml amber vials 
Autosampler PTFE/silicon vial seals
Fisher Scientific UK, 
Loughborough, Leicestershire
Sterile plastic syringes, disposable 10ml, 20ml, 
50ml BD Plastipak®
Becton Dickinson, Drogheda, 
Ireland
Sterile disposable needles, 19G /21G BD 
Microlance®
Becton Dickinson, Drogheda, 
Ireland
Disposable pasteur pipettes, 3 ml 
Liquippettes®
Elkay Laboratory Products 
Ltd, Basingstoke, Hampshire
Microcentrifuge tubes with caps, 1.5 ml 
Fisherbrand®
Fisher Scientific UK, 
Loughborough, Leicestershire
Magnetic stirrer Fisher Scientific UK, 
Loughborough, Leicestershire
Micropipettes 200 pL, 1000 pL Fisher Scientific UK, 
Loughborough, Leicestershire
Weighing balance Sartorius® Model A02, 
RC2100
Sartorius AG, Goettingen, 
Germany
Ultra-low temperature freezer Sanyo Electric Biomedical 
Co., Moriguci City, Osaka
Pharmaceutical refrigerator Lee Refrigeration, Prescot, 
Merseyside
pH meter Orion Research, Inc., Beverly, 
Massachusetts
2.3.3. The Water-soluble Vitamins
Solivito® N Adult is an injectable multivitamin, in the form of a yellow 
powder for reconstitution. It contains nicotinamide 40 mg, pyridoxine 
hydrochloride 4.9 mg (corresponds to 4 mg vitamin B6), riboflavin sodium 
phosphate 4.9 mg (corresponds to 3.6 mg vitamin B2), sodium ascorbate 113 
mg (corresponds to 100 mg vitamin C), sodium pantothenate 16.5 mg 
(corresponds to 15 mg pantothenic acid), thiamine mononitrate 3.1 mg 
(corresponds to 2.5 mg vitamin Bi), biotin 60 micrograms, cyanocobalamin 
(vitamin B12) 5 micrograms and folic acid 400 micrograms. The inactive 
ingredients consist of methyl parahydroxybenzoate 0.5 mg, glycine 300 mg and 
disodium edetate 0.5 mg.
2.3.3.1. Reference Standards for Water-soluble Vitamins Assay
The reference standards used are as listed in Table 2.2.
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Table 2.2: Reference standards for water-soluble vitamins
Water-soluble Vitamins Grade
I- Ascorbic acid A-2218 USP
p- Aminobenzoic acid A-9878 Analytical Reagent
d- Biotin B-4501 Analytical Reagent
Cyanocobalamin C-3607 USP
Folic acid F-7876 Analytical Reagent
Niacinamide (Nicotinamide) N-3376 Analytical Reagent
Calcium pantothenic acid P-2250 Analytical Reagent
Pyridoxine hydrochloride P-9755 Analytical Reagent
Riboflavin R-4500 Analytical Reagent
Sodium riboflavin 5-phosphate R-7774 Analytical Reagent
Thiamine hydrochloride T-4562 USP
2.3.3.2. HPLC Analysis for Water-soluble Vitamins Assay
All HPLC assays were carried out at ambient temperature. A reversed phase 
HPLC analysis with a gradient elution method was used. The mobile phase was 
a mixture of phosphate buffer 0.05 M pH 7.00 and methanol. The following 
gradient run was employed:
1% methanol from 1-5 minutes,
1% to 30% methanol from 5-20 minutes, and 
30% methanol from 20-25 minutes.
An equilibration time of 5 minutes was set before the next sample run. The 
flow rate was set at 1 ml/min with UV detection at 265 nm. 20 pL sample was 
injected via the autosampler.
2.3.3.3. Preparation of Phosphate Buffer
The mobile phase consisted of methanol and phosphate buffer. Fresh solution 
of 0.05 M phosphate buffer was prepared by dissolving 0.05 moles 
K2HPO4.3 H2O in ultrafiltered deionised water, stirred with a magnetic stirrer in 
a beaker. To make a 2 litre buffer solution, the amount of K2HPO4.3 H2O 
(formula mass FM= 228.22) to be weighed was:
0.05 M x 228.22 x 2 = 22.82 g (±0.05 g)
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The solution was adjusted to pH 7.00 ± 0.05 units with orthophosphoric acid, 
made up to volume in a 2 L volumetric flask and finally filtered under vacuum 
through a 0 .2  pm polyamide filter.
2.3.3.4. Preparation of Water-soluble Vitamins Standard Solution
All preparations were carried out in diffused light. Stock solutions and standard 
solutions were protected from light to minimise photodegradation by covering 
the volumetic flasks with aluminium foil.
Stock standard solutions were prepared by dissolving in ultrafiltered deionised 
water in volumetric flasks, in each case an amount equivalent to about 2 0  times 
the content of the respective vitamins as in Solivito® N Adult solution. For 
folic acid which is only slightly soluble in water (0.016 mg/ml (O'Neil 2001)), 
about 0.2 ml NaOH 0.02% (0.05 M) solution was added to aid with its 
solubilisation.
For identification of the peaks, the stock solutions were further diluted to an 
amount equivalent to about twice the content of the respective vitamins as in 
Solivito N® solution. The standard solutions were analysed individually, as 
well as mixed with the Solivito N® solution and analysed by reversed phase 
HPLC.
2.3.3.5. Preparation of Water-soluble Vitamins Sample Solution
One vial of Solivito N® Adult was reconstituted with 10 ml ultrafiltered 
deionised water. 10  ml of the reconstituted solution was syringed out, 
transferred to a volumetric flask and made up to 1 0 0  ml with deionised water.
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2.3.3.6. Identification, Calibration and Stability-Indicating Tests for
Water-soluble Vitamins
The peaks were identified by injecting the standard solutions individually and 
by the spiking method, i.e. mixing the sample with the individual standards. To 
validate the method of analysis, calibration curves of each individual vitamin to 
be analysed and separated from the gradient run were determined. Five 
standard solutions at concentrations of 40, 60, 80, 100 and 120% of Solivito® 
N Adult solution were prepared and triplicate analyses were carried out at each 
concentration level.
Separate samples of Solivito N® solutions were also subjected to the following 
conditions to cause forced degradation, to examine if the degradation peaks 
interfered with the vitamin peaks:
a. with hydrochloric acid to pH of less than 2
b. with sodium hydroxide solution to pH 12 or higher
c. heated at 80°C in a water bath for 3 hours
d. exposed to sunlight, by placing samples in clear vials near a window 
sill
e. with hydrogen peroxide 37%
Sample solution was also kept in the freezer at -80°C for up to 132 nights to 
check its stability.
2.3.3.7. Results and Discussion for Water-soluble Vitamins Assay
The chromatograms of the Solivito N® solution are illustrated in Figures 2.1 
and 2.2. The chromatogram peaks with the approximate retention times (rt) 
identified were:
Ascorbic acid approximate rt of 0.76 minutes
Pyridoxine hydrochloride (P) approximate rt of 3.7 minutes
Nicotinamide (N) approximate rt of4.8 minutes
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Pantothenic acid
Thiamine hydrochloride (T)
Folic acid (FA)
Riboflavin sodium phosphate (RSP)
approximate rt of 6.3 minutes 
approximate rt of 11. 1 minutes
approximate rt of 12.4, 14.9, 16.9,
17.3, 20.5 minutes 
approximate rt of 22.47 minutes
From the chromatogram, 5 peaks were identified for riboflavin sodium 
phosphate (Figure 2.3), as confirmed by the chromatogram of its standard 
solution. These peaks may be the isomers of riboflavin phosphate, riboflavin 
diphosphate and that of free riboflavin but tests were not carried out to 
ascertain this. For the purpose and ease of reporting, the highest peak identified 
at about 17.3 minutes was used and further evaluated for method validation.
Ascorbic acid was eluted very early in the gradient run at less than one minute. 
It would have been thought that ascorbic acid would be eluted much later if the 
pH of the buffer was made acidic as ascorbic acid has a pKa of 4.2, therefore 
ascorbic acid would be in the unionised form. A test run using phosphate buffer 
of pH 4.5 instead of pH 7.0 however, showed similar retention time whereby 
the ascorbic acid was eluted at less than one minute.
Peaks for panthothenic acid and cyanocobalamin were also identified, where 
the peaks were detected after 20 minutes gradient run. The concentration of 
cyanocobalamin in the multivitamin solution was too minute, such that when 
run at the concentration found in the solution, there was hardly a noticeable 
peak. The biotin peak could not be identified in this gradient run.
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Figure 2.1: Chromatogram of Solivito® N Adult solution (full scale)
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Figure 2.2: Chromatogram of Solivito® N Adult solution. Separation of 
pyridoxine (rt 3.77 min), nicotinamide (rt 4.80 min), thiamine (rt 6.29 min), folic 
acid (rt 11.07 min), and riboflavin sodium phosphate (rt 12.4 min, 14.9 min, 16.9 
min, 17.31 min, 20.5 min) from Solivito® N Adult solution
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Figure 2.3: Chromatogram of Solivito N® solution (black) and riboflavin sodium 
phosphate standard solution with Solivito N® mixture (red)
There were slight variations in the retention times of the peaks identified 
depending on the temperature conditions and column life. However, the 
sequence of the peaks identified remained the same throughout every HPLC 
run.
Peaks of degraded products, such as those from exposure to sunlight (Figure 
2.4), were found mostly at retention times of less than 2 minutes, therefore it 
was decided that this method would not be appropriate to analyse ascorbic acid 
as the peaks of the degraded products would interfere with the ascorbic acid 
peak. Peaks of degraded products were also detected after 20 minutes, 
therefore making this assay unsuitable for the analysis of pantothenic acid.
Therefore five vitamins were found to be suitable for assay by this method, 
which are pyridoxine, nicotinamide, thiamine, folic acid and riboflavin sodium 
phosphate. The vitamins chosen were based on convenience as they could be 
assayed in a single run, hence the ease of their analysis. These vitamins were 
further evaluated for validation and stability-indicating.
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The assay method was shown to be stability-indicating by subjecting sample 
solutions to degradation by acid, base, heat, hydrogen peroxide and exposure to 
sunlight, and examining the retention times of the degradation components. 
These did not interfere with the rest of the vitamin peaks of interest. Figure 2.4 
shows the vitamin peaks after exposure to sunlight, whilst Figure 2.5 shows the 
chromatograms obtained after exposure to hydrogen peroxide.
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Figure 2.4: Chromatogram of Solivito® N Adult solution (black) and Solivito® N 
Adult solution exposed to sunlight (blue)
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Figure 2.5: Chromatogram of Solivito® N Adult solution (black) and Solivito® N 
Adult solution degraded with hydrogen peroxide (magenta)
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It was noted that there were variations in the retention times of the vitamin 
peaks of Figure 2.5 compared with those from Figure 2.4. This was due to the 
fact that the assay of the chromatogram in Figure 2.5 was carried out on a 
different column and at a different time period.
All the vitamins analysed were also stable when stored in the freezer, as shown 
in Table 2.3.
Table 2.3: Percentage of water-soluble vitamins remaining after 132 nights from 
freezing
Vitamin P N T FA RSP
% Vitamin remaining 96.0 98.7 96.2 94.4 97.9
Calibration curves of each individual vitamin to be analysed were determined 
by analysing five different concentrations at the concentration range between 
40% to 120% of the sample solution in triplicate, namely 40, 60, 80,100 and 
120%. The calibration curves were constructed by plotting peak area versus 
concentration. The correlation coefficients (r2) and the coefficient of variations 
or relative standard deviations (rsd) obtained for the vitamins were as follows 
(Table 2.4):
Table 2.4: Correlation coefficients (r2) and relative standard deviations (rsd) of 
the water-soluble vitamin samples
Vitamin ✓ rsd
Pyridoxine HC1 0.9929 0.0029
Nicotinamide 0.9993 0.0013
Thiamine 0.9942 0.0351
Folic Acid 0.9665 0.0024
Riboflavin sodium phosphate 0.9990 0.0029
The coefficient of variations for all the above vitamins range from below 1% to 
4%.
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The sample vial analysed was left in the autosampler overnight for 20 hours 
and reanalysed. The chromatograms were found to have similar peak areas of 
within ± 3% indicating stability during analysis.
The validated stability-indicating method described was able to determine five 
vitamins present in Solivito® N Adult injection diluted with 0.9% sodium 
chloride, namely pyridoxine, nicotinamide, thiamine, folic acid and riboflavin 
sodium phosphate, in a single run. A test run of this method was also carried 
out with Solivito® N Adult injection diluted with glucose 5% intravenous 
solution, and the test run showed that similar peaks were obtained. This method 
may be used for analysis of Solivito® N Adult when diluted in glucose 5% 
solution, if further tests on forced degradation were conducted to ensure that 
degradation peaks would not interfere with the vitamin peaks of interest.
2.3.4. The Fat-soluble Vitamins
Vitlipid® N Adult is a fat-soluble multivitamin injection. A 10 ml ampoule of 
Vitlipid® N Adult contains retinol palmitate 1940 pg, corresponding to 
vitamin A 990 pg (3300 IU), ergocalciferol 5 pg (200 IU), dl-alpha-tocopherol
9.1 mg (10 IU), and phytomenadione 150 pg. The inactive ingredients consist 
of fractionated soybean oil 1 0 0 0  mg, fractionated egg phospholipids 1 2 0  mg 
and glycerol anhydrous 2 2 0  mg.
2.3.4.I. Reference Standards for Fat-soluble Vitamins Assay 
The reference standards used are listed in Table 2.5.
Table 2.5: Reference standards for fat-soluble vitamins
Fat-soluble Vitamins Grade
all trans-retinol palmitate (vitamin A )-1,800,000 
USP units/g R-1512
Analytical Reagent
Ergocalciferol (vitamin D2) -40,000,000 USP 
units/g E-5750
Analytical Reagent
dl-alpha- tocopherol -95% HPLC T-3251 HPLC
Vitamin Ki V-3501 Analytical Reagent
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2 .3 .4 .2 . HPLC Analysis for Fat-soluble Vitamins Assay
A reversed phase HPLC analysis using two different UV detections in a single 
run was employed. The mobile phase was methanol HPLC grade, set at a flow 
rate of 1.5 ml/min. The wavelengths used were 292 nm from 0-7 minutes, for 
the detection of vitamins D, E and K, and wavelength 325 nm from 7-15 
minutes for the detection of vitamin A. A 20 pL sample was injected via the 
autosampler.
2.3.4.3. Preparation of Fat-soluble Vitamins Standard Solutions
Stock and standard solution volumetric flasks and containers were protected 
from light by wrapping with aluminium foil and preparations were carried out 
in diffused light. A 100 ml stock standard solution of each vitamin equivalent 
to about 20 times the amount in one vial Vitlipid® N Adult was prepared. 
Vitamin A standard was mixed with about 50 ml absolute ethanol to aid with 
its dissolution, and then made up to 100 ml with methanol. Vitamin D and 
vitamin E were respectively mixed and made up to volume with methanol. The 
stock solutions were stored in the freezer at -80°C.
Freshly prepared standard solutions of concentrations equivalent to 40, 60, 80, 
1 0 0 , and 1 2 0 % of the sample solution were prepared from the stock solutions 
in volumetric flasks and diluted with methanol.
2.3.4.4. Preparation of Fat-soluble Vitamins Sample Emulsion
10 ml of Vitlipid® N Adult injection was syringed out, transferred to a 100 ml 
flask and made up to volume with ultrafiltered deionised water.
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2.3.4.5. Identification, Calibration and Stability-Indicating Tests for 
Fat-soluble Vitamins Assay
The sample emulsion was injected into the HPLC system to determine the 
chromatogram peaks. The peaks and retention times of vitamins A and E were 
identified by individually injecting the standard solutions equivalent to 1 0 0 % 
of sample emulsion, and by spiking, as a mixture, with an equal amount of the 
standard solutions. Identification of Vitamin K and Vitamin D peaks was 
achieved by spiking with ten times the concentration of those in the sample 
emulsions, in order for the peaks to show as the concentrations in the original 
sample were too small.
Validation of the HPLC method was determined by running the vitamin assays 
in triplicate at five different concentrations equivalent to 40, 60, 80, 100 and 
1 2 0 % of the sample emulsion, and plotting calibration curves of area versus 
concentration.
Forced degradation of the sample emulsion was also carried out at conditions 
similar to those performed with the water-soluble vitamins (see 2.4.6.) to 
determine if the degradation products interfered with the peaks of interest.
2.3.4.6. Results and Discussion for Fat-soluble Vitamins Assay
A typical chromatogram of the sample Vitlipid® N Adult emulsion is shown in 
Figure 2.6. Peaks were observed at 2.07 minutes for Vitamin D, 2.37 minutes 
for Vitamin E, 6.09 minutes for Vitamin K and 8.82 minutes for Vitamin A.
At the time of determining the assay method for the fat-soluble vitamins, it was 
believed that the Vitamin K peak was too small with lack of sensitivity, to be 
clearly assayed in this HPLC run, therefore it was omitted in further analysis. 
With new computer software and expertise now available, this would allow the 
data to be looked at in the future.
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Figure 2.6: Typical chromatogram of Vitlipid® N Adult emulsion. Vitamin D 
peak at 2.07 min, vitamin £  peak at 2.37 min and vitamin A peak at 8.82 min
Depending on the temperature condition and column life, a slight shift of the 
retention time was observed.
The relative standard deviations (rsd) and correlation coefficients (r ) obtained 
from plots of the peak areas versus concentrations of the standards for the 
vitamins were as follows (Table 2.6):
Table 2.6: Correlation coefficients (r2) and relative standard deviations (rsd) of 
the fat-soluble vitamin samples
Vitamin r2 rsd
Ergocalciferol (Vitamin D) 0.8036 0.0510
Tocopherol (Vitamin E) 0.9993 0.0121
Retinol palmitate (Vitamin A) 0.9933 0.0077
From the calibration curve, the r2 of ergocalciferol was found to be less than 
0.900, indicating less linearity of Vitamin D and therefore less precision, hence 
the decision not to analyse Vitamin D content. Furthermore, when analysing a 
sample of the known standard and comparing with similar concentration of the 
test sample, the peak of the standard was much lower than the test sample.
,
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The chromatogram after forced degradation showed that decomposition 
products did not interfere with the vitamin peaks of interest. An example of the 
chromatogram after exposure to sunlight is shown in Figure 2.7.
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Figure 2.7: Chromatogram of Vitlipid® N Adult sample before (black) and after 
(blue) exposure to sunlight
In Figure 2.7, very large losses of Vitamins A and E were observed which were 
as expected as the sample was exposed to sunlight, but the degradation 
products did not interfere with the vitamin peaks.
Frozen samples were tested for up to 43 nights. Results of tests of frozen 
samples were found to be inconsistent as at times vitamins were shown to be 
stable but at other times were also found to have degraded to 72%, as shown in 
Table 2.7.
Table 2.7: Percentage of fat-soluble vitamins remaining after 43 nights from 
freezing
Vitamin Vitamin D Vitamin E Vitamin A
% Vitamin remaining 75.3 74.7 72.0
Samples refrigerated for up to 3 nights and samples left in the autosampler for 
up to 22 hours showed losses of less than 2%. With these data gathered, it was
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decided that test samples could be kept refrigerated for up to 3 days before 
HPLC analysis without deterioration and it was decided that analysis should be 
checked against a fresh sample.
For the fat-soluble Vitlipid® N Adult (Fresenius Kabi) vitamins assay, in 
conclusion, the stability-indicating method described was able to determine 
two vitamins, namely Vitamin A and Vitamin E in a single run.
2.3.5. Degradation Tests for Combined Fat-soluble and Water- 
soluble Vitamin Admixtures
The combined fat-soluble and water-soluble vitamin admixture was prepared 
by reconstituting one vial of Solivito N® Adult injection with 10 ml Vitlipid® 
N Adult injection. 10 ml of the reconstituted emulsion was then syringed out, 
transferred to a volumetric flask and made up to 1 0 0  ml with deionised water.
HPLC assays were carried out according to the water-soluble vitamins assay 
for the water-soluble vitamin components, and according to the fat-soluble 
vitamins assay for the fat-soluble vitamin components. Forced degradation of 
this emulsion sample was carried out at conditions similar to those performed 
with the water-soluble vitamins as described in 2.4.6.
Examples of chromatograms of the water-soluble and the fat-soluble vitamins 
in the combined admixture after forced degradation are shown in Figure 2.8 
and Figure 2.9 respectively. The chromatograms after forced degradation did 
not show any decomposition products that would interfere with the peaks of 
interest.
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Figure 2.8: Chromatogram of a water-soluble vitamin analysis of combined 
Solivito® N Adult with Vitlipid® N Adult sample before (black) and after (red) 
exposure to sunlight
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Figure 2.9: Chromatogram of a fat-soluble vitamin analysis of combined 
Solivito® N Adult and Vitlipid® N Adult sample (black) and sample degraded 
with sodium hydroxide (green).
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2.4. Physical Analysis
2.4.1. Aqueous Water-soluble Vitamin Solutions
The following analyses were carried out. Solutions were visually checked with 
the unaided eyes and by using fibreoptic lighting system for clarity of the 
solution. The turbidity of the solutions was determined using a Hach® 
nephelometer. The dissolved oxygen (DO) content was determined using 
Jenway® DO meter, and the pH was determined using Orion® pH meter.
2.4.2. Aqueous Fat-soluble Vitamin Emulsions and Combined 
Water-soluble and Fat-soluble Vitamin Emulsions
The following analyses were carried out. Emulsions were visually checked 
with the unaided eye, by using fibreoptic lighting system and by light 
microscopy. DO content was determined using Jenway® DO meter. The lipid 
globule size was measured with Malvern Mastersizer®, and the pH was 
determined using Orion® pH meter.
2.5. Instruments for Physical Tests Analysis
The instruments and materials for physical analysis are as listed in Table 2.8.
Table 2.8: Instruments and materials used for physical analysis
Instruments /  Materials Manufacturer
Fibreoptic lighting system Schott KL 1500 Schott Glaswerke, Mainz, 
Germany
Hach Turbidimeter Model 43900 Ratio/XR Hach Company, Ames, Iowa
Orion pH Meter Model 420A Orion Research, Inc., Beverly, 
Massachusetts
Jenway Dissolved Oxygen meter model 
9500
Jenway, Felsted, Dunmow, 
Essex
Microflow Laminar Flow cabinet, 
horizontal
Bioquell UK Limited, 
Andover, Hants
Microscope Olympus BH-2 Olympus Optical Co. Limited, 
Shinjuku-ku, Tokyo
Thoma welled slides and cover slips Weber Scientific International 
Limited, Teddington, 
Middlesex
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Instruments /  Materials Manufacturer
Weighing balance Sartorius Model A02 Sartorius AG, Goettingen, 
Germany
Malvern Mastersizer® X Malvern Instruments Limited, 
Malvern, Worcestershire
Pharmaceutical Stability Chamber PSC 062 Sanyo Weiss Gallenkamp, 
Loughborough, Leicestershire
Pharmaceutical Refrigerator Lee Refrigeration, Prescot, 
Merseyside
Magnetic stirrers Fisher Scientific UK, 
Loughborough, Leicestershire
pH Buffers Fisher Scientific UK, 
Loughborough, Leicestershire
Sodium sulphite anhydrous Fisher Scientific UK, 
Loughborough, Leicestershire
Glassware Fisher Scientific UK, 
Loughborough, Leicestershire
2.5.1. Nephelometer -  Hach Turbidimeter
A nephelometer measures the intensity of light scattered at right angles to the 
incident light beam, this scattered light relates to the samples actual turbidity. 
Turbidity is the interaction between light and suspended particles in water, 
producing the Tyndall effect (European Pharmacopoeia Commission 2005). 
The higher the intensity of scattered light, the higher is the turbidity. A 90°- 
detection angle offers a system that is relatively free from stray light (Hach 
Company Manual 1991)
Forward
Scatter
Lamp
Figure 2.10: Schematic diagram of Hach® Ratio/XR nephelometer (Hach 
Manual 1991)
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The nephelometer used is the Hach Ratio™/XR Turbidimeter (Figure 2.10) 
which can measure nephelometric turbidity unit (NTU) as low as 0.001 NTU to 
as high as 1999 NTU. The signal output measures the ratio between the 
scattered light at right angles and the weighted sum of forward-scattered light 
and transmitted light. It also compensates for absorption due to colour in the 
sample solution, changes in lamp output variation, or any film build-up on the 
Hach® tubes.
To measure turbidity with this meter, the glass Hach® tube was filled with 25 
ml solution and coated with a thin film of silicone oil to mask any 
imperfections in the glass. The tube was then placed into the sample holder, 
with its index mark aligned with the mark on the spill ring around the holder 
opening, and covered with the light shield cap. The turbidity of the sample was 
measured from the digital display.
2.5.2. Dissolved Oxygen Meter
The DO meter measures the amount of oxygen dissolved in water. Jen way® 
DO meter uses the principle of the Clark oxygen electrode or polarographic 
oxygen sensor as illustrated in Figure 2.11.
Anode
G as permeable membrane
Figure 2.11: Jenway® DO meter and its schematic representation.
The meter consists of a probe with gold and silver electrodes supplied with a 
protective cap, a gas-permeable membrane and a 5% potassium chloride (KC1) 
electrolyte solution. The probe is connected to the membrane filled with KC1 
solution and is polarised at a constant voltage. Dissolved oxygen in the sample
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diffuses through the membrane into the KC1 solution and is reduced at the 
cathode. The resulting current flow is directly proportional to the amount of 
oxygen present, and the sensor converts the current measurement into 
concentration units. The oxidation-reduction reactions are as follows:
Reaction at cathode (oxygen is reduced):
0 2 + 4H+ +4e~ —>2 H20  
Reaction at anode (silver is oxidised):
4Ag + 4Cl~ -> 4AgCl + 4e~
Because diffusion gradients are set up across the membrane, a magnetic stirrer 
is needed to replenish the fluid across the membrane surface. This probe comes 
with a temperature compensating element and the DO meter can be adjusted 
for salinity.
To measure DO, the probe was immersed in the solution such that it covered 
the silver ring of the probe. The solution was stirred with a magnetic stirrer to 
avoid oxygen starvation at the membrane. Sufficient time was allowed when 
taking measurement to allow the reading to become stable. After each test, the 
probe was rinsed with ultrafiltered water. The probe was calibrated regularly 
using freshly prepared sodium sulphite 2% solution as the zero standard 
solution.
2.5.3. pH Meter
The Orion® pH meter measures pH of solutions by the glass electrode method, 
that is by measuring the potential difference between the glass and reference 
electrode. The pH meter was calibrated using either two of the three standard 
buffer solutions, namely phthalic acid buffer (pH 4.01), phosphate buffer (pH 
7.00), and borate buffer (pH 10.01).
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2.5.4. Fibre-optic Lighting System
The fibre-optic light uses halogen cold light source where the infrared 
component is removed by a filter, therefore at the point of light output, heat is 
not generated but yet it produces intensive illumination (Schott KL 1500 
Instruction Manual).
For examination of the water-soluble vitamin samples using this light, the 
samples were placed above the light source and viewed against a dark 
background. This enhanced visualisation of haze and small particles (Trissel 
and Bready 1992). For examination of the fat-soluble vitamins, the samples 
were viewed against dark and white backgrounds with the light placed at 
approximately 45° above the sample to enhance visualisation of creaming and 
oil globules.
2.5.5. Mastersizer® X  Laser Diffraction Particle Size Analyser
The Malvern MasterSizer® X  particle size analyser uses the laser diffraction 
technique which is based on the principle of laser light scattering. Laser 
diffraction technique relies on the fact that the diffraction angle is directly 
proportional to particle size. The instrument consists of a laser light, a detector, 
and a small volume sampler as a means of passing the sample through the laser 
light beam (Malvern Application Note).
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Figure 2.12: Reverse Fourier Optical Configuration (adapted from Malvern 
Reference Manual)
The Malvern MasterSizer® X  employs reverse Fourier optics (Figure 2.12). 
For conventional Fourier optics configuration, particles from the sample cell 
scatter the collimated beam of laser light and through use of a Fourier 
transform lens, focus it on a detector. In the reverse Fourier optics 
configuration, the laser output beam, instead of forming a collimated laser 
beam, is focused to a detector plane. The sample cell is placed at a distance 
from the detector plane in the converging analyser beam. The advantage of the 
reverse Fourier optics configuration is that it allows measurement size range of 
samples dispersed in liquids to be extended down to 0.1 pm (Malvern 
Instruments Ltd 1993).
For analysis of the Vitlipid® N Adult in 0.9% sodium chloride sample, the 
Mastersizer® was set to polydisperse mode of analysis and “SOYA” 
presentation, which is the optical presentation optimised for soybean oil lipids, 
based on their refractive index and light absorption properties. The number of 
sweeps of the detector readings was set to 30,000.
For the measurement of lipid globules, they are measured by passing the laser 
beam through the emulsion samples dispersed in ultrapure deionised water. To
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analyse the sample, the small volume sampler was filled with ultrapure 
deionised water and stirred at a constant flow rate to minimise air bubble 
introduction. A background measurement was made to subtract stray light 
picked up from other sources such as daylight and flare off optical surfaces. 
Then the sample was added slowly and allowed to mix through the system. The 
amount of sample required was adjusted to an obscuration value of between 
19% and 21%. The obscuration of the beam means the fraction of light ‘lost’ 
from the incident laser beam when the sample is introduced, either to scattering 
or to absorption. Initial tests carried out with Vitlipid® N Adult emulsion 
resulted in about 3 ml sample being required to obtain this obscuration 
concentration. The particle size data of the measured sample was analysed 
using the Malvern Mastersizer® software version 2.19.
2.5.6. Light Microscope
A pre-calibrated light microscope (Olympus® BH-2) with a phase contrast 
attachment was employed to view the appearance and size of the lipid globules 
of the Vitlipid® N Adult vitamin samples. A phase-contrast optical system was 
selected to enable better visibility of the samples.
When counting under the microscope, slight refocusing was required 
occasionally to keep the globules in sharp focus. Air bubbles, which may pose 
a problem as they appear similar in shape and appearance to lipid globules, 
were distinguished from lipid globules by their halo rings surrounding them.
Each test sample was placed on a Thoma welled counting chamber slide having 
a height of 0.2 mm, and with gridlines having a total of 256 squares. The slide 
was covered with a disposable cover slip, care being taken not to introduce any 
air bubbles. Samples within the calibrated grid were viewed at a magnification 
of 200 times, one unit gridline of the scale being equivalent to 5 pm in size, 
and any globules size greater than 5 pm diameter were then recorded.
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2.5.7. Pharmaceutical Stability Chamber
The pharmaceutical stability chamber Pharma-Safe PSC 062 (Sanyo 
Gallenkamp) meets the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) standards for stability and photostability (ICH Steering Committee 1996; 
2003a). The cabinet provides uniform lighting conditions as well as uniform 
temperature and humidity, thus ensuring that samples are exposed in identical 
manner. The PSC 062 cabinet has two shelves with visible light sources and 
another two shelves with near ultraviolet (UV) light sources, placed alternately 
and spaced evenly, 24 cm apart. Each shelf has light sensor for measurement of 
the respective light exposure. The lux sensor measures visible light in Lux unit, 
while the UVA sensor measures UVA radiation between 320 -  380 nm from 
the UV lamp, with units in Watts per square metre (W/m2) (PSC 062 
Instruction Manual).
In all the studies conducted, unless otherwise specified, this stability chamber 
was used to subject all samples to test conditions. The stability chamber was 
set at 60% ± 5% relative humidity, while the temperature settings deviation 
was set at ± 2°C.
2.5.8. Laminar Flow Cabinet
This horizontal laminar-flow cabinet, Microflow® (Bioquell), is fitted with 
high efficiency particulate air (HEPA) filter with 99.97% efficiency, thus 
providing ultrafiltered air and allowing a clean air work environment.
All compounding works for the minibag vitamin formulations were performed 
in the laminar-flow cabinet throughout the entire project thesis. Aseptic 
technique was used during preparation and during sample taking to avoid 
bacterial contamination.
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2.6. Conclusions
Validated stability-indicating assay methods were carried out to identify the 
vitamins that could be analysed in single runs for the water-soluble vitamins in 
Solivito® N Adult and the fat-soluble vitamins in Vitlipid® N Adult injections. 
These were found to be the vitamins pyridoxine, nicotinamide, thiamine, folic 
acid and riboflavin sodium phosphate for the water-soluble vitamins, and 
retinol palmitate (vitamin A) and tocopherol (vitamin E) for the fat-soluble 
vitamins. These vitamins to be analysed were based on the convenience of 
assay methods as they could be determined simultaneously in single runs. The 
other vitamins in the formulation such as ascorbic acid, Vitamin D and Vitamin 
K were not looked at in the following chapters.
The five water-soluble vitamins analysed were assayed simultaneously by 
reversed phase HPLC and gradient run method. The fat-soluble Vitamin A and 
Vitamin E were assayed by reversed phase HPLC assay method, and using two 
different wavelengths in a single run.
Both methods produced satisfactory results and had good separation of the 
peaks of interest. Forced degradation of the samples (Solivito® N Adult 
solution, Vitlipid® N Adult emulsion and the combined Solivito® N Adult and 
Vitlipid® N Adult emulsion) showed no interference of the degradation 
products with the peaks of interest. The methods developed for these vitamins 
were found to be repeatable and stability indicating.
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CHAPTER THREE 
DISSOLVED OXYGEN CONTENT ASSESSMENT
3.1. Introduction
The use of plastic delivery containers in parenteral formulations is widely 
increasing, they are lighter, unbreakable and more economical than glass 
bottles. However, a number of studies have shown that the phthalate 
plasticizers in the polyvinyl chloride (PVC) plastics pose problems of 
interactions such as sorption of drugs or leaching of chemicals from the PVC 
containers (Allwood 1986; Moorhatch and Chiou 1974; Pearson and Trissel 
1993). Recent innovations have seen the development of plastic containers free 
from such plasticizers and able to withstand heat sterilisation (Lund 1994). One 
such innovation is the Freeflex® (Fresenius Kabi) plastic container.
For this project, Freeflex® plastic minibags were employed. The Freeflex® 
plastic bag is made from polyolefine, a polymer that is free from phthalate 
plastizers and PVC material, as well as free from adhesives or latex. It can also 
be heat sterilised (Freeflex® Technical Manual). A study by Henton and 
Merritt (1990) found increased recovery of vitamin A from polyolefin tubing 
than from PVC, indicating greater interaction of vitamin A with PVC than with 
polyolefin. Therefore, problems of interactions are greatly minimised with this 
Freeflex® bag.
One of the factors that can affect vitamins stability in PN formulations is the 
presence of air or dissolved oxygen (DO) in the solution. This study therefore 
aimed to assess the permeability of Freeflex® 100 ml minibags to oxygen, by 
assessing the DO content of the base system, in this case 0.9% sodium 
chloride. 100 ml capacity glass bottles were used as comparison. This study
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also assessed the DO content when the containers were subjected to various 
storage conditions, to be used as baseline information.
3.2. Materials and Methods
The instruments and general methods for measurement of DO content are as 
described in Chapter Two.
Other materials used are as outlined in Table 3.1.
Table 3.1: Materials used for DO assessment
Materials Supplier/ Manufacturer
Specimen glass tubes with the screw caps Fisher Scientific UK, 
Loughborough, Leicestershire
0.9% Sodium Chloride (NaCl) Intravenous 
infusion BP, 100 ml, Freeflex®
Fresenius Kabi Limited, 
Birchwood, Warrington
Magnetic stirrers Fisher Scientific UK, 
Loughborough, Leicestershire
Type 1 glass bottles, 100 ml, clear 
Flurotec injection stopper, 20 mm 
Aluminium caps, 20 mm
Adelphi (Tubes) Limited, 
Haywards Heath, West sussex
0.9% Sodium Chloride (NaCl) Intravenous 
infusion BP, 500 ml
Fresenius Kabi Limited, 
Birchwood, Warrington
Vial capping hand crimping tongs 
Vial decapping hand crimping tongs
Adelphi Manufacturing, 
Haywards Heath, West sussex
Needles 21G, sterile 
Syringe 10 ml, sterile
Becton Dickinson, Drogheda, 
Ireland
3.2.1. Experimental Design
3.2.1.1. Experiment 1
The containers were stored in the pharmaceutical stability chamber (PSC) for 
one week at 4, 25, 30 and 40°C, at a relative humidity of 60%. In addition, with 
the exception of the samples stored at 4°C, experimental solutions were also 
tested by exposing them to artificial fluorescent white light having an 
illuminance of 0.7 klux, this light intensity is equivalent to office and general 
hospital ward lighting conditions that have specifications of around 0.5 klux 
(Baker et al. 1993).
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The DO content of the solutions was measured at 0,48 and 168 hours.
3.2.1.2. Experiment 2
The containers were stored in the pharmaceutical refrigerator at 4°C for either 7 
days or 30 days. This was followed by exposing the containers to either 25°C 
or 40°C in the PSC for the next 24 hours. The fluorescent white light was set to
1 .2  klux for containers exposed to light, this light intensity is equivalent to 
hospital operating theatre lighting condition (Baker et al. 1993).
The DO content of the solutions was measured at 0 hour, on day 7 or day 30, 
and at 24 hours after subjection to exposure condition.
3.2.2. Sample Preparation
Using a sterile syringe and needle, 10 ml of air was added to 100 ml 0.9% 
sodium chloride in either 100 ml Freeflex® plastic bags or 100 ml glass 
bottles. 0.9% sodium chloride in 100 ml glass bottles were prepared by 
aseptically transferring 100 ml of 0.9% Sodium Chloride Intravenous Infusion 
from 500 ml Freeflex® bags into sterile 100 ml type 1 glass bottles and capped 
with sterile Flurotec® stoppers and aluminium seals. The solutions were then 
stored according to the experimental design as described above. Normal saline 
solutions without addition of air acted as controls. For Freeflex® bags, the 
outer overwraps were also removed.
3.2.3. Sampling
For DO analysis of normal saline from glass bottle, the bottle was decapped 
and about 25 ml sample solution was run down the side of a marked glass 
specimen tube, taking care to minimise air introduction. In the case of the 
Freeflex® bag, the addition port was snipped off and the solution was run 
down the side of the marked tube, care was taken not to introduce any air
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bubbles. The glass specimen tube was immediately capped and DO 
measurement was carried out as early as possible. This handling technique was 
adapted from the work of Ball (1997).
Containers wrapped in aluminium foil serve as the light protected containers. 
Separate bags were used for measurement at each time point. In each case, 
triplicate readings were taken from each sample solution and triplicate samples 
were prepared for each set of conditions.
3.3. Results
The following abbreviations are used to denote the type of containers and 
conditions for which the solutions are stored:
FNN4 (25/30/40) Freeflex® bags, no air added, light protected, stored at
4°C (or at 25°C /30°C /40°C)
Freeflex® bags, air added, light protected, stored at 4°C 
(or at 25°C /30°C /40°C)
Freeflex® bags, no air added, light exposed, stored at 
25°C (or at 30°C /40°C)
Freeflex® bags, air added, light exposed, stored at 25°C 
(or at 30°C /40°C)
glass bottles, no air added, light protected, stored at 4°C 
(or at 25°C /30°C/40°C)
GAN4 (25/30/40) glass bottles, air added, light protected, stored at 4°C (or
at 25°C /30°C /40°C)
glass bottles, no air added, light exposed, stored at 25°C 
(or at 30°C /40°C)
glass bottles, air added, light exposed, stored at 25°C (or 
at 30°C /40°C)
FAN4 (25/30/40) 
FNL25 (30/40) 
FAL25 (30/40) 
GNN4 (25/30/40)
GNL25 (30/40) 
GAL25 (30/40)
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The results of the DO content for experiment 1 are shown from Figure 3.1, to 
Figure 3.4, while the results for experiment 2 are shown from Figure 3.5 to 
Figure 3.8.
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0 24 48 72 96 120 144 168
Time (h)
Oh 48 h 168 h
FNN4 7.21 ±0.12 10.29 ± 1.21 9.83 ±0.56
FNN25 7.21 ±0.12 6.99 ± 0.25 6.81 ±0.05
FNN30 7.21 ±0.12 6.57 ± 0 .06 6.64 ± 0.06
FNN40 7.21 ±0.12 5.51 ±0.15 5.62 ±0.03
GNN4
GNN25
GNN30
GNN40
0 24 48 72 96 120 144 168
Time (h)
Oh 48 h 168 h
GNN4 7.18 ± 0.10 8.65 ± 0.29 8.74 ±0.38
GNN25 7.18 ± 0.10 6.88 ± 0.22 6.87 ± 0.26
GNN30 7.18 ± 0.10 6.73 ±0.11 6.60 ±0.37
GNN40 7.18 ± 0.10 6.27 ±0.18 6.07 ± 0.23
Figure 3.1: Dissolved oxygen content of Freeflex® bags/ glass bottles, no air
added, light protected, stored at 4oC/25oC/30oC/40°C (control)
I
o>
E
Oo
9.00
8.00
7.00
6.00
FNN4
FNN25
FNN30
FNN40
72
*  FAN4 
FAN25
j  - A — FAN30
*  - X -  FAN40
16
8
Oh 48 h 168 h
FAN4 7.12 ± 0.17 9.37 ± 0 .06 9.19 ± 0.15
FAN25 7.12 ± 0.17 6.75 ± 0.26 6.85 ±0.18
FAN30 7.12 ± 0.17 6.63 ± 0.04 6.71 ±0.18
FAN40 7.12 ±0.17 5.68 ± 0.14 5.71 ±0.16
— GAN4 
— GAN25 
—A— GAN30 
— GAN40
Time (h)
Oh 48 h 168 h
GAN4 7.45 ±0.11 8.97 ±0.10 8.97 ± 0.29
GAN25 7.45 ±0.11 7.82 ± 0.66 7.79 ± 0.28
GAN30 7.45 ±0.11 7.71 ±0 .24 7.68 ±0.23
GAN40 7.45 ±0.11 6.84 ± 0.43 7.52 ±0.33
Figure 3.2: Dissolved oxygen content of Freeflex® bags/ glass bottles, air added,
light protected, stored at 4°C/25oC/30oC/40°C
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— FNL25 
— FNL30 
FNL40
0 24 48 72 96 120 144 168
Time (h)
g  6.00
Oh 48 h 168 h
FNL25 7.28 ±0.16 6.87 ±0.14 6.81 ±0.04
FNL30 7.28 ±0.16 6.47 ±0.21 6.58 ± 0.02
FNL40 7.28 ±0.16 5.75 ±0.13 5.78 ±0.10
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0 24 48 72 96 120 144 168
Time (h)
Oh 48 h 168 h
GNL25 7.42 ±0.16 7.00 ±0.15 6.93 ± 0.08
GNL30 7.42 ±0.16 6.78 ± 0 .14 6.78 ± 0.28
GNL40 7.42 ±0.16 6.31 ±0.05 6.25 ± 0.07
Figure 3.3: Dissolved oxygen content of Freeflex® bags / glass bottles, no air
added, light exposed, stored at 25oC/30°C/40°C
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Oh 48 h 168 h
FAL25 7.21 ±0.22 6.78 ±0.24 6.85 ±0.13
FAL30 7.21 ±0.22 6.62 ± 0.03 6.69 ± 0.09
FAL40 7.21 ± 0.22 5.74 ±0.15 5.83 ±0.12
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GAL25
GAL30
GAL40
24 48 72 96 120 144 168 
Time (h)
Oh 48 h 168 h
GAL25 7.58 ±0.22 7.80 ± 0 .60 7.91 ±0.12
GAL30 7.58 ±0.22 7.96 ± 0.03 7.76 ± 0.22
GAL40 7.58 ±0.22 7.30 ±0.05 7.09 ± 0.05
Figure 3.4: Dissolved oxygen content of Freeflex® bags, air added, light exposed, 
stored at 25°C/30°C/40°C
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FNN
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Time (d)
Day 0 Day 7 7 d + 24 h
FNN 7.90 ±0.13 14.07 ±0 .74 7.04 ± 0.07
FNL 7.90 ±0.13 14.07 ±0 .74 7.18 ±0.08
GNN 7.87 ±0.16 11.45 ± 0 .20 7.06 ± 0.09
GNL 7.87 ±0.16 11.45 ± 0 .20 6.98 ±0.17
FAN 7.38 ±0.17 11.58 ±0 .66 6.89 ± 0.08
FAL 7.38 ±0.17 11.58 ±0 .66 6.89 ±0.08
GAN 7.60 ±0.13 11.57 ±0 .27 7.82 ±0.01
GAL 7.60 ±0.13 11.57 ±0 .27 7.83 ±0.19
Figure 3.5: Dissolved oxygen content of containers stored for 7 days at 4°C, then 
exposed to 25°C for 24 hours
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Time (d)
Day 0 Day 7 7 d + 24 h
FNN 7.90 ±0.13 14.07 ± 0.74 5.45 ± 0.04
FNL 7.90 ±0.13 14.07 ±0 .74 5.37 ±0.10
GNN 7.87 ±0.16 11.45 ± 0 .20 5.50 ±0.08
GNL 7.87 ±0.16 11.45 ±0 .20 5.86 ±0.09
FAN 7.38 ±0.17 11.58 ±0 .66 5.41 ±0.09
FAL 7.38 ±0.17 11.58 ± 0 .66 5.39 ±0.10
GAN 7.60 ±0.13 11.57 ±0 .27 6.08 ±0.12
GAL 7.60 ±0.13 11.57 ±0 .27 6.52 ±0.12
Figure 3.6: Dissolved oxygen content of containers stored for 7 days at 4°C, then 
exposed to 40°C for 24 hours
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14.00
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4.00
2.00 
0.00
Day 0 Day 30 30 d  + 24 h
FNN 7.90 ±0.13 13.43 ±0 .69 7.24 ± 0.29
FNL 7.90 ±0.13 13.43 ±0 .69 6.57 ±0.14
GNN 7.87 ±0.16 12.75 ±0 .48 6.65 ±0.19
GNL 7.87 ±0.16 12.75 ±0.48 6.69 ±0.03
FAN 7.38 ±0.17 12.85 ±0 .38 6.59 ±0.03
FAL 7.38 ±0.17 12.85 ±0 .38 6.57 ± 0.05
GAN 7.60 ±0.13 12.23 ±0 .19 7.59 ±0.06
GAL 7.60 ±0.13 12.23 ±0 .19 7.56 ±0.15
Figure 3.7: Dissolved oxygen content of containers stored for 30 days at 4°C, then 
exposed to 25°C for 24 hours
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Day 0 Day 30 30 d  + 24 h
FNN 7.90 ±0.13 13.43 ±0 .69 5.71 ± 0.04
FNL 7.90 ±0.13 13.43 ±0 .69 6.57 ± 0.04
GNN 7.87 ±0.16 12.75 ±0 .48 6.65 ±0.14
GNL 7.87 ±0.16 12.75 ± 0.48 6.69 ± 0.04
FAN 7.38 ±0.17 12.85 ± 0.38 6.59 ±0.06
FAL 7.38 ±0.17 12.85 ±0 .38 6.57 ±0.15
GAN 7.60 ±0.13 12.23 ±0 .19 7.59 ±0.15
GAL 7.60 ±0.13 12.23 ±0 .19 7.56 ±0.13
Figure 3.8: Dissolved oxygen content of containers stored for 30 days at 4°C, then
exposed to 40°C for 24 hours
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3.4. Discussion
In experiment 1, 0.9% sodium chloride in either Freeflex® or glass containers 
were subjected to storage conditions of 4, 25, 30 and 40°C for 168 hours 
duration. The results are depicted in Figure 3.1 and Figure 3.2. Figure 3.1 and 
Figure 3.2 show that the highest DO content is achieved when stored at 4°C 
and the DO content is lowest at 40°C, in both the glass and Freeflex® 
containers, and this difference is statistically significant (p<0.001). As the 
temperature increased, the DO concentration decreased, this is comparable to 
the dissolved oxygen content of the base solution being dependent on 
temperature, with the oxygen solubility decreasing with higher temperatures. It 
is a known fact that the solubility of oxygen in a particular solvent depends on 
the temperature, pressure, and the nature of the solvent (Florence and Attwood 
1998).
Comparison between Figure 3.1 and Figure 3.2 shows that with the addition of 
air, the graph patterns of the solutions upon subjecting to different temperatures 
are similar to those without air added. In addition, in Figure 3.2, it was found 
that samples in Freeflex® bags with added air and stored at higher 
temperatures showed a lower DO concentration than glass bottles and reached 
a plateau upon time, signifying increased permeability of air through the plastic 
bags, whilst those in glass containers showed higher DO concentration 
compared to their baseline value signifying the dissolved oxygen could not 
diffuse through the glass containers. The DO content reached a plateau as the 
dissolved oxygen in the solutions was used up.
In addition, for storage conditions of 25, 30 and 40°C, the containers were also 
exposed to fluorescent white light, and the results of the DO content upon the 
effects of light are depicted in Figure 3.3 and Figure 3.4. Figure 3.3 and Figure
3 .4  show that exposing the samples to light did not have a significant effect on 
the dissolved oxygen content of the base solution.
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It would be noted that only three sampling times were taken for the 
measurement of the dissolved oxygen, when marked changes of the DO 
readings were already noticeable at 48 hours. These sampling times were not 
changed to an earlier time in order to have better graphical illustrations of the 
DO content within 48 hours storage in the containers, as the aim was more of 
looking at the total DO content over the one week storage as baseline 
information for clinical practice.
In experiment 2, the samples were stored for a longer duration at 4°C, and all 
the samples showed a high DO content compared to 0 hour. Upon exposure to 
25°C or 40°C, the DO content decreased, again signifying that the solubility of 
oxygen being dependent on temperature. Exposure to light did not have 
significant effect on the DO content. It is interesting to note that the DO 
content after storage for 7 days in the refrigerator from experiment 2 (Figure
3.5 and Figure 3.6) was much higher than from experiment 1 (Figure 3.1 and 
Figure 3.2). Possibilities are that in experiment 1, the containers were stored in 
the PSC whilst in experiment 2, they were stored in the pharmaceutical 
refrigerator which may result in the difference in DO content. Also, for 
experiment 2 , there was less opening of the refrigerator door during 
experimental duration compared to that of experiment 1 when samples had to 
be taken to be tested.
In both these experiments, there was minimal air headspace in the containers 
which would be of a consistent size as the capacities of the containers are the 
same throughout the experiments. Saline solutions in the Freeflex® bags are 
prepared by an automated process, whereby the bags are dosed with sterile 
filtered air before in-line filling of the bags with sterile filtered saline solutions 
(Freeflex® Technical Manual). Preparation of the saline solutions in glass 
containers have been discussed under 3.2.2.
In hospital practice, variable amounts of air can be introduced into PN 
formulations during compounding (Ball and Barnett 1996). The problem with
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oxidation is that it requires only a small amount of oxygen to initiate a chain 
reaction. Therefore, although it is helpful to keep the oxygen content of PN 
solutions at a minimum, it is not sufficient to prevent degradation from 
occurring. One method to obtain the minimum amount of free oxygen is to 
purge with inert gas such as nitrogen or helium. For plain water, Lachman et al 
(1986) recommended that it be first boiled and then purged with carbon dioxide 
or nitrogen gas.
Compounded PN bags may be wrapped with a gas-impermeable material, such 
as aluminium foil (Allwood et al. 1996). Another possible way to minimise 
oxygen transmission is by using low permeability multilayered bags (Balet et 
al. 2004), which are manufactured commercially. Parenteral preparations 
nowadays also have plastic overwraps to protect from moisture loss and some 
come with oxygen absorber sachets within the overwraps to minimise the 
amount of oxygen available to permeate the plastic bags. These commercial 
modalities improve the stability of the parenteral preparations and are 
increasingly used in PN formulations for hospital inpatients and for some home 
PN patients.
3.5. Conclusions
This study provides baseline information of DO content of normal saline in 
Freeflex® bags and glass bottles. The results confirm that the level of 
dissolved oxygen is dependent on temperature and that different types of 
packaging have different levels of permeability to air or oxygen. Therefore, 
when carrying out PN stability studies, monitoring the DO content of the 
formulations is essential to check on the effects of DO upon the stability of the 
vitamins.
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CHAPTER FOUR
STABILITY OF WATER-SOLUBLE VITAMINS UPON 
DIFFERENT STORAGE CONDITIONS
4.1. Introduction
It has been shown that standardised PN formulation made from ready mixed 
formulae can have considerable advantages for PN patients (Mansell et al. 
1989). These include a reduction in time and cost of preparation as well as ease 
of use by less experienced medical and pharmacy staff, thus reducing any 
potential errors. Thus, many pharmaceutical companies nowadays have 
introduced ready-made compartmentalized multichamber PN bags of longer 
shelf life, consisting of the three macronutrient solutions, which are glucose, 
amino acids and fats, with or without the electrolytes (Muhlebach 2005). These 
solutions can easily be mixed by opening the seals within the bag system. 
However, this PN bag is still incomplete because there are no vitamins and 
trace elements in the bag as these micronutrients limit the shelf life of the PN 
admixture.
In a hospital setting, these micronutrients are added to the bag shortly before 
use by trained staff, however for home patients, who may be on PN for life, 
this may pose some difficulties. Some vitamins need reconstitution before they 
can be added to the big bag, hence requiring a lot of manipulations by the home 
patients or their care-providers, besides having to add the vitamins to the bag 
themselves. Because of the potential market to home patients, a compounded 
micronutrient-based, vitamin minibag preparation is being looked into for 
possible development, where it can be infused together with the PN. In 
addition, this small volume minibag formulation would be an ideal ready-to- 
use product which does not require reconstitution or for the solution being 
drawn into a syringe, thus releasing home patients from making their own
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additions. Throughout this thesis, 100 ml 0.9% sodium chloride (normal saline) 
and Freeflex® plastic containers were used as the base system.
In this chapter, a water-soluble multivitamin infusion in Freeflex® plastic 
minibag was formulated and assessed for physico-chemical stability 
parameters. The formulation consists of Solivito® N Adult multivitamin 
injection, prepared in 0.9% sodium chloride in 100 ml Freeflex® plastic bags. 
The abbreviation SV is given to this test solution throughout this thesis.
The aims of the study were:
a) To examine the physical stability of the multivitamin solutions stored for 
one week at different temperature conditions over varying time intervals as 
well as to examine the effects when exposed to artificial lighting conditions 
that are equivalent to general ward light exposure.
b) To determine the chemical stability of pyridoxine (P), nicotinamide (N), 
thiamine (T), folic acid (FA) and riboflavin sodium phosphate (RSP) in the 
multivitamin solutions when stored as outlined in (a) above. These vitamins 
were selected for analysis based on their identification by HPLC in a single 
gradient run as described in Chapter Two.
4.2. Methods
4.2.1. Experimental Design
The bags were stored and subjected to storage conditions as outlined under 
Experiment 1 of Chapter Three.
4.2.2. Preparation of Test Solutions SV
Each vial of Solivito® N Adult injection was reconstituted with 10 ml of Water 
for Injections, an additional vial was reconstituted as overage to make
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allowance during transfer. These reconstituted solutions were then pooled to a 
250 ml EVA Freka® IV-Bag (Fresenius Kabi) in order to minimise dilution 
error. 10 ml reconstituted Solivito® N Adult solution was then syringed out 
and added to the 100 ml sterile 0.9% sodium chloride in Freeflex® minibag. 
This test solution is given the abbreviation SV throughout this thesis.
Two bags were prepared for each set of conditions, one bag was for HPLC 
analysis and another bag for physical analysis. Sample bags wrapped in 
aluminium foil acted as dark Freeflex® bags. Bags wrapped in aluminium foil 
unexposed to light acted as controls. In each case, triplicate samples were 
prepared for the set of conditions. Therefore, 12 bags of SV were prepared for 
storage condition at 4°C while 24 bags of SV were each prepared for the other 
storage conditions.
4.2.3. Sampling
For physical analysis, 25 ml samples were withdrawn from the minibags using 
sterile 21G needles and 20 ml syringes, and placed in the Hach® glass tubes 
and capped. With the needle detached from the syringe, care was taken to run 
the sample from the syringe down the side of the tube to minimise air 
introduction during handling. The glass tubes were only uncapped when 
performing the DO measurement where the probe was required to be immersed 
in the solution. Samples were tested at times 0, 24, 48 and 168 hours. The tests 
were performed in the following order: firstly, the physical appearance by 
visual inspections followed by nephelometry test, DO measurement and lastly 
pH measurement. Visual inspections were performed with the unaided eye and 
by using the fibreoptic lighting system. The test instruments and their 
principles and methods of operation have been described in Chapter Two.
For chemical analysis, 3 ml samples were withdrawn via the additive port 
using sterile 21G needles and 5 ml syringes at 0 hour immediately after 
preparation, then at 3, 6 , 24, 48, 72 and 168 hours and placed into two separate
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microcentrifuge tubes. Samples were stored in the pharmaceutical freezer at 
-80°C before analysis and analysed using a validated HPLC stability-indicating 
method as described in Chapter Two. The peak areas of all the samples at 0 
hour were averaged and the content analysis of these samples was regarded as 
the baseline content of 1 0 0 %.
4.3. Results
The following abbreviations are used to denote the type of containers and 
conditions for which the multivitamin solutions are stored. The numerals in 
parentheses denote the different temperature settings used for each group of 
experiment.
in clear Freeflex® minibags, stored at 4°C (or at
25°C/30°C/40°C)
in dark Freeflex® minibags, stored at 4°C (or at
25°C/30°C/40°C)
in clear Freeflex® minibags, stored at 25°C (or at
30°C/40°C), exposed to light
in dark Freeflex® minibags, stored at 25°C (or at
30°C/40°C), exposed to light
FF4 (25/30/40) 
FPL4 (25/30/40) 
FFW25 (30/40) 
FPLW25 (30/40)
4.3.1. Physical Analysis
4.3.1.1. Colour and Appearance
All solutions wrapped in aluminium foil and solutions in clear bags protected 
from light had no change in colour from the initial light yellow colour. When 
viewed with the fibreoptic light, the solutions had a light green haze 
appearance.
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Exposure of the clear bags to fluorescent white light turned the solutions to 
pale yellow, and upon increasing temperature, the haze became less intense at 
30°C and disappeared at 40°C.
4.3.1.2. Turbidity
The results of the turbidity measurement of SV solutions at different storage 
conditions are tabulated in Table 4.1.
Table 4.1: Mean turbidity measurement in NTU of SV at different storage 
conditions
Storage
condition
0 h (n=12) 24 h 48 h 168 h
FF4 5.10 ±0.26# 5.17 ±0.40 5.09 ±0.15 5.14 ± 0.18
FPL4 5.10 ±0.26# 5.21 ±0.37 5.15 ±0.31 5.16 ± 0.13
FF25 4.58 ± 0.45 4.51 ±0.47 4.56 ±0.43 4.68 ±0.14
FFW25 4.58 ± 0.45 4.47 ± 0.37 4.19 ±0.26 0.22 ±0.01 *
FPLW25 4.58 ± 0.45 4.50 ±0.54 4.46 ±0.57 4.65 ± 0.03
FPL25 4.58 ±0.45 4.54 ± 0.43 4.54 ±0.37 4.72 ±0.11
FF30 4.89 ±0.37 4.85 ± 0.04 4.89 ± 0.02 4.63 ± 0.03
FFW30 4.89 ±0.37 4.90 ±0.14 3.76 ±0.16 0.17 ±0.05 *
FPLW30 4.89 ±0.37 4.47 ± 0.64 4.38 ±0.60 4.05 ± 0.66 *
FPL30 4.89 ±0.37 4.98 ±0.13 4.89 ± 0.04 4.68 ± 0.04
FF40 5.01 ±0.07 4.81 ±0.11 4.65 ±0.15 4.08 ±0 .12*
FFW40 5.01 ±0.07 4.33 ± 0.02 2.30 ±0.97 0.17 ±0.01 *
FPLW40 5.01 ±0.07 4.88 ± 0.08 4.69 ±0.11 4.21 ±0.09*
FPL40 5.01 ±0.07 4.76 ± 0.02 4.62 ±0.06 4.03 ± 0.05 *
#: n=6
*: change in NTU of more than 0.5 units
The results showed that test solutions exposed to light and those stored at 40°C 
had NTU change of more than 0.5 units (marked with asterisks *).
4.3.1.3. Dissolved Oxygen
The mean DO measurements of SV solutions are tabulated in Table 4.2.
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Table 4. 2: Mean DO measurement (mg/1) of SV solutions at different storage 
conditions
Storage
condition
0h(n=12) 24 h 48 h 168 h
FF4 2.52 ± 1.56# 5.58 ±0.71 5.26 ± 1.27 5.37 ±0.58
FPL4 2.52 ± 1.56# 6.42 ±0.14 5.56 ± 1.02 5.55 ± 0.47
FF25 2.58 ± 1.05 3.19 ± 0.19 2.88 ±0.60 3.59 ±0.49
FFW25 2.58 ± 1.05 1.10 ± 0.12 2.06 ±0.81 6.12 ±0.23
FPLW25 2.58 ± 1.05 2.08 ± 0.75 1.98 ±0.99 3.85 ±0.32
FPL25 2.58 ± 1.05 3.3 ±0.30 3.22 ±0.53 3.99 ±0.59
FF30 2.25 ± 1.34 1.90 ± 1.11 2.36 ± 1.24 1.40 ± 1.70
FFW30 2.25 ± 1.34 1.10 ± 0.34 3.30 ± 0.11 6.37 ±0.07
FPLW30 2.25 ± 1.34 1.04 ±0.99 1.62 ± 1.68 1.56 ±2.08
FPL30 2.25 ± 1.34 2.30 ±0.80 3.07 ±0.33 1.61 ±2.14
FF40 2.87 ± 0.70 2.59 ±0.10 2.53 ± 1.07 3.84 ±0.55
FFW40 2.87 ±0.70 1.14 ± 0.10 4.56 ± 0.44 5.65 ±0.14
FPLW40 2.87 ±0.70 1.89 ±0.57 2.34 ± 1.09 4.30 ±0.16
FPL40 2.87 ±0.70 2.44 ±0.36 2.73 ± 1.07 4.30 ±0.12
#: n=6
The above results are illustrated by the following graphs from Figure 4.1 to 
Figure 4.4:
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Figure 4.1: DO content of SV in clear minibags stored at different temperatures
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Figure 4.2: DO content of SV in dark minibags stored at different temperatures
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Figure 4.3: DO content of SV in clear minibags exposed to artificial light and 
stored at different temperatures
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Figure 4.4: DO content of SV in dark minibags exposed to artificial light and 
stored at different temperatures
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4.3.I.4. pH
A pH change of less than 0.5 units was observed for solutions stored at 4°C 
(Table 4.3). All solutions at other temperatures had more than 0.5 units pH 
change at 168 hours storage duration, the most marked changes were when the 
solutions were not light protected.
Table 4.3: Mean pH of SV at different storage conditions.
Storage
condition
0h(n=12) 24 h 48 h 168 h
FF4 6.23 ± 0.05# 6.44 ± 0.06 6.30 ±0.14 6.37 ±0.20*
FPL4 6.23 ± 0.05# 6.32 ± 0.06 6.41 ±0.07 6.39 ±0.09*
FF25 6.32 ±0.17 6.14 ±0.08 5.91 ±0.04 5.34 ±0.08
FFW25 6.32 ±0.17 5.53 ±0.09 4.95 ± 0.09 4.10 ±0.04
FPLW25 6.32 ±0.17 6.18 ±0.07 5.82 ±0.06 5.08 ± 0.09
FPL25 6.32 ±0.17 6.23 ±0.01 6.03 ± 0.08 5.44 ±0.04
FF30 6.23 ± 0.09 5.56 ±0.47 4.51 ±0.04 4.17 ±0.03
FFW30 6.23 ± 0.09 4.90 ±0.14 3.76 ±0.16 0.17 ±0.05
FPLW30 6.23 ± 0.09 6.00 ±0.13 5.72 ±0.12 5.19 ± 0.09
FPL30 6.23 ± 0.09 6.11 ±0.02 5.84 ±0.07 5.45 ±0.04
FF40 6.31 ±0.14 5.75 ±0.08 5.69 ±0.08 5.06 ±0.11
FFW40 6.31 ±0.14 5.02 ±0.06 4.37 ±0.04 4.27 ± 0.06
FPLW40 6.31 ±0.14 5.75 ±0.11 5.55 ±0.12 4.90 ±0.10
FPL40 6.31 ±0.14 5.79 ± 0.14 5.65 ±0.06 5.11 ±0.10
#:n= 6
*: change in pH of less than 0.5 units 
The results are illustrated in Figure 4.5 to Figure 4.8.
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Figure 4.5: pH of SV in clear minibags at different storage temperatures
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Figure 4.6: pH of SV in dark minibags at different storage temperatures
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Figure 4.7: pH of SV in clear minibags stored at different temperatures and 
exposed to 0.7 klux/h light intensity
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Figure 4.8: pH of SV in dark minibags stored at different temperatures and 
exposed to 0.7 klux/h light intensity
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4.3.2. HPLC Analysis
The results of HPLC analysis of the water-soluble vitamins analysed are 
tabulated in Table 4.4 to Table 4.8 while the corresponding graphs are 
illustrated from Figure 4.9 to Figure 4.13.
4.3.2.1. Pyridoxine
Table 4.4: Percentage content of pyridoxine from 0 h in SV stored at different 
storage conditions
Storage
condition
Oh 3 h 6 h 24 h 48 h 72 h 168 h
PFF4 100
±0
101.65
±2.57
103.84
±4.28
101.69
±2.98
99.43
±2.88
99.59 
± 1.59
99.11
±2.72
PFPL4 100
±0
96.24
±4.33
104.23
±4.88
100.95
±4.55
101.24
±3.32
99.16
±4.74
98.54
±4.76
PFF25 100
± 0
99.53
±5.53
97.45
±2.32
97.25
±2.78
99.38
±3.07
95.47
±3.99
92.33
±3.83
PFPL25 100
± 0
101.15 
± 1.86
100.00
±6.47
98.41
±6.96
97.77
±4.87
97.04
±6.25
97.31
±5.63
PFFW25 100
± 0
97.29 
± 1.62
95.55 
± 1.88
95.80 
± 1.96
85.85
±2.58
82.27
±3.41
nd
nd
PFPLW25 100
±0
98.60
±2.15
97.02 
± 1.27
95.28
±2.02
94.67 
± 1.56
92.73
±3.13
90.88 
± 1.11
PFF30 100
±0
104.29
±4.32
100.62
±2.60
101.24
±4.68
100.32
±3.31
100.54
±4.29
96.91
±5.00
PFPL30 100
±0
100.34 
± 1.55
103.67
±0.31
97.27
±3.13
98.61
±3.12
100.51
±2.63
99.35
±2.05
PFFW30 100
±0
96.24
±4.42
100.43
±2.38
96.21
±2.55
87.81 
± 1.82
77.90
±4.93
nd
nd
PFPLW30 100
±0
97.86
±4.27
99.11
±4.45
99.02 
± 1.97
101.34
±3.93
95.76
±5.33
96.01
±2.25
PFF40 100
±0
95.89
±2.56
98.03
±0.46
94.05
±0.20
90.80 
± 1.28
88.55 
± 1.25
86.27
±2.29
PFPL40 100
±0
95.52
±2.65
97.56
±2.12
93.66 
± 1.29
91.24 
± 1.98
89.44 
± 1.11
88.90 
± 1.63
PFFW40 100
±0
99.21
±2.70
96.85
±0.43
92.50
±2.24
64.66
±2.78
nd
nd
nd
nd
PFPLW40 100
±0
97.69
±0.92
96.44
±2.33
93.05
±2.37
91.16 
± 1.51
89.60
±3.70
88.94 
± 1.25
nd: not detected
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Figure 4.9: Percentage content of pyridoxine in SV solutions upon different
storage conditions
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4 3 .2.2. Nicotinamide
Table 4.5: Percentage content of nicotinamide from 0 hour in SV upon different 
storage conditions
Storage
condition
Oh 3 h 6 h 24 h 48 h 72 h 168 h
NFF4 100
± 0
100.16 
± 1.36
100.82 
± 1.76
99.34
±0.92
98.06 
± 1.21
99.73
±0.72
99.94
±1.38
NFPL4 100
±0
97.46
±3.77
100.94 
± 1.52
100.64 
± 1.60
100.76 
± 1.46
99.48
±0.30
97.28
±3.34
NFF25 100
±0
96.33
±2.76
98.43 
± 1.08
98.75
±0.72
97.13
±2.80
98.71 
± 1.09
98.27
±0.68
NFPL25 100
± 0
101.83
±2.78
99.45
±4.90
98.92 
± 1.98
100.31 
± 1.99
101.08 
± 1.85
101.46
±2.03
NFFW25 100
± 0
100.37
±0.85
97.60
±4.04
100.38
±0.21
98.58 
± 1.09
99.29
±0.17
97.64
±2.51
NFPLW25 100
± 0
99.51
±0.56
99.43
±0.94
99.34
±0.50
99.37
±0.75
98.35
±0.47
98.74 
± 1.10
NFF30 100
± 0
104.06
±5.05
103.11
±0.65
107.08
±0.49
103.72
±4.31
103.74
±5.24
100.76
±2.93
NFPL30 100
±0
101.08
±2.29
100.06
±2.90
100.07
±3.13
100.84
±3.56
100.13
±3.92
102.27
±0.61
NFFW30 100
±0
99.80
±0.51
98.68
±2.60
97.94 
± 1.07
98.52
±0.67
99.20
±0.76
97.69 
± 1.20
NFPLW30 100
±0
101.53
±2.06
100.33
±0.92
101.11 
± 1.61
101.26 
± 1.30
98.03
±3.21
99.81
±0.81
NFF40 100
±0
97.39 
± 1.92
99.82
±2.49
100.99 
± 1.02
98.33
±2.50
97.41
±2.19
98.77 
± 1.67
NFPL40 100
±0
99.22
±0.73
97.16
±4.42
99.04
±0.84
98.58
±0.57
98.42
±0.88
98.37
±0.40
NFFW40 100
±0
99.18 
± 1.85
98.55 
± 1.72
99.68
±2.35
98.79
±2.57
99.84
±2.76
99.54
±2.57
NFPLW40 100
±0
98.88 
± 1.42
98.70 
± 1.94
99.90
±2.33
98.35 
± 1.96
99.76
±2.74
99.56
±2.58
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Figure 4.10: Percentage content of nicotinamide in SV solutions upon different 
storage conditions
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4.3.2.3. Thiamine
Table 4.6: Percentage content of thiamine from 0 h in SV upon different storage 
conditions
Storage
condition
Oh 3 h 6 h 24 h 48 h 72 h 168 h
TFF4 100
± 0
102.68
±3.08
105.30 
± 4.64
102.26
±2.28
100.91
±2.65
99.89
±2.18
100.11
±2.76
TFPL4 100
± 0
97.24
±2.48
104.94
±6.35
100.73
±4.29
102.59
±3.81
99.97
±8.05
99.35
±6.93
TFF25 100
± 0
95.83
±3.41
96.49 
± 1.19
95.85 
± 1.04
97.04 
± 1.08
94.73
±2.24
93.14
±2.43
TFPL25 100
± 0
100.14
±2.91
95.94 
± 1.05
98.68 
± 1.08
95.71
±2.48
95.54 
± 1.54
95.79
±2.08
TFFW25 100
± 0
97.91 
± 1.63
100.29 
± 1.12
97.16
±3.54
92.00 
± 1.88
89.77 
± 2.60
86.82
±2.49
TFPLW25 100
± 0
101.59
±2.10
98.49
±0.68
96.87
±2.27
98.37
±0.92
95.24
±3.50
94.59 
± 1.07
TFF30 100
±0
102.38
±4.09
102.31 
± 1.53
104.58
±2.71
99.49
±3.60
99.05
±4.93
98.17
±4.93
TFPL30 100
± 0
99.93
±2.53
99.81
±4.25
98.66
±2.94
98.23
±3.98
100.09
±7.08
100.73
±2.59
TFFW30 100
± 0
101.07 
± 1.45
99.47
±2.74
95.73 
± 1.74
93.03
±2.21
95.05
±5.13
90.78 
± 1.89
TFPLW30 100
± 0
102.50 
± 1.14
102.25
±3.32
103.08
±3.29
105.31
±2.57
95.50
±2.29
98.38
±2.67
TFF40 100
± 0
97.80 
± 1.38
101.24
±4.99
102.37
±7.65
97.15
±5.68
95.59
±5.48
91.53
±0.83
TFPL40 100
± 0
97.41
±0.92
95.42
±2.73
95.90
±0.65
95.84
±0.19
94.48
±3.16
93.89
±2.94
TFFW40 100
± 0
94.71
±1.66
93.67
±2.04
92.39
±0.44
91.92
±0.15
78.24
±2.80
80.80 
± 1.13
TFPLW40 100
±0
99.92
±0.83
101.38 
± 1.21
99.39 
± 1.27
96.97
±0.82
96.17 
± 1.56
95.38 
± 1.04
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Figure 4.11: Percentage content of thiamine in SV solutions upon different
storage conditions
4.3.2.4. Folic Acid
Table 4.7. Percentage content of folic acid from 0 h in SV upon different storage 
conditions
Storage
condition
Oh 3 h 6 h 24 h 48 h 72 h 168 h
FAFF4 100 98.52 97.25 97.57 100.57 97.98 100.17
0 ±4.00 ±2.62 ± 1.81 ± 1.21 ±3.89 ±2.37
FAFPL4 100 97.21 100.59 98.07 99.06 99.55 96.87
0 ±3.82 ±4.20 ±0.75 ±5.37 ±2.27 ±3.08
FAFF25 100 97.61 97.48 98.45 98.99 96.38 95.03
0 ±2.79 ± 1.46 ± 1.26 ±3.98 ±4.34 ±2.16
FAFPL25 100 99.79 96.42 96.61 95.00 93.66 93.37
0 ±2.46 ± 1.64 ± 1.64 ± 1.67 ±0.89 ± 1.71
FAFFW25 100 98.72 97.29 97.62 93.63 89.58 nd
0 ±3.45 ±3.79 ±6.17 ±2.95 ±3.23 nd
FAFPLW25 100 100.55 97.63 96.22 96.24 93.89 92.34
0 ±3.78 ± 1.28 ±3.99 ±3.16 ±2.25 ±0.39
FAFF30 100 101.77 95.83 100.12 101.72 101.60 92.70
0 ±4.40 ±8.89 ±7.57 ±4.81 ±6.40 ±2.27
FAFPL30 100 100.83 100.72 98.36 98.97 97.56 95.87
0 ±2.05 ±4.94 ±3.38 ±4.16 ±4.22 ±4.79
FAFFW30 100 99.17 97.96 95.85 91.74 nd nd
0 ±2.14 ±4.12 ± 1.98 ± 1.80 nd nd
FAFPLW30 100 101.34 99.90 99.91 101.62 96.80 92.29
0 ± 1.23 ±2.16 ±2.74 ±0.19 ±2.48 ± 1.70
FAFF40 100 96.85 99.93 97.54 95.58 93.50 90.31
0 ± 1.88 ±0.11 ±0.63 ± 1.75 ±0.81 ± 1.11
FAFPL40 100 98.04 96.16 95.93 94.69 94.54 91.61
0 ±3.05 ±2.07 ±2.26 ±2.86 ±5.19 ± 4.64
FAFFW40 100 98.26 98.19 93.29 nd nd nd
0 ±2.91 ±3.22 ±3.56 nd nd nd
FAFPLW40 100 98.71 98.37 97.22 94.39 93.44 87.78
0 ±0.79 ± 1.55 ± 1.39 ± 1.86 ± 1.66 ±2.36
nd: not detected
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Figure 4.12: Percentage content of folic acid in SV solutions upon different
storage conditions
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4.3.2.5. Riboflavin Sodium Phosphate
Table 4.8: Percentage content of riboflavin sodium phosphate from 0 h in SV 
upon different storage conditions
Storage
condition
Oh 3 h 6 h 24 h 48 h 72 h 168 h
RSPFF4 100 102.24 102.71 100.44 99.56 100.32 98.35
0 ±3.95 ±5.21 ±4.69 ±3.68 ±4.07 ±2.72
RSPFPL4 100 101.43 102.34 99.63 99.39 97.05 96.31
0 ±3.17 ±3.94 ±3.77 ±2.76 ± 1.36 ± 1.41
RSPFF25 100 97.89 97.23 98.10 97.19 96.98 94.30
0 ±3.67 ±3.27 ±0.88 ±0.89 ± 1.24 ± 1.68
RSPFPL25 100 97.65 99.28 99.63 98.63 99.85 100.25
0 ±4.62 ±5.32 ±4.13 ±3.25 ±3.57 ±2.72
RSPFFW25 100 96.48 92.48 87.29 65.33 37.37 nd
0 ±3.40 ±4.66 ± 1.89 ±3.11 ± 1.08 nd
RSPFPL25 100 97.65 99.28 99.63 98.63 99.85 100.25
0 ±4.62 ±5.32 ±4.13 ±3.25 ±3.57 ±2.72
RSPFPLW25 100 99.48 97.61 95.88 94.70 93.09 88.99
0 ±0.42 ±0.55 ±2.41 ± 1.33 ±2.97 ±2.51
RSPFF30 100 101.18 99.53 100.73 97.51 95.74 92.03
0 ±5.23 ±4.75 ±6.88 ±5.80 ±6.34 ±3.61
RSPFPL30 100 100.53 98.98 97.46 96.54 94.89 93.67
0 ±2.64 ±3.46 ±4.41 ±4.58 ±4.28 ±2.15
RSPFFW30 100 95.13 91.22 71.66 49.32 12.85 nd
0 ±0.90 ± 1.22 ±0.79 ± 1.60 ± 1.54 nd
RSPFPLW30 100 100.96 100.27 98.40 97.70 93.68 90.34
0 ±2.02 ± 1.16 ± 1.07 ± 1.62 ±4.21 ±0.15
RSPFF40 100 96.63 98.53 94.57 90.83 88.50 84.84
0 ±2.47 ±0.45 ±0.08 ± 1.38 ± 1.13 ± 1.83
RSPFPL40 100 96.83 98.40 93.80 91.26 87.78 85.38
0 ± 1.40 ±2.25 ±0.50 ± 1.09 ± 1.86 ± 1.37
RSPFFW40 100 92.52 86.80 62.29 15.73 nd nd
0 ±3.15 ±3.00 ±4.83 ±0.31 nd nd
RSPFPLW40 100 97.14 95.98 94.78 91.79 87.26 85.62
0 ±0.68 ±0.46 ±3.75 ±2.74 ±2.37 ±3.15
nd: not detected
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Figure 4.13: Percentage content of riboflavin sodium phosphate in SV solutions
upon different storage conditions
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4.3.3. Summary of Results of HPLC Analysis
The summary of the vitamins analysed in SV solutions is shown in Table 4.9.
Table 4.9: Stability duration (hours) of the vitamins (more than 90% remaining) 
upon different storage conditions
Storage
condition
Temperature P N T FA RSP
FF4 4°C 168 168 168 168 168
FPL4 4°C 168 168 168 168 168
FF25 25°C 168 168 168 168 168
FPL25 25°C 168 168 168 168 168
FFW25 25°C 24 168 72 72 6
FPLW25 25°C 168 168 168 168 168
FF30 30°C 168 168 168 168 168
FPL30 30°C 168 168 168 168 168
FFW30 30°C 24 168 168 48 6
FPLW30 30°C 168 168 168 168 168
FF40 40°C 48 168 168 168 48
FPL40 40°C 48 168 168 168 48
FFW40 40°C 24 168 48 24 3
FPLW40 40°C 48 168 168 72 48
4.4. Discussion
Exposure of the sample solutions to 25°C with 60% relative humidity would 
provide a similar test condition to Zone I and II of the ICH Stability Guideline 
(ICH Steering Committee 2003a), which includes countries like United 
Kingdom and the European countries. In addition, 25°C is also regarded as the 
normal room temperature. Exposing solutions to 30°C would provide a similar 
test condition for tropical climates, including countries like Malaysia (ICH 
Steering Committee 2003b). The vitamin solution was also tested at the 
extreme temperature of 40°C, this temperature being chosen to make 
allowances for preparations that are to be administered to infants and preterm 
infants who are placed in incubators. For solutions exposed to light, light
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intensity was set at 0.7 klux. This is equivalent to office and hospital ward 
lightings that have specifications of around 0.5 klux (Baker et al. 1993).
The multivitamin solution SV showed maximum stability when stored at 4°C, 
where physical tests showed no obvious colour change and minimum change in 
pH and turbidity, and chemical analysis of all vitamins tested showed 
negligible loss of the vitamins.
Turbidity measurement showed that there was no obvious NTU change over 
time when stored at 4°C, but the NTU readings decreased over time at higher 
temperatures. In the presence of light, the difference in NTU from 0 hour was 
more than 0.5 units. Generally, NTU measurement should not be more than 0.5 
units in range from its initial value as this could indicate solution 
incompatibility (Trissel and Bready 1992), however, the 0.5 units in range is 
for an increase in NTU. On the contrary, in this case, the turbidity of SV 
solutions showed decreased NTU instead of an increase, therefore the NTU 
readings of the SV solutions are acceptable. SV solution is from lyophilised 
powder of Solivito® N Adult injection. The fact that NTU decreased over time 
and that the decrease is greater at higher temperatures in the presence of light 
may indicate that the lyophilised powder solubilises over time, and temperature 
and light aid with the solubilisation.
The DO measurement showed similar trends as has been discussed in Chapter 
Three with increased DO content at lower temperature. The DO contents of 
this study and that of Chapter Three however, were different as the solvent 
systems for DO content measurements were different. In Chapter Three, 
measurement was in the normal saline base vehicle while in this Chapter, DO 
measurement was in water-soluble SV vitamin solution. As pointed out in 
Chapter Three, the solubility of oxygen is also dependent on the type of solvent 
used.
101
As for pH, with the exception of storage at 4°C which showed negligible pH 
change, there was more than 0.5 units of pH difference from 0 hour at other 
conditions and was towards a decrease. The pH difference of 0.5 units is the 
generally accepted marker of physical instability by the present laboratory 
research group. Tests of the pH of the individual vitamin components were not 
carried out, but the possible decrease in pH value could be due to the 
degradation of the vitamin components, such as ascorbic acid and folic acid, to 
more acidic degradation products. It is interesting to note that with multiple 
vitamins present in the test solution, pH test alone is not a good marker of 
instability as can be seen from the results of the chemical stability of the 
individual vitamins still remaining stable.
From the HPLC analysis, as the solution was exposed to higher temperature, 
different stability profiles of the vitamins were noted. At 25°C and 30°C (see 
Table 4.9, FF25/30/40), the vitamins remained stable, with less than 10% 
potency loss, however at 40°C, thiamine, nicotinamide and folic acid were 
stable but the stability duration of pyridoxine and riboflavin sodium phosphate 
was reduced to 48 hours.
From the results (see 4.3.3), in general it can be seen that nicotinamide is the 
most stable of all the five vitamins tested. Nicotinamide showed stability over 
the range of conditions tested, which is to be expected as nicotinamide is not 
heat labile nor light sensitive. Overall, these results are comparable to 
referenced data on the individual vitamins (DeRitter 1982) and to an earlier 
study by Dahl et.al (1986) who studied the stability of Soluvit® N vitamins up 
to 96 h storage at 2-8°C but in a different container.
Pyridoxine was stable for 168 hours at 25°C and 30°C when light protected but 
the stability was reduced to 24 hours when exposed to the artificial fluorescent 
light. Riboflavin sodium phosphate too was stable at 25°C and 30°C when light 
protected but the stability was reduced to 6  hours when exposed to artificial 
fluorescent light. Chen et al. (1983) reported pyridoxine and riboflavin sodium
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phosphate as stable under fluorescent light, as their study was conducted over 8 
hours duration. So far, no vitamin studies have been carried out over 168 hours 
for conditions exposed to artificial fluorescent light.
Thiamine stability was also comparable to the study conducted by Baumgartner 
and colleagues (Baumgartner et al. 1997), where they found no significant 
degradation of thiamine in PN salt solution containing neither carbohydrates 
nor amino acids, stored at either room temperature (25°C) or refrigerated (4°C). 
A study by Allwood (1982b) also reported thiamine to be stable under 
refrigeration for up to 28 days. It must be stressed that if the solution contained 
sulphites, then thiamine stability may be compromised as shown by studies 
performed by many investigators (Bowman and Nguyen 1983; Kearney et al. 
1995; Scheiner et al. 1981). However, amino acid solutions in the European 
market contain no sulphites.
According to Baumgartner and colleagues (Baumgartner et al. 1997) too, their 
study showed that thiamine, as a component of multivitamin, degraded faster in 
aqueous PN solution with less than 90% thiamine available when stored at 
25°C. They attributed the thiamine loss to either direct or indirect interaction 
with either the amino acids and/or carbohydrates used, as well as with one or 
more of the other vitamins. In their study, a different multivitamin product and 
a different plastic bag container were used when compared to this study.
For folic acid, studies conducted by Barker et al. (1984) revealed that the 
stability of folic acid depended on pH. If the pH is greater than 5.0, then folic 
acid remains in solution. Thus, they found folic acid to be stable for at least 2 
weeks in amino acid solutions but not in glucose solutions which have a low 
pH. In this study, the pH of SV vitamin solution is greater than 5.0, hence folic 
acid is found to be stable in the normal saline solution.
When SV solutions are, in addition, exposed to artificial fluorescent white 
light, the stability of the solutions is greatly reduced. Notable changes in colour
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of the solutions from light yellow to pale yellow were observed, and the light 
green haze appearance became less intense when light exposed at 30°C and 
40°C. Chemical analysis confirmed the decrease in stability of some vitamins. 
At 25°C and exposed to light, the stability of pyridoxine, folic acid and 
riboflavin sodium phosphate was reduced from 168 hours to 24 hours, 72 hours 
and 6  hours, respectively. At 30°C, the stability of folic acid was reduced to 48 
hours and riboflavin sodium phosphate was reduced to 6  hours, and at 40°C, 
the stability of riboflavin sodium phosphate was further reduced to 3 hours.
It has been pointed out that vitamins are less sensitive to artificial light as 
compared to ultraviolet light. However, this study has shown that loss of 
vitamins does occur even when exposed to continuous artificial light. Most 
stability studies from the effects of artificial light exposure carried out were 
only for a duration of between 8 to 24 hours (Chen et al. 1983), but in this case, 
the solutions were subjected to continuous exposure to fluorescent white light 
for up to 168 hours. Therefore when exposed for a longer duration to 
fluorescent white light, there is a potential for vitamins to degrade. Besides, 
there is also the possibility that difference in light intensity, and wavelengths 
absorbed, may affect the degradation of the vitamins differently, as studied by 
Ahmad et al. (2006) on the effects of riboflavin.
4.5. Conclusions
All the water-soluble vitamins analysed were stable at 4°C throughout the 168 
hours study duration. Nicotinamide was found to be the most stable of all the 
vitamins tested. If the water-soluble SV vitamin solution is to be kept at 25°C, 
it is best to protect the solution from light where stability is maintained for up 
to 168 hours. Vitamin loss is least when the solutions are stored in the 
refrigerator and light protected.
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CHAPTER FIVE
STABILITY STUDY OF FAT-SOLUBLE VITAMINS 
SUBJECTED TO VARIOUS STORAGE CONDITIONS
5.1. Introduction
Similar to Chapter Four, the stability of a fat-soluble multivitamin infusion
upon different storage conditions was tested. This study evaluates the stability 
of Vitlipid® N Adult vitamin injection, prepared in 0.9% sodium chloride in 
100ml Freeflex® minibags. The abbreviation VL is given to this test emulsion 
throughout this thesis.
The physical stability of the emulsion was assessed and the chemical stability 
of Vitamin A (retinol palmitate) and Vitamin E (tocopherol) was examined, the 
HPLC method has been described in Chapter Two.
5.2. Methods
The experimental set-up was similar to the study as described under 
Experiment 1 of Chapter Three.
5.2.1. Preparation of Test Solutions VL
Each ampoule of Vitlipid® N Adult injection was pooled into a 250 ml EVA 
Freka® IV-Bag (Fresenius Kabi), with an extra ampoule added as excess 
allowance. 10 ml of this Vitlipid® N Adult injection was then added to 100 ml 
sterile 0.9% sodium chloride in Freeflex® minibags.
Different bags were prepared for physical analysis and for HPLC analysis 
respectively, as outlined in Chapter Four.
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5.2.2. Sampling
For physical analysis, samples were tested at times 0, 24, 48 and 168 hours. 
Using sterile 20 ml syringes and 21G needles, 20 ml samples were withdrawn 
from the minibags via the additive port. The needles were then detached from 
the syringes and the samples were collected into Hach® glass tubes, running 
the samples down the side of the tubes, and then capped immediately. These 
samples were for visual inspection, and to test the DO content and pH. Another 
set of 5 ml samples were withdrawn for particle size analysis and for 
examination by light microscopy. This amount was determined by conducting 
preliminary trials which showed that about 3 ml of sample emulsion was 
required for the particle size analysis by laser diffraction. These methods for 
determining physical stability have been described under Chapter Two.
For chemical analysis, 3 ml samples were withdrawn using sterile 21G needles 
and 5 ml syringes at 0 hour immediately after preparation and split into two 
separate 2 ml amber autosampler vials, then at 3, 6 , 24, 48, 72 and 168 hours. 
Samples were then stored in the pharmaceutical refrigerator at 4°C before 
analysis and analysed within 3 days using a validated HPLC stability- 
indicating method as described in Chapter Two. A fresh sample prepared in a 
100 ml glass bottle was also prepared and analysed as reference. Samples taken 
at 168 hours were also analysed against the freshly prepared reference sample. 
Adjustments were made in relation to the fresh reference peaks. Content 
analysis of these samples at 0  hour was regarded as the baseline content of 
100%.
5.3. Results
The abbreviations used to denote the type of containers and conditions for 
storage of the multivitamin emulsions are the same as those used in Chapter 
Four.
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5.3.1. Physical Analysis
5.3.1.1. Colour and Appearance
All emulsions showed no change in colour from the initial white colour for all 
storage conditions. There seemed to be no separation of the oily phase in all 
emulsions, except for the samples stored at 40°C for 168 h, which seemed to 
have an oily streak along the side of the Hach® tube. No other changes were 
observed even when viewed with the fibreoptic light.
5.3.1.2. Dissolved Oxygen
The results of DO content of the sample emulsions are tabulated in Table 5.1 
with the corresponding graphs illustrated in Figure 5.1 to Figure 5.4.
Table 5.1: Mean DO measurement in mg/1 of VL emulsions at different storage 
conditions
VL 0 h fn=12) 24 h 48 h 168 h
FF4 5.46 ±0.16# 6.91 ±0.19 6.94 ±0.15 7.01 ±0.22
FPL4 5.46 ±0.16# 7.02 ±0.17 7.06 ±0.07 6.94 ± 0.08
FF25 5.26 ±0.33 5.01 ±0.11 4.90 ±0.13 4.78 ±0.38
FFW25 5.26 ±0.33 5.06 ± 0.09 4.98 ± 0.23 4.76 ±0.13
FPLW25 5.26 ±0.33 4.99 ± 0.40 4.46 ± 0.09 4.80 ± 0.24
FPL25 5.26 ±0.33 4.95 ±0.13 5.16 ±0.23 5.12 ± 0.15
FF30 4.73 ± 0.32 4.88 ±0.11 4.58 ±0.13 4.42 ±0.38
FFW30 4.73 ± 0.32 4.65 ± 0.23 4.38 ±0.19 4.39 ±0.36
FPLW30 4.73 ± 0.32 4.68 ± 0.24 4.70 ±0.18 4.34 ±0.30
FPL30 4.73 ± 0.32 4.08 ± 0.04 4.03 ±0.19 3.09 ±0.30
FF40 4.68 ±0.18 3.94 ±0.21 3.57 ±0.04 3.87 ±0.23
FFW40 4.68 ±0.18 3.83 ±0.05 3.65 ±0.06 4.06 ±0.28
FPLW40 4.68 ±0.18 3.87 ±0.08 3.74 ±0.26 3.99 ±0.02
FPL40 4.68 ±0.18 2.99 ±0.11 2.52 ±0.27 2.74 ± 0.03
# : n= 6
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Figure 5.1: Mean DO content of VL in clear minibags at different storage 
conditions
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Figure 5.2: Mean DO content of VL in clear minibags at different storage 
conditions and exposed to light
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Figure 5.3: Mean DO content of VL in dark minibags at different storage
conditions
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Figure 5.4: Mean DO content of VL in dark minibags at different storage 
conditions and exposed to light
Figures 5.1 and 5.3 show that the DO content increased with lower temperature 
and decreased as the temperature increased, whilst Figure 5.2 and Figure 5.4 
show that exposure to light did not have significant difference in the DO 
content between the clear and dark minibags.
5.3.I.3. pH
The results of mean pH are tabulated in Table 5.2.
Table 5.2: Mean pH of VL at different storage conditions
VL 0 h (n=12) 24 h 48 h 168 h
FF4 7.17 ± 0 .0 8 # 7.08 ± 0.06 7.11 ±0.06 6.83 ± 0.05
FPL4 7.17 ± 0 .0 8 # 7.13 ±0.04 7.14 ±0.02 6.84 ± 0.03
FF25 7.15 ±0.05 7.05 ± 0.03 7.02 ± 0.03 6.74 ± 0.04
FFW25 7.15 ±0.05 7.01 ±0.04 6.90 ± 0.04 6.71 ±0.05
FPLW25 7.15 ±0.05 7.04 ±0.01 7.00 ±0.01 6.72 ± 0.04
FPL25 7.15 ±0.05 7.04 ± 0.02 7.01 ±0.04 6.75 ± 0.07
FF30 7.07 ±0.05 7.05 ± 0.07 6.98 ± 0.03 6.70 ±0.07
FFW30 7.07 ± 0.05 7.04 ± 0.04 6.92 ± 0.02 6.64 ± 0.05
FPLW30 7.07 ± 0.05 7.03 ± 0.03 6.93 ± 0.02 6.74 ± 0.02
FPL30 7.07 ± 0.05 7.10 ±0.03 6.96 ±0.03 6.75 ± 0.03
FF40 6.97 ± 0.05 6.92 ± 0.06 6.89 ±0.06 6.41 ± 0 .1 6 *
FFW40 6.97 ± 0.05 6.93 ± 0.04 6.84 ±0.03 6.28 ± 0.08 *
FPLW40 6.97 ±0.05 6.96 ±0.01 6.91 ±0.03 6.54 ±0.06
FPL40 6.97 ± 0.05 6.98 ± 0.00 6.91 ±0.01 6.54 ± 0.05
#: n= 6
*: change in pH of more than 0.5 units
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Changes in pH o f more than 0.5 units (marked with asterisks) were noted with 
the clear samples stored at 40°C. The most marked changes were when the 
sample emulsions in the clear bags were also exposed to light.
5.3.I.4. Laser Diffraction
A typical plot from Malvern Mastersizer is as shown in Figure 5.5.
Result: Analysis Table
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A nalysed: 21/4/2005 14:30PM 
Source: Analy sed
Range: 45 mm 
Presentation: 2-SOYA 
Modifications: None
Beam : 2 .40  mm Sampler. MS1 
Analysis: Polydisperse
Obs': 2 0 .0 %  
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Density = 1.000 g/cm A3 
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D(v, 0.9) = 0.59 urn
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Figure 5.5: Typical laser diffraction graph of VL by Malvern® Mastersizer
In the Malvern® analysis table, D[4,3] is the volume mean, D[3,2] is the 
surface area mean while D(u,0.5) is the volume median diameter or the mean 
diameter at 50% volume distribution. D[4,3] is the mean diameter chosen in the 
analysis of the sample emulsions as this volume mean has good reproducibility
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and a narrow margin of error for determining particle size (Malvern 
Application Note).
At 0 hour, all samples had maximum diameter of less than 4.30 pm with D[4,3] 
of between 0.35 to 0.37 pm. The results remained the same at 168 hours with 
the exception o f samples that were exposed to temperature at 40°C.
At 168 hours, samples stored at 40°C had maximum diameter of more than 
12.21 pm with the percentages o f lipid globules with a diameter of greater than 
4.30 pm ranging from 0.14 to 10.12%. The D[4,3] of these samples also 
increased with results ranging from 0.52 pm to 1.60 pm.
5.3.1.5. Light Microscopy
At 0 hour, occasional samples contained lipid globules size of 5 pm, but 
always with less than 5 globules of 5 pm size within the calibrated grid. A 
typical picture o f lipid globules at 0 hour as seen under the microscope is 
shown in Figure 5.6.
Figure 5.6: Typical picture of lipid globules in VL. Magnification 200 times
When exposed to higher temperatures at 30°C and 40°C, a greater number of 5 
pm size lipid globules (range 7-25) was noted at 168 hours. In addition, larger 
lipid globules from 7.5 pm to 12.5 pm in size were identified, with some 
smaller globules tending to aggregate around the larger lipid globules.
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5.3.2. HPLC Analysis
The results of Vitamin A and Vitamin E analysed by HPLC are tabulated in 
Table 5.3 and Table 5.4 respectively, and the corresponding graphs at different 
temperature conditions are shown in Figure 5.7 and Figure 5.8.
5.3.2.I. Vitamin A
Table 5.3: Percentage content of Vitamin A in VL from 0 hour upon different 
storage conditions
Storage
condition
Oh
(*=12)
3 h 6 h 24 h 48 h 72 h 168 h
FF4 100#
± 0
103.94
±0.44
104.67
±0.81
106.80
±0.71
107.31 
± 1.02
109.97
±0.72
114.54
±4.02
FPL4 100#
± 0
104.45 
± 1.39
104.81
±2.03
106.49 
± 1.92
107.21 
± 1.69
109.37 
± 1.60
115.36
±3.94
FF25 100
± 0
99.92
±3.23
98.52
±2.69
98.99 
± 1.58
99.99
±0.42
101.55 
± 1.51
95.03
±2.22
FPL25 100
± 0
100.19
±0.55
98.62 
± 1.22
97.06
±0.52
98.94 
± 1.11
100.69 
± 1.68
93.14
±0.54
FFW25 100
± 0
99.50
±2.06
99.48 
± 1.10
93.23
±0.63
81.42 
± 1.47
80.28
±0.93
55.84 
± 1.63
FPLW25 100
± 0
101.19 
± 1.57
100.72
±3.81
98.91
±3.26
97.45
±2.99
101.51
±2.24
92.70 
± 1.40
FF30 100
± 0
98.45 
± 1.50
98.67 
± 1.21
97.73
±0.42
101.11
±1.05
106.35 
± 1.15
72.63
±3.40
FPL30 100
± 0
96.33
±0.94
98.14 
± 1.35
96.57 
± 1.32
103.73
±0.68
106.61
±0.91
73.19 
± 1.07
FFW30 100
± 0
94.71
±0.68
95.58 
± 1.03
88.41
±0.42
84.74
±0.63
80.58
±0.36
40.06
±0.87
FPLW30 100
± 0
97.50 
± 1.19
99.09 
± 1.26
97.82
±0.40
103.48
±0.26
106.68
±2.72
74.51 
± 1.46
FF40 100
± 0
98.86 
± 1.25
96.72 
± 1.21
95.52
±0.68
94.63
±0.86
92.57
±0.80
77.83
±0.53
FPL40 100
0
98.43
±0.63
96.65 
± 1.16
96.09
±0.53
94.25
±0.90
92.02
±0.88
77.70
±0.48
FFW40 100
0
96.48
±0.56
92.98
±0.77
84.86
±2.55
74.90
±3.47
66.04
±5.23
34.28
±7.86
FPLW40 100
0
99.04
±0.95
96.11
±0.55
95.88
±0.53
94.25
±0.78
92.53
±0.78
75.90 
± 1.91
#: n= 6
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Figure 5.7: Percentage content of Vitamin A upon different storage conditions
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5 3 .2.2. Vitamin E
Table 5.4: Percentage content of Vitamin E in VL from 0 hour upon different 
storage conditions
Storage
condition
Oh
(n=12)
3 h 6 h 24 h 48 h 72 h 168 h
FF4 100#
± 0
104.99
±0.69
106.05
±0.65
109.18 
± 1.78
110.29
±0.40
112.70 
± 1.12
116.72
±4.34
FPL4 100#
± 0
106.16 
± 1.24
105.92
±2.29
107.84 
± 1.35
110.69
±0.99
110.76 
± 1.85
117.22
±3.27
FF25 100
± 0
105.09
±2.53
100.41
±2.54
101.58
±3.31
101.59 
± 1.74
100.38
±5.59
96.25
±0.98
FPL25 100
± 0
105.08
±2.42
103.48
±2.06
100.31 
± 1.03
100.74
±2.05
97.44
±5.27
98.35
±0.82
FFW25 100
± 0
103.98
±2.72
105.69 
± 1.87
102.39
±4.42
96.29
±5.72
97.84
±4.56
87.00 
± 1.01
FPLW25 100
± 0
105.98 
± 1.84
107.72 
± 1.61
103.87
±2.55
99.99
±7.40
93.47
±0.31
93.23
±4.66
FF30 100
± 0
100.78
±2.41
103.37 
± 1.39
101.37 
± 1.83
105.55
±4.86
102.13
±4.20
73.08
±5.32
FPL30 100
± 0
98.14 
± 1.29
105.07 
± 1.50
99.55 
± 1.44
103.39
±0.87
100.34 
± 1.16
73.00
±2.79
FFW30 100
± 0
97.05
±0.21
102.28 
± 1.36
96.80
±0.30
100.33
±0.22
98.75 
± 1.70
58.14
±2.08
FPLW30 100
± 0
102.52
±2.14
103.78 
± 1.14
100.22
±0.29
104.58
±0.76
105.42
±2.09
74.26 
± 1.52
FF40 100
0
97.07 
± 1.27
96.36 
± 1.17
96.65
±0.88
94.13 
± 1.58
89.00
±0.57
74.03 
± 1.14
FPL40 100
0
99.39
±0.91
95.58 
± 1.07
97.31 
± 0.66
91.81
±2.21
88.16
±0.70
73.72
±0.28
FFW40 100
0
97.45 
± 1.64
92.69 
± 1.98
90.99
±0.27
89.67 
± 1.12
83.02
±0.02
55.79
±0.55
FPLW40 100
0
99.47 
± 0.26
97.69 
± 1.22
92.73
±0.40
92.87 
± 1.16
87.73
±0.66
71.09
±2.68
#: n= 6
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Figure 5.8: Percentage content of Vitamin E upon different storage conditions
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Vitamin A and Vitamin E remained stable when stored at 4°C throughout the 
seven days storage duration. At 25°C storage, both vitamins were stable when 
light-protected, however, Vitamin A stability was reduced to 24 hours when 
the minibags were exposed to artificial light. In addition, when stored at 30°C 
and 40°C with light exposure, Vitamin A stability was reduced to 6  hours. On 
the other hand, Vitamin E was stable for 72 hours at 30°C and for 48 hours at 
40°C, either with or without light exposure.
5.3.3. Summary of the Stability of Fat-soluble Vitamins Analysed
The summary of the vitamins analysed in VL emulsions is summarised in 
Table 5.5.
Table 5.5: Stability duration (hours) of Vitamin A and Vitamin £  (more than 
90% remaining) upon different storage conditions
Storage
condition
Temperature Vitamin A Vitamin E
FF4 4°C 168 168
FPL4 4°C 168 168
FF25 25°C 168 168
FPL25 25°C 168 168
FFW25 25°C 24 72
FPLW25 25°C 168 168
FF30 30°C 72 72
FPL30 30°C 72 72
FFW30 30°C 6 72
FPLW30 30°C 72 72
FF40 40°C 72 48
FPL40 40°C 72 48
FFW40 40°C 6 48
FPLW40 40°C 72 48
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5.4. Discussion
Vitlipid® N injection is recommended by the supplier to be added to a fat 
emulsion before infusion. The stability of these vitamins in lipid based 
emulsions or in ‘all-in-one’ PN admixture has been previously studied. In this 
case however, the stability of the fat-soluble vitamins in an aqueous based 
formulation using a normal saline diluent was studied.
The formulation was found to be homogenous upon mixing. The emulsifying 
agent present in Vitlipid® N injection formulation is egg phospholipids, which 
has been proven to be a good emulsifying agent for intravenous emulsions 
since it possesses both hydrophilic and hydrophobic molecules which orient at 
the oil-water interface. As a result, phospholipids also confer stability by 
creating electrostatic repulsive forces in the hydrophilic portion. Lipid 
emulsions have a surface potential of about -35 mV (Brown et al. 1986), the 
greater the surface potential or zeta potential of the oil globule, the more 
effective is the emulsion system in preventing coalescence. Mixing of lipid 
emulsions with electrolytes may reduce the zeta potential due to ion 
interactions and thereby causing emulsion instability. The dilution with normal 
saline in these experiments showed a homogenous emulsion and did not result 
in phase separation.
A number of methods can be used to determine the physical stability of fat 
emulsions (Driscoll et al. 2001; Washington 1990). These include particle 
sizing techniques such as laser diffraction, optical microscopy and visual 
inspection.
Particle size measurement of oil globules is one of the requirements of the BP 
1980, whereby it states that the diameter should not exceed 5 pm. 5 pm is taken 
as the upper limit since larger particles may pose a risk of lung embolism. In 
the later editions of the BP, this requirement has been removed, when new 
perception of the behaviour of lipid globules in vivo was presented, such as the 
reversible nature of the blockade since the lipid globules are biodegradable,
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and that a globule with a diameter of even greater than 7.5 pm can deform and 
pass through the pulmonary capillaries without difficulty (Koster et al. 1996). 
Nevertheless, particle size testing of lipid globules continues as a physical 
marker of emulsion stability. Driscoll et al (1995) showed that emulsions in 
which greater than 0.4% of the lipid globules are above 5 pm are likely to 
become unstable. Recently, the USP has proposed a standard for testing lipid 
emulsion where the volume-weighted percentage of the lipid globule size 
greater than 5 pm (PFAT5) is to be limited to less than 0.05% (Driscoll 2005). 
Studies on animals have shown that the infusion of unstable lipid emulsions 
having PFAT5 greater than 5 pm may have pathological consequences such as 
injury to the liver and lungs as a result of abnormal deposition of lipid globules 
causing oxidative stress and reduced blood flow from embolised lipid globules 
(Driscoll et al. 2006; Driscoll et al. 2005).
The results o f particle size measurement by laser diffraction indicated that 
there was destability of the emulsions at 40°C after 168 hours storage, with the 
emulsions having lipid globules of diameter greater than 4.30 pm to be more 
than 0.14%. In addition, when viewed under the light microscope, larger lipid 
globules of more than 7.5 pm diameter were noted, with smaller globules 
tending to aggregate around the larger lipid globules.
When the emulsions were exposed to higher temperature of 40°C, with visual 
inspection, it was difficult to detect any sign of creaming or phase separation 
such as an oil layer in the minibags as they were handled when taking them out 
from the stability chamber, thus they had been subjected to agitation, which 
could have redispersed the phases. This was despite the fact that they were 
handled with care. A trace of oil on the Hach® tubes for 40°C storage at the 
end of the study was noted whilst washing the tubes. There is a possibility too 
that while withdrawing the sample with a syringe and needle, shearing of the 
sample could occur (Washington 1990), thus causing coalescence although this 
was not detected by laser diffraction.
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The DO content again showed similar trend to Chapter Three and Chapter Four 
with respect to temperature, and the DO content at 0 hour was different from 
Chapter Three or Chapter Four since DO measurement was carried out in a 
different solvent system. These data serve as baseline information for future 
work.
With respect to pH, the emulsions showed negligible pH change from time 0 
hour when exposed to the different storage conditions, the only exception was 
when the emulsions were stored in clear bags at 40°C where changes in pH of 
more than 0.5 units were noted.
Chemical analysis by HPLC showed that both the fat-soluble vitamins were 
stable when stored at 4°C throughout the study duration. These are in 
agreement with other studies (Dahl et al. 1986; Dupertuis et al. 2002). Dahl et 
al (1986) observed insignificant loss of the vitamins during the six days study 
duration in darkness. Another study carried out by Allwood and Plane (1984) 
on Vitamin A found no degradation of the vitamin when stored for 28 days in 
the refrigerator.
During storage at 4°C, there was an apparent higher content of the vitamins at 
168 hours. In a study on Vitamin E, Balet et al (2004) attributed the higher 
concentration of the vitamin after 7 days storage at 4°C as being due to the 
natural variability of the vitamin in vegetable oils. In this study, for Vitamin E 
for example, the higher concentration of the vitamin may be attributed to the 
variability of the synthetic dl-alpha-tocopherol which consists of a mixture of 
the tocopherol stereoisomers, as discussed in Chapter One. Another possibility 
may be due to moisture loss from the minibag when stored in the 
pharmaceutical stability chamber, although this requires further investigation.
Table 5.5 summarises the stability duration of Vitamin A and Vitamin E upon 
various storage conditions. Vitamins A and E were also stable for 168 hours at 
25°C, besides storage at 4°C, and for 72 hours at 30°C when light protected. At
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40°C and protected from light, Vitamin A stability was reduced to 72 hours 
while Vitamin E stability was reduced to 48 hours. With artificial light 
exposure, Vitamin A stability was reduced to 24 hours at 25°C and to 6  hours 
at 30°C and 40°C, while Vitamin E was stable for 72 hours at 25°C and 30°C, 
and for 48 hours at 40°C.
The results of this study show that degradation is least when samples are 
protected from light and this is in agreement with results from other studies 
(Dahl et al. 1986; Drott et al. 1991). In a study by Allwood (1982a) on the 
effects of light on Vitamin A palmitate over a 24 hour period, it was pointed 
out that fluorescent light did not significantly degrade the vitamin, and that 
photodegradation of the vitamin is caused by the ultraviolet light below the 
wavelength of 400 nm. The result of this study after storage at 25°C for 24 
hours was comparable to the study by Allwood (1982a). However, when 
exposed for a longer duration, artificial fluorescent light was seen to affect the 
stability of Vitamin A. Therefore, the same precautions need to be taken even 
when exposing the vitamin in emulsion formulation to fluorescent light.
Upon exposure to artificial fluorescent light, both vitamins showed greater loss 
of concentrations when compared to the results when subjected to temperature 
effects only, and the extent of degradation was higher for vitamin A.
5.5. Conclusions
The fat-soluble Vitamin A and Vitamin E in the final aqueous test formulations 
were stable for the storage duration of the study period at 4°C and at 25°C 
when protected from light. The results indicate that Vitamin A was more light- 
sensitive whilst Vitamin E stability was more affected by temperature.
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CHAPTER SIX
SIMULATION STUDY OF VITAMINS MIMICKING REAL 
CLINICAL SET-UP
6.1. Introduction
Besides considering the stability of vitamins during storage immediately after 
preparation or compounding, their stability must also be considered during 
administration, as some vitamins can undergo degradation during 
administration (Allwood and Kearney 1998).
This chapter investigates the stability of the water-soluble and fat-soluble 
vitamins in situations simulating hospital clinical practice relating to 7 days 
storage before use and 24 hours infusion. In addition, the increasing demand 
for PN for home patients and the fact that many studies have shown that 
patients receiving long term PN have inadequate vitamin status (Forbes and 
Forbes 1997; Steephen et al. 1991; Zak III et al. 1991), have created a demand 
for PN formulations with longer shelf lives. Thus, a clinical set-up with an 
extended 30 days storage period for the vitamins in minibag formulations 
mimicking use by home patients was also examined.
During the 24 hours infusion, multivitamin bags may be exposed to either 
artificial fluorescent light or to sunlight (ultraviolet light). This study therefore 
looked into the stability of the vitamins under these exposure conditions after 
their designated storage durations at 4°C.
It is also most convenient to add the water-soluble and the fat-soluble vitamins 
together to a minibag and infuse as one infusion fluid. In view of this, the 
stability of the vitamins as combined admixtures of Solivito® N Adult and 
Vitlipid® N Adult in normal saline minibags was investigated.
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6.2. Methods
There were 3 different test solutions evaluated, which were Solivito® N Adult 
in 0.9% sodium chloride minibags (SV), Vitlipid® N Adult in 0.9% sodium 
chloride minibags (VL) and the combination of these fat and water-soluble 
vitamins in 0.9% sodium chloride minibags (CB).
6.2.1. Experimental Design
The minibags were stored in the pharmaceutical refrigerator for either one 
week or for 30 days at 4°C. This was followed by subjecting the minibags to 
either 25°C or 40°C in the pharmaceutical stability chamber (PSC) for the next 
24 hours. One set of minibags wrapped with aluminium foil was placed on the 
PSC shelf without the lights turned on, another set was exposed to artificial 
fluorescent light having an illuminance of 1 .2  klux/hour intensity, this light 
intensity being similar to exposure under extreme hospital unit lighting, such as 
in the operating theatre (Baker et al. 1993). The third set of minibags was 
placed on a shelf with ultraviolet A (UVA) lamps turned on, whereby the 
minibags were irradiated with UVA light of 3.5 Watts per square metre per 
hour (W/m2/h). The total UVA irradiation was about 84 W/m2, and this 
exposure simulates about 1 0 - 2 0  hours of exposure on a sunny window sill 
(Anderson and Byard 2004).
A summary of the experimental set-up is shown in Figure 6.1. Hence, there 
were four simulation conditions, two conditions at 7 days and two conditions at 
30 days, i.e: 7 days storage in the refrigerator followed by 25°C or 40°C for 24 
hours (7d25C and 7d40C), and 30 days storage in the refrigerator followed by 
25°C or 40°C for 24 hours (30d25C and 30d40C). These simulation studies 
mimicked real clinical settings for best case (7d25C, light protect) and worst 
case (30d40C, exposed to UVA) storage and administration conditions for use 
by ward inpatients and home patients.
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PSC at 40°C 
(7d40C)
PSC at 25°C 
(30d25C)
Test solutions in minibags
Kept in refrigerator 
for 30 days
Kept in refrigerator 
for 7 days
Exposed to:
- artificial light 
-UVA
Light protected 
Figure 6.1: Experimental set-up of simulation study
6.2.2. Preparation of Test Solutions
A total of 18 minibags were compounded for each set of simulation conditions, 
with 2  bags required for chemical and physical analyses, for each of the three 
exposure conditions, carried out in triplicate.
Test solutions SV were prepared as in Chapter Four (see 4.2.2) while test 
emulsions VL were prepared as in Chapter Five (see 5.2.1).
Test emulsions CB were prepared in the following way:
The Solivito® N Adult injection vial was reconstituted with the 10 ml vial of 
Vitlipid® N Adult Injection. These reconstituted emulsions were then pooled 
to a 250 ml EVA Freka® IV-Bag (Fresenius Kabi). 10 ml of the reconstituted 
emulsion formulation was then syringed out and added to the 1 0 0  ml sterile 
0.9% sodium chloride in Freeflex® minibag.
123
6.2.3. Sampling
For both physical and chemical analyses, samples were taken on day 0 before 
storage in the refrigerator, on day 7 or day 30, and then 24 hours after the 
temperature with/without light exposure. The physical and HPLC analyses 
carried out are described in Chapter Two.
For SV and VL samples, the sampling methods are described in Chapter Four 
for SV (see 4.2.3) and in Chapter Five for VL (see 5.2.2).
For CB, the method of sampling for its physical analysis is the same as for VL 
(see 5.2.2). For its chemical analysis, 3 ml samples were withdrawn from the 
minibags via the additive port using 21G needles and 5 ml syringes. 1.5 ml of 
the sample taken was placed into a microcentrifuge tube and another 1.5 ml 
sample into a 2 ml amber autosampler vial. Samples placed into the 
microcentifuge tubes were stored at -80°C in the pharmaceutical freezer, and 
analysed for the water-soluble vitamin components at the end of the study 
period for each simulation condition, as described in Chapter Two (see 2.3.3.2) 
and Chapter Four.
CB samples placed in the amber autosampler vials were stored in the 
pharmaceutical refrigerator and analysed within 3 days for analysis of the fat- 
soluble vitamin components, as described in Chapter Two (see 2.3.4.2). A fresh 
CB sample prepared in a 100 ml glass bottle was analysed together as a 
reference for fresh peaks, and adjustments were made in relation to the fresh 
reference peaks. Content analysis of samples at 0 hour was regarded as the 
baseline content of 1 0 0 %.
For HPLC analysis, the peak areas of all the 9 samples on day 0 were averaged 
and the content analysis of day 0  was regarded as 1 0 0 %.
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6.3. Results
The following abbreviations are used to denote the exposure conditions after 
the stipulated storage durations:
FFlgt - minibags exposed to artificial fluorescent light, intensity 1.2 klux/h 
FFuv - minibags irradiated with UVA, intensity 3.5 W/m /h 
FPL - minibags protected from light
The abbreviations for the simulation conditions have been described under 
experimental design of this chapter.
6.3.1. Physical Analysis
6.3.1.1. Water-soluble Vitamin Solutions SV
6.3.1.1.1. Appearance
There was no change of colour when the SV samples were stored for either 7 
days or for 30 days. No apparent colour change was observed when these 
samples were then exposed to the simulation conditions at 25°C. However, at 
40°C, the following observations were noted, as in Table 6.1.
Table 6.1: Appearance of water-soluble vitamins SV for 7d40C and 30d40C 
simulation conditions
Exposure
condition
Day 0 Day 7/30 7d40C 30d40C
FFlgt LY; LGH LY; LGH PY; PY;
less intense LGH less intense LGH
FFuv LY; LGH LY; LGH PY; PY;
less intense LGH less intense LGH
FPL LY; LGH LY; LGH LY; LY;
LGH LGH
LY: light yellow, PY: pale yellow, LGH: light green haze
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6.3.1.1.2. Turbidity
Turbidity measurement results are tabulated in Table 6.2.
Table 6.2: Results of turbidity measurement in NTU of SV
Simulation
condition
Exposure
condition
Day 0 (n=9) Day 7/30 7d/30d + 24 h
7d25C FFlgt 4.99 ± 0.07 4.99 ±0.05 4.55 ±0.18
FFuv 4.99 ±0.07 4.81 ±0.10 3.54 ±0.06*
FPL 4.99 ±0.07 5.04 ±0.14 4.91 ±0.19
7d40C FFlgt 4.85 ± 0.23 4.90 ±0.18 2.24 ±0.76*
FFuv 4.85 ± 0.23 4.90 ±0.06 0.74 ± 0.08 *
FPL 4.85 ±0.23 4.94 ± 0.29 4.73 ± 0.29
30d25C FFlgt 5.00 ±0.12 4.90 ±0.13 4.40 ±0.23 *
FFuv 5.00 ±0.12 4.81 ±0.10 3.54 ±0.06*
FPL 5.00 ±0.12 4.98 ±0.10 4.90 ± 0.09
30d40C FFlgt 4.94 ±0.15 4.78 ± 0.37 1.36 ±0.63 *
FFuv 4.94 ±0.15 4.88 ±0.09 0.44 ±0.01 *
FPL 4.94 ±0.15 4.88 ±0.32 4.75 ±0.34
*: values with change in NTJ of more than 0.5 units
The NTU results above clearly show that there was a decrease in NTU units 
from the time of preparation at 0 hour. The change in NTU of more than 0.5 
units (marked with asterisk *) were observed for 7d40C, 30d25C and 30d40C 
samples exposed to either artificial light or UVA light.
6.3.I.I.3. Dissolved Oxygen
The DO results of SV minibags are shown in Figure 6.2 and 6.3. They show 
increasing trend in DO when minibags were kept in the refrigerator, and then 
decreased upon exposure to higher temperatures.
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Figure 6.2: DO content of SV for 7 days + 24 hours simulation study
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Figure 6.3: DO content of SV for 30 days + 24 hours simulation study
6.3.1.1.4. pH
The results o f pH measurements of SV samples are tabulated in Table 6.3. 
Only the light protected SV sample exposed to 7d25C simulation condition had 
a pH change o f less than 0.5 units.
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Table 6.3: Results of pH measurement of SV
Simulation
condition
Exposure
condition
Day 0 (n=9) Day 7/30 7d/30d + 24 h
7d25C FFlgt 6.11 ±0.13 6.32 ± 0.05 5.08 ±0.18
FFuv 6.11 ±0.13 6.49 ± 0.03 5.13 ±0.03
FPL 6.11 ±0.13 6.33 ± 0.03 5.84 ±0.02*
7d40C FFlgt 6.20 ±0.12 6.35 ±0.12 4.43 ± 0.03
FFuv 6.20 ±0.12 6.49 ±0.03 4.38 ± 0.02
FPL 6.20 ±0.12 6.36 ± 0.09 5.47 ±0.02
30d25C FFlgt 6.16 ± 0.11 5.61 ±0.00 5.00 ± 0.02
FFuv 6.16 ± 0.11 5.53 ±0.01 4.80 ± 0.04
FPL 6.16 ± 0.11 5.64 ± 0.04 5.44 ±0.05
30d40C FFlgt 6.24 ± 0.09 5.55 ±0.02 4.34 ± 0.04
FFuv 6.24 ± 0.09 5.48 ±0.01 4.22 ±0.01
FPL 6.24 ± 0.09 5.58 ± 0.03 5.38 ±0.08
*: values with change in pH of less than 0.5 units
6.3.1.2. Fat-soluble Vitamin Emulsions VL
6.3.1.2.1. Appearance
The VL emulsions were milky white in colour and appeared homogenous 
throughout the study duration. Upon removing from the refrigerator, some 
white emulsion was noted to stick on to the sides of the plastic bags but 
redispersed upon agitation and upon exposing to simulation temperatures.
6.3.1.2.2. Dissolved Oxygen
The results of DO content in VL minibags are shown in Figure 6.4 and Figure
6.5. The trend of DO contents of the VL minibags is similar to those of SV 
bags.
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Figure 6.4: DO content of VL for 7 days + 24 hours simulation study
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Figure 6.5: DO content of VL for 30 days + 24 hours simulation study
6.3.I.2.3. pH
The results o f pH of VL minibags are shown in Table 6.4. From the table, VL 
minibags exposed to UVA during 40°C administration condition produced pH 
changes of more than 0.5 units.
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Table 6.4: Results of pH measurement of VL
Simulation
condition
Exposure
condition
Day 0 (n=9) Day 7/30 7d/30d + 24 h
7d25C FFlgt 7.01 ±0.03 6.99 ± 0.05 6.95 ± 0.06
FFuv 7.01 ±0.03 7.03 ± 0.04 6.82 ± 0.03
FPL 7.01 ±0.03 7.01 ±0.03 6.99 ± 0.02
7d40C FFlgt 7.26 ± 0.04 7.03 ±0.01 6.92 ± 0.02
FFuv 7.26 ± 0.04 6.99 ±0.01 6.55 ± 0.07 *
FPL 7.26 ± 0.04 6.98 ± 0.03 6.94 ±0.01
30d25C FFlgt 7.04 ±0.02 6.63 ± 0.02 6.81 ±0.01
FFuv 7.04 ± 0.02 6.68 ±0.01 6.71 ±0.04
FPL 7.04 ± 0.02 6.65 ±0.01 6.82 ±0.01
30d40C FFlgt 7.08 ±0.15 6.64 ± 0.07 6.81 ±0.01
FFuv 7.08 ±0.15 6.54 ± 0.04 6.54 ±0.01 *
FPL 7.08 ±0.15 6.54 ±0.05 6.78 ± 0.05
*: values with changes in pF of more than 0.5 units
6.3.1.2.4. Laser Diffraction
The maximum diameter for all samples and for all simulation conditions was 
less than 4.3 pm with D[4,3] of between 0.32 to 0.36 pm throughout the study.
6.3.I.2.5. Light Microscopy
All samples had lipid globules sizes of less than 7.5 pm diameter and were 
seen as individual globules with occasional 5 pm size globules seen.
6.3.I.3. Fat-soluble and Water-soluble Vitamin Admixtures CB
6.3.1.3.1. Appearance
For the CB samples, the presented admixtures were a homogenous milky 
yellow and had a milky white meniscus. There was no change in appearance 
when kept in the refrigerator although some milky yellow emulsion was noted 
to stick to the side of the plastic bags. The admixture returned to a homogenous 
emulsion upon gentle agitation. No change in appearance was noted upon 
exposure at 25°C after the storage durations in the refrigerator, but a decrease
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in colour intensity was noted upon exposure to 40°C and light, as shown in 
Table 6.5.
Table 6.5: Appearance of Combined Fat and Water-soluble Vitamin Admixtures 
CB
Exposure
condition
Day 0 Day 7/30 7 days, then 
40°C for 24 h
30 days, then 
40°C for 24 h
FFlgt MY MY PMY PMY
FFuv MY MY PMY PMY
FPL MY MY MY MY
MY: milky yellow; PMY: pale milky yellow
6.3.1.3.2. Dissolved Oxygen
The results of DO mesurement of CB minibags are tabulated in Table 6 .6  while 
the graphs are depicted in Figure 6 .6  and Figure 6.7.
Table 6 .6 : Results of DO measurement in mg/1 for CB
Simulation
condition
Exposure
condition
Day 0 (n=9) Day 7/30 7d/30d+24 h
7d25C FFlgt 4.93 ± 0.56 6.32 ± 0.06 1.35 ±0.33
Ffuv 4.93 ± 0.56 5.55 ±0.56 1.13 ± 0.18
FPL 4.93 ± 0.56 5.71 ±1.65 4.46 ± 0.56
7d40C FFlgt 3.89 ±0.55 5.94 ±0.22 2.45 ± 0.30
Ffuv 3.89 ±0.55 5.66 ±0.51 2.73 ± 0.27
FPL 3.89 ±0.55 6.18 ±0.27 3.38 ±0.21
30d25C FFlgt 3.38 ±0.33 5.51 ±0.55 1.10 ± 0.53
Ffuv 3.38 ±0.33 5.26 ±0.22 1.74 ±0.71
FPL 3.38 ±0.33 5.37 ±0.57 2.22 ± 0.34
30d40C FFlgt 4.97 ±0.71 1.26 ±0.43 2.76 ±0.11
Ffuv 4.97 ±0.71 2.81 ±0.65 3.83 ±0.40
FPL 4.97 ±0.71 4.66 ± 0.67 3.07 ±0.32
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Figure 6.6: DO for CB minibags 7 days + 24 hours simulation study
30d25C FFlgt 
30d25C FFuv 
30d25C FPL 
30d40C FFlgt 
30d40C FFuv 
30d40C FPL
0 5 10 15 20 25 30 35
Time (d)
Figure 6.7: DO for CB minibags 30 days + 24 hours simulation study
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6.3.I.3.3. pH
The results of pH measurements of CB minibags are tabulated in Table 6.7.
Table 6.7: Results of pH measurement of CB
Simulation
condition
Exposure
condition
Day 0 (n—9) Day 7/30 7d/30d + 24 h
7d25C FFlgt 6.44 ± 0.03 6.35 ± 0.03 5.10 ±0.04
FFuv 6.44 ± 0.03 6.33 ± 0.05 5.13 ±0.08
FPL 6.44 ± 0.03 6.41 ±0.10 5.94 ±0.10*
7d40C FFlgt 6.41 ±0.06 6.34 ± 0.04 4.69 ± 0.02
FFuv 6.41 ±0.06 6.35 ± 0.00 4.66 ± 0.00
FPL 6.41 ±0.06 6.34 ±0.01 5.75 ± 0.04
30d25C FFlgt 6.30 ± 0.03 5.73 ± 0.03 4.82 ±0.16
FFuv 6.30 ±0.03 5.68 ±0.01 4.71 ±0.01
FPL 6.30 ± 0.03 5.70 ±0.03 5.58 ±0.01
30d40C FFlgt 6.27 ± 0.06 5.93 ±0.01 4.56 ±0.02
FFuv 6.27 ± 0.06 5.90 ±0.04 4.54 ± 0.03
FPL 6.27 ± 0.06 5.89 ± 0.04 5.66 ±0.01
*: values with change in pH of less than 0.5 units
Only CB minibags for 7d25C simulation condition with light protection had 
pH change of 0.5 units or less. All other minibags had change of pH values of 
more than 0.5 units.
6.3.1.3.4. Laser Diffraction
For the simulation temperature of 25°C after the stipulated storage durations in 
the refrigerator, all samples had a maximum diameter of less than 4.3 pm with 
a D[4,3] of 0.35 to 0.37 pm.
However, for the simulation temperature of 40°C after the storage durations in 
the refrigerator, the samples had a maximum diameter of more than 15.04 pm, 
with the percentage having diameter more than 4.3 pm ranging from 0.36% to 
2.0%. The D[4,3] values had increments ranging from 0.36/0.37 pm at time 0 
hour to 0.36 pm -  0.49 pm at the end of the simulation conditions.
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6.3.1.3.5. Light Microscopy
There was no change observed in the number and size of the lipid globules for 
the 7d25C simulation condition. All the lipid globules remained at less than 7.5 
pm with an occasional 5 pm globule seen. For 30d25C simulation condition, 
the number of 5 pm lipid globules had increased, with one or two 7.5 pm 
globules seen and one sample that was exposed to UVA had one 10 pm globule 
observed.
For 7d40C and 30d40C simulation conditions, there was no obvious change of 
the size of the lipid globules during storage in the refrigerator observed. 
However upon exposure at 40°C, 7.5 pm size lipid globules were observed 
with a range from 10 -  12 in numbers. Larger globule sizes were also 
observed; a 25 pm lipid globule size was observed for the 7d40C simulation 
condition while a 40 pm lipid globule size was observed for the 30d40C 
simulation condition.
6.3.2. Chemical Analysis
6.3.2.I. Water-soluble Vitamins in SV
The results of pyridoxine, nicotinamide, thiamine, folic acid and riboflavin 
sodium phosphate in SV solutions are tabulated from Table 6 .8  to Table 6.12, 
while the graphs are displayed from Figure 6 .8  to Figure 6.17.
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6.3.2.I.I. Pyridoxine
Table 6.8: Percentage content of pyridoxine in SV upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d + 24 h
%
7d25C FFlgt 100 ± 0 97.21 ±0.39 88.74 ±3.80
FFuv 100 ± 0 96.17 ±3.99 56.60 ±3.30
FPL 100 ± 0 95.01 ±0.78 96.00 ±3.06
7d40C FFlgt 100 ± 0 98.09 ±2.73 87.47 ±2.01
FFuv 100 ± 0 98.58 ± 1.33 46.12 ± 1.23
FPL 100 ± 0 95.98 ±3.80 95.21 ±2.29
30d25C FFlgt 100 ± 0 95.16 ±2.24 86.34 ±3.33
FFuv 100 ± 0 95.68 ±5.86 58.57 ± 1.62
FPL 100 ± 0 97.23 ± 1.52 92.82 ±2.07
30d40C FFlgt 100 ± 0 93.51 ±1.14 92.23 ± 3.79
FFuv 100 ± 0 92.84 ±5.55 45.58 ± 1.90
FPL 100 ± 0 96.54 ±2.52 94.21 ±4.99
_ □ d7+24h
FFuv FPL FFlgt FFuv FPL
7d25C 7d40C
Figure 6.8: Content of pyridoxine in SV for 7d25C and 7d40C simulation 
conditions
FFlgt FFuv FPL 
30d25C
FFlgt FFuv FPL 
30d40C
□ dO 
■ d30
□ d30+24h
Figure 6.9: Content of pyridoxine in SV for 30d25C and 30d40C simulation
conditions
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6.3.2.I.2. Nicotinamide
Table 6.9: Percentage content of nicotinamide in SV upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d + 24 h
%
7d25C FFlgt 100 ± 0 100.90 ±0.21 100.34 ±2.38
FFuv 100 ± 0 99.18 ±4.48 93.28 ±3.50
FPL 100 ± 0 98.84 ± 1.33 99.41 ±0.58
7d40C FFlgt 100 ± 0 100.66 ± 1.09 99.55 ±1.31
FFuv 100 ± 0 100.86 ± 1.60 98.65 ± 1.04
FPL 100 ± 0 99.70 ±2.52 99.93 ± 1.68
30d25C FFlgt 100 ± 0 99.12 ±0.68 97.83 ± 0.64
FFuv 100 ± 0 97.13 ±5.55 95.34 ±3.52
FPL 100 ± 0 100.41 ± 1.06 98.88 ±2.29
30d40C FFlgt 100 ± 0 99.39 ±0.87 99.60 ± 1.46
FFuv 100 ± 0 93.33 ± 1.27 94.20 ±3.64
FPL 100 ± 0 100.80 ±3.26 98.53 ±5.90
□ d7+24h
FFlgt FFuv FPL FFlgt FFuv FPL
7d25C 7d40C
Figure 6.10: Content of nicotinamide in SV for 7d25C and 7d40C simulation 
conditions
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□ d30+24h
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Figure 6.11: Content of nicotinamide in SV for 30d25C and 30d40C simulation
conditions
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6.3.2.I.3. Thiamine
Table 6.10: Percentage content of thiamine in SV upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d + 24 h 
%
7d25C FFlgt 100 ± 0 97.99 ±0.91 96.14 ±2.99
FFuv 100 ± 0 97.33 ± 4.00 88.18 ±2.87
FPL 100± 0 95.95 ±2.24 96.15 ±3.29
7d40C FFlgt 100 ± 0 99.47 ± 2.45 93.87 ± 1.75
FFuv 100± 0 104.00 ±0.62 87.50 ±2.24
FPL 100 ± 0 96.75 ±2.12 97.28 ± 0.40
30d25C FFlgt 100 ± 0 97.50 ± 1.65 94.69 ± 1.29
FFuv 100 ± 0 95.14 ± 5.51 85.48 ±2.19
FPL 100 ± 0 99.29 ± 1.98 94.27 ±2.55
30d40C FFlgt 100 ± 0 95.37 ± 1.97 85.06 ±3.63
Ffuv 100 ± 0 93.80 ±1.14 83.40 ±2.76
FPL 100 ± 0 95.88 ± 1.93 93.27 ± 1.48
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Figure 6.12: Content of thiamine in SV for 7d25C and 7d40C simulation 
conditions
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Figure 6.13: Content of thiamine in SV for 30d25C and 30d40C simulation
conditions
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6.3.2.I.4. Folic Acid
Table 6.11: Percentage content of folic acid in SV upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d+ 24 h 
%
7d25C FFlgt 100 ± 0 96.69 ± 1.15 92.29 ± 1.97
FFuv 100 ± 0 99.45 ± 2.47 82.38 ±5.99
FPL 100 ± 0 95.41 ± 1.11 97.34 ±5.53
7d40C FFlgt 100 ± 0 100.37 ± 1.76 99.28 ±5.07
FFuv 100± 0 100.22 ± 1.66 87.87 ± 1.94
FPL 100 ± 0 97.12 ±1.24 100.87 ± 1.24
30d25C FFlgt 100 ± 0 96.39 ±5.20 95.70 ±6.56
FFuv 100 ± 0 95.51 ±4.67 85.73 ± 2.22
FPL 100 ± 0 101.28 ±8.79 94.12 ± 1.10
30d40C FFlgt 100 ± 0 96.95 ± 1.82 76.83 ± 8.87
FFuv 100 ± 0 96.40 ±6.51 40.58 ±6.03
FPL 100 ± 0 96.48 ±5.10 94.54 ±3.79
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Figure 6.14: Content of folic acid in SV for 7d25C and 7d40C simulation 
conditions
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Figure 6.15: Content of folic acid in SV for 30d25C and 30d40C simulation
conditions
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6.3.2.I.5. Riboflavin Sodium Phosphate
Table 6.12: Percentage content of riboflavin sodium phosphate in SV upon 
simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d + 24 h
%
7d25C FFlgt 100 ± 0 99.73 ± 4.88 62.78 ± 1.71
FFuv 100 ± 0 95.94 ±3.21 47.56 ±2.75
FPL 100 ± 0 97.54 ±5.41 95.51 ± 1.64
7d40C FFlgt 100 ± 0 97.26 ±2.11 39.72 ±3.17
FFuv 100 ± 0 99.33 ± 1.43 20.11 ±1.34
FPL 100 ± 0 96.26 ± 1.61 92.75 ±3.17
30d25C FFlgt 100 ± 0 95.28 ± 1.99 59.99 ± 6.29
FFuv 100 ± 0 94.20 ± 4.47 40.11 ±3.05
FPL 1 0 0 ± 0 96.41 ±0.60 95.20 ±2.14
30d40C FFlgt 100 ± 0 93.83 ±0.58 37.32 ±8.27
FFuv 100 ± 0 93.27 ±4.16 8.63 ±2.32
FPL 100 ± 0 94.15 ±0.21 92.13 ± 1.71
7d40C
■ dO
■ d7
□ d7+24h
Figure 6.16: Content of riboflavine sodium phosphate in SV for 7d25C and 
7d40C simulation conditions
FFlgt FFuv FPL 
30d25C
FFlgt FFuv FPL 
30d40C
■ dO
■ d30
□ d30+24h
Figure 6.17: Content of riboflavin sodium phosphate in SV for 30d25C and
30d40C simulation conditions
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6.3.2.2. Fat-soluble vitamins in VL
The results o f Vitamin A (retinol palmitate) and Vitamin E (tocopherol) in VL 
emulsions are tabulated from Table 6.13 to Table 6.14, while the graphs are 
displayed from Figure 6.18 to Figure 6.21.
6.3.2.2.I. Vitamin A
Table 6.13: Percentage content of Vitamin A in VL upon simulation conditions
Simulation
condition
Exposure
condition
Day 0 (N=9) 
%
Day 7/30 
%
7d/30d+ 24 h
%
7d25C FFlgt 100 ± 0 100.55 ±0.94 83.35 ±3.21
FFuv 100 ± 0 100.21 ± 1.45 1.20 ± 0.11
FPL 100 ± 0 101.17 ± 0.62 97.09 ±0.35
7d40C FFlgt 100 ± 0 100.70 ±0.70 84.35 ± 1.36
FFuv 100 ± 0 102.03 ±0.19 nd
FPL 100 ± 0 100.60 ±1.17 99.87 ± 0.23
30d25C FFlgt 100 ± 0 103.88 ±4.07 88.81 ±5.42
FFuv 100 ± 0 106.05 ±3.10 nd
FPL 100 ± 0 103.41 ± 1.62 98.19 ± 1.36
30d40C FFlgt 100 ± 0 96.09 ±0.67 78.91 ±0.81
FFuv 100 ± 0 92.31 ±0.17 nd
FPL 100 ± 0 95.63 ± 0.94 92.31 ± 1.00
nd: not detected
120  t —  
100
80
60
40
20
0
FFlgt FFuv FPL FFlgt FFuv FPL
7d25C 7d40C
□ d0
□ d7
□ d7+24h
Figure 6.18: Content of Vitamin A in VL for 7d25C and 7d40C simulation
conditions
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Figure 6.19: Content of Vitamin A in VL for 30d25C and 30d40C simulation 
conditions
6.3.2.2.2. Vitamin E
Table 6.14: Percentage content of Vitamin E in VL upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d+ 24 h 
%
7d25C FFlgt 100 ± 0 99.93 ±6.01 100.26 ±0.55
FFuv 100 ± 0 104.07 ±0.39 68.65 ±0.38
FPL 100 ± 0 98.79 ±6.31 100.00 ± 1.85
7d40C FFlgt 100 ± 0 101.29 ±0.82 93.63 ±2.33
FFuv 100 ± 0 102.44 ± 1.76 53.44 ±0.36
FPL 100 ± 0 98.59 ±5.86 99.17 ±0.45
30d25C FFlgt 100 ± 0 103.51 ± 1.53 100.18 ± 6.17
FFuv 100 ± 0 107.80 ±3.53 65.13 ±0.73
FPL 100 ± 0 103.71 ±7.32 98.70 ± 1.48
30d40C FFlgt 100 ± 0 92.87 ± 1.09 75.95 ±3.89
FFuv 100 ± 0 90.61 ± 1.92 37.51 ±4.06
FPL 100± 0 92.47 ± 1.11 83.66 ± 1.74
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Figure 6.20: Content of Vitamin E in VL for 7d25C and 7d40C simulation 
conditions
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Figure 6.21: Content of Vitamin E in VL for 30d25C and 30d40C simulation 
conditions
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6.3.2.3. Water-soluble and Fat-soluble Vitamins in CB Admixtures
The results o f pyridoxine, nicotinamide, thiamine, folic acid, riboflavine 
sodium phosphate, vitamin A and vitamin E in CB admixtures are tabulated 
from Table 6.15 to Table 6.21, while the graphs are displayed from Figure 6.21 
to Figure 6.34.
6.3.2.3.I. Pyridoxine
Table 6.15: Percentage content of pyridoxine in CB upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d+ 24 h
%
7d25C FFIgt 100 ± 0 99.70 ± 1.13 94.42 ± 0.26
FFuv 100 ± 0 99.88 ±0.65 76.89 ± 1.10
FPL 100 ± 0 98.49 ± 1.99 98.08 ± 1.57
7d40C FFIgt 100 ± 0 97.77 ±0.45 94.01 ± 1.57
FFuv 100 ± 0 98.50 ±0.39 65.26 ±0.14
FPL 100 ± 0 97.15 ± 1.62 96.51 ±2.99
30d25C FFIgt 100 ± 0 99.74 ± 0.64 95.67 ±0.92
FFuv 100 ± 0 94.90 ±3.68 76.06 ± 1.66
FPL 100 ± 0 97.19 ±0.32 93.11 ±4.52
30d40C FFIgt 100 ± 0 100.43 ± 1.36 99.16 ±3.90
FFuv 100± 0 99.09 ±2.71 69.97 ± 1.70
FPL 100 ± 0 101.70 ± 1.47 99.12 ±4.03
□  d7+24h
FFIgt FFuv FPL 
7d25C
FFIgt FFuv FPL 
7d40C
Figure 6.22: Content of pyridoxine in CB for 7d25C and 7d40C simulation
conditions
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Figure 6.23: Content of pyridoxine in CB for 30d25C and 30d40C simulation 
conditions
6.3.2.3.2. Nicotinamide
Table 6.16: Percentage content of nicotinamide in CB upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d+ 24 h
%
7d25C FFIgt 100 ± 0 100.90 ± 1.37 98.74 ± 0.64
FFuv 100 ± 0 100.58 ±0.41 100.35 ±0.80
FPL 100 ± 0 99.83 ±2.15 100.05 ± 1.57
7d40C FFIgt 100 ± 0 99.38 ±0.69 98.82 ± 1.58
FFuv 100 ± 0 101.96 ±3.03 102.51 ±2.75
FPL 100 ± 0 97.76 ± 1.77 98.21 ±2.99
30d25C FFIgt 100 ± 0 101.32 ±0.60 100.67 ±0.72
FFuv 100 ± 0 98.14 ±2.34 99.83 ± 1.51
FPL 100 ± 0 99.77 ±0.45 96.53 ±3.75
30d40C FFIgt 100 ± 0 102.61 ± 1.69 101.59 ±4.11
FFuv 100 ± 0 101.57 ± 2.71 98.00 ± 1.32
FPL 100 ± 0 103.52 ± 1.20 100.01 ±3.77
□ d7+24h
FFIgt FFuv FPL 
7d25C
FFIgt FFuv FPL 
7d40C
Figure 6.24: Content of nicotinamide in CB for 7d25C and 7d40C simulation
conditions
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Figure 6.25: Content of nicotinamide in CB for 30d25C and 30d40C simulation 
conditions
6.3.2.3.3. Thiamine
Table 6.17: Percentage content of thiamine in CB upon simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d+ 24 h 
%
7d25C FFIgt 100 ± 0 103.31 ±0.83 94.26 ± 0.70
FFuv 100 ± 0 100.98 ±0.43 94.97 ± 1.49
FPL 100 ± 0 100.17 ± 1.44 101.62 ± 1.97
7d40C FFIgt 100 ± 0 97.13 ± 1.06 92.97 ± 1.55
FFuv 100 ± 0 98.32 ±0.66 87.25 ± 1.02
FPL 100 ± 0 97.00 ±0.88 95.06 ±3.29
30d25C FFIgt 100 ± 0 98.56 ± 1.15 99.19± 1.89
FFuv 100 ± 0 97.24 ±3.90 92.60 ±1.19
FPL 100 ± 0 101.28 ± 1.23 99.13 ±8.99
30d40C FFIgt 100 ± 0 102.61 ± 1.69 101.59 ± 4.11
FFuv 100 ± 0 101.57 ± 2.71 98.00 ± 1.32
FPL 100 ± 0 103.52 ± 1.20 100.01 ±3.77
110  -
□ d7+24h
FFIgt FFuv FPL 
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Figure 6.26: Content of thiamine in CB for 7d25C and 7d40C simulation
conditions
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Figure 6.27: Content of thiamine in CB for 30d25C and 30d40C simulation 
conditions
6.3.2.3.4. Folic acid
Table 6.18: Percentage content of folic acid in CB upon simulation conditions
Simulation
condition
Exposure
condition
DayO
%
Day 7/30 
%
7d/30d+ 24 h 
%
7d25C FFIgt 100 ± 0 98.84 ±0.73 95.25 ± 0.53
FFuv 100 ± 0 100.10 ±0.69 96.18 ±0.26
FPL 100 ± 0 98.17 ± 3.17 98.97 ±2.00
7d40C FFIgt 100 ± 0 97.80 ±0.45 92.77 ± 1.82
FFuv 100 ± 0 99.09 ± 0.56 92.01 ± 1.28
FPL 100 ± 0 97.13 ± 1.43 95.62 ±3.17
30d25C FFIgt 100 ± 0 99.44 ±2.98 97.04 ±2.21
FFuv 100 ± 0 97.17 ± 1.16 91.76 ±2.75
FPL 100 ± 0 98.78 ±3.21 93.16 ±3.65
30d40C FFIgt 100 ± 0 97.67 ± 1.63 89.45 ± 0.73
FFuv 100 ± 0 96.23 ± 2.77 68.16 ± 1.86
FPL 100 ± 0 99.43 ± 1.29 94.23 ± 1.60
120 x
□ d7+24h
FFIgt FFuv FPL 
7d25C
FFIgt FFuv FPL 
7d40C
Figure 6.28: Content of folic acid in CB for 7d25C and 7d40C simulation
conditions
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Figure 6.29: Content of folic acid in CB for 30d25C and 30d40C simulation 
conditions
6.3.2.3.S. Riboflavin Sodium Phosphate
Table 6.19: Percentage content of riboflavin sodium phosphate in CB upon 
simulation conditions
Simulation
condition
Exposure
condition
Day 0
%
Day 7/30 
%
7d/30d + 24 h 
%
7d25C FFIgt 100 ± 0 98.50 ± 1.04 73.33 ±0.59
FFuv 100 ± 0 101.31 ±0.69 62.73 ± 2.02
FPL 100 ± 0 96.70 ±4.70 99.63 ± 1.64
7d40C FFIgt 100 ± 0 98.34 ±0.35 63.06 ±3.60
FFuv 100 ± 0 99.42 ± 0.22 43.18 ± 1.16
FPL 100 ± 0 97.93 ± 1.41 98.90 ±5.63
30d25C FFIgt 100 ± 0 96.82 ± 0.93 71.14 ± 1.09
FFuv 100 ± 0 95.29 ±2.84 63.27 ±0.93
FPL 100 ± 0 96.28 ±2.47 92.87 ± 0.97
30d40C FFIgt 100± 0 98.45 ± 0.50 52.57 ± 1.45
FFuv 100 ± 0 97.00 ±3.17 31.42 ±0.68
FPL 100 ± 0 101.25 ± 1.61 93.90 ±0.65
□  d7+24h
FFIgt | FFuv| FPL 
7d40C
FFIgt | FFuv| FPL 
7d25C
Figure 6.30: Content of riboflavin sodium phosphate in CB for 7d25C and 7d40C
simulation conditions
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Figure 6.31: Content of riboflavin sodium phosphate in CB for 30d25C and 
30d40C simulation conditions
6.3.2.3.6. Vitamin A
Table 6.20: Percentage content of Vitamin A in CB upon simulation conditions
Simulation Exposure Day 0 Day 7/30 7d/30d + 24 h
condition condition % % %
7d25C FFIgt 100 ± 0 94.49 ± 1.39 95.59 ± 1.97
Ffuv 100 ± 0 101.41 ±3.02 8.67 ±0.35
FPL 100 ± 0 96.00 ± 0.45 106.44 ±2.22
7d40C FFIgt 100 ± 0 103.97 ± 1.45 85.59 ±3.11
Ffuv 100 ± 0 105.72 ±0.32 12.30 ±0.42
FPL 100 ± 0 105.92 ± 1.29 95.30 ±0.91
30d25C FFIgt 100 ± 0 97.94 ± 1.24 96.27 ±0.81
Ffuv 100±0 96.99 ±0.36 15.54 ± 3.13
FPL 100 ± 0 102.42 ±9.97 103.82 ±3.32
30d40C FFIgt 100 ± 0 96.92 ±3.23 92.28 ± 2.00
Ffuv 100 ± 0 99.99 ± 1.43 8.27 ±3.17
FPL 100 ± 0 95.49 ±2.42 111.77 ±2.03
LH :no O j
□ d7+24h
FFIgt| FFuv| FPL 
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Figure 6.32: Content of Vitamin A in CB for 7d25C and 7d40C simulation
conditions
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Figure 6.33. Content of Vitamin A in CB for 30d25C and 30d40C simulation 
conditions
6.3.2.3.7. Vitamin E
Table 6.21: Percentage content of Vitamin E in CB upon simulation conditions
Simulation Exposure Day 0 Day 7/30 7d/30d + 24 h
condition condition % % %
7d25C FFIgt 100 ± 0 95.28 ± 1.45 107.66 ±2.81
Ffuv 100 ± 0 101.38 ±2.48 108.69 ± 1.11
FPL 100 ± 0 96.28 ± 0.40 112.49 ±2.34
7d40C FFIgt 100 ± 0 103.39 ± 1.43 93.37 ±0.75
Ffuv 1 00±0 103.13 ±0.40 92.21 ±0.84
FPL 100 ± 0 105.55 ± 1.41 95.90 ±0.89
30d25C FFIgt 100 ± 0 97.65 ± 1.69 105.30 ± 1.33
Ffuv 100 ± 0 97.27 ± 2.63 103.01 ±0.78
FPL 100 ± 0 100.75 ±7.08 111.46 ±2.38
30d40C FFIgt 100 ± 0 95.99 ±3.32 97.34 ±2.28
Ffuv 100 ± 0 97.56 ±3.27 97.29 ±2.20
FPL 100 ± 0 95.98 ± 1.43 111.46 ±2.38
120  -
- □ d7+24h
FFuv FPL FFIgt FFuv FPL
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Figure 6.34. Content of Vitamin E in CB for 7d25C and 7d40C simulation
conditions
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Figure 6.35. Content of Vitamin E in CB for 30d25C and 30d40C simulation 
conditions
6.3.3. Results Summary for Clinical Simulation Studies
The results o f the clinical simulation studies are summarised in Table 6.22 and 
Table 6.23.
Table 6.22: Stability summary of vitamins for 7d + 24 h simulation conditions
Simulation
condition
Vitamin Sample Light
Protected
Light
Exposed
UVA
Exposed
7d25C P SV S U U
P CB S S U
N SV S S S
N CB S s S
T SV S s u
T CB S s s
FA SV S s u
FA CB S s s
RSP SV S s u
RSP CB S s u
Vitamin A VL S u u
Vitamin A CB S s u
Vitamin E VL S s u
Vitamin E CB S s s
7d40C P SV S u u
P CB S s u
N SV s s s
N CB s s s
T SV s s u
T CB s s u
FA SV s s u
FA CB s s s
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Simulation
condition
Vitamin Sample Light
Protected
Light
Exposed
UVA
Exposed
7d40C RSP SV S U U
RSP CB S u U
Vitamin A VL S u u
Vitamin A CB S u u
Vitamin E VL S s u
Vitamin E CB S s s
S: Stable; U: 
Table 6.23: St
Jnstable
ability summary of vitamins for 30 d + 24 h simulation conditions
Simulation
condition
Vitamin Admixture Light
Protected
Light
Exposed
UVA
Exposed
30d25C P SV S U U
P CB S s U
N SV S s s
N CB S s s
T SV S s u
T CB S s s
FA SV S s u
FA CB S s s
RSP SV S u u
RSP CB S u u
Vitamin A VL S u u
Vitamin A CB S s u
Vitamin. E VL S s u
Vitamin E CB S s s
30d40C P SV S s u
P CB S s u
N SV S s s
N CB S s s
T SV S u u
T CB S s s
FA SV S u u
FA CB S u u
RSP SV S u u
RSP CB S u u
Vitamin A VL S u u
Vitamin A CB S s u
Vitamin E VL U u u
Vitamin E CB s s s
S: Stable; U: Unstable
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6.4. Discussion
In all the three different samples tested, there was no obvious physical sign of 
degradation when stored for up to 7 days. Physical appearance remained 
unchanged and physical assessments remained within specified limits. Upon 
storage for 30 days, physical appearance appeared stable with no colour change 
observed and, for VL and CB samples, there was no change in the size of the 
lipid globules observed.
Subject to the exposure conditions after storage in the refrigerator, the samples 
showed different physical profiles. There was colour change in the SV samples 
when exposed to 40°C without light protection. The turbidity of SV samples 
decreased from its baseline at 0  hour, as expected due to the dissolution of the 
lyophilised powder upon time and aided by the increase in temperature and 
light.
In all samples, there was a decrease in pH from baseline value at 0 hour, 
possibly due to some degradation to a more acidic product taking place. It 
could be argued that this pH change could be due to a normal fall associated 
with absorbed carbon dioxide in solution, from the possible increase of carbon 
dioxide with time from the headspace. In the time available, the actual cause 
could not be identified, but it would be thought that the amount of carbon 
dioxide absorbed was negligible as the headspace was very small, besides the 
fact that all the samples would have consistently the same headspace. The 
varying pH results of the samples from the dark controls would indicate that 
the decrease in pH was more likely due to vitamin degradation.
No colour change, phase separation, or lipid globules size greater than 7.5 pm 
was observed for VL samples, but a pH change of more than 0.5 units for 
samples exposed to UVA at 40°C was observed. For the CB samples, colour 
change and an increase in the size of the lipid globules were observed when 
UVA exposed at 40°C after 7 days and after 30 days.
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Based on the physical analysis, 30d40C samples exposed to UVA were the 
most unstable in all the samples, with colour change observed in SV and CB 
samples, a change in pH of greater than 0.5 units for all samples, and in CB, 
lipid globules greater than 5 pm size were observed by light microscopy and 
laser diffraction.
DO measurements showed the DO content to increase upon storage in the 
refrigerator and decrease when samples were subjected to higher temperatures. 
These results are similar in trend to those obtained in the earlier chapters. A 
study of the DO content of the base vehicle, 0.9% sodium chloride, in the 
Freeflex® minibags and in 100 ml glass bottles, having the same experimental 
design as in this chapter has also been conducted (see 3.2.1.2). These results 
serve as baseline information for the DO content present in the minibag.
Upon exposure to the simulation conditions, different stability profiles of the 
vitamins were gathered. Chemical analysis revealed all vitamins examined to 
be stable at 7d25C and 7d40C, provided samples were light-protected. The 
stability of the vitamins at these simulation conditions is summarised in Table 
6.22. A study by Dahl et al (1986) also found the chemical stability of the 
vitamins to be acceptable during the one week storage and administration at 
ambient temperature.
For the 30d25C and 30d40C simulation studies, the stability of the vitamins 
examined is summarised in Table 6.23. The long stability of Vitamin A at 4°C 
was comparable to the study by Allwood and Plane (1984) who found no 
degradation of Vitamin A when stored for 28 days in the refrigerator.
Upon exposure to the simulation temperatures after 30 days storage, all 
vitamins analysed, with the exception of Vitamin E, were stable, provided that 
they were light protected. As for Vitamin E, at 30d40C study in VL with light 
protection, the content left was about 84%, so even though Vitamin E is 
regarded as unstable based upon the 30 days simulation study, there was still a
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considerable amount of the vitamin available. It may be suggested that the 
content of vitamin E be increased to accommodate for this loss, but the stability 
at a higher concentration would require further investigation.
These experiments also highlighted the effects of the vitamins to different light 
exposures. From Table 6.22 (7d25C), it can be seen that while thiamine, folic 
acid and riboflavin sodium phosphate in SV solutions were stable under 
fluorescent white light, they became unstable when exposed to UVA light. 
Similarly with Vitamin E in VL emulsion, whilst stable under fluorescent light, 
it was unstable under UVA light.
It can be seen too that the vitamins are somewhat affected by UVA to varying 
degree compared to artificial fluorescent light, as shown from the reduced 
concentrations of the vitamins when exposed to UVA. The reduction of the 
contents of the vitamins varies from slight to high. For 7d25C study, while 
nicotinamide is not affected by UVA (see Table 6.9), thiamine is slightly 
affected to 8 8 % (see Table 6.10) and Vitamin A is greatly affected to the extent 
that it was not detected after exposure to UVA (see Table 6.13).
Comparison between the 7 days and 30 days simulation studies revealed that 
some vitamins may degrade even more after prolonged storage and subjecting 
to the same extreme exposure conditions. For example, with folic acid, the 
experiment at 7d40C exposed to UVA (see Table 6.11) resulted in a percentage 
content of 8 8 %, but at 30d40C exposed to UVA, its percentage content was 
reduced to 41%. Another example is the riboflavin sodium phosphate where 
the content was 20% when UVA exposed at 7d40C but was reduced to 9% 
when UVA exposed at 30d40C.
From the results, it is interesting to find that the combined CB admixture gives 
some protection from light to some vitamins. In the combined CB admixture, 
although riboflavin sodium phosphate was degraded when the admixture was 
irradiated by UVA, it was found that the degradation was less as compared to
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SV solution. For 7d25C simulation study, the content of riboflavin sodium 
phosphate in clear Freeflex® bag in CB emulsion was 63% while its content in 
SV solution was 48% (refer Table 6.12 and Table 6.19). This was suggested by 
Smith et al (1988) to be due to the fact that riboflavin was protected by 
emulsification whereby the opacity of the emulsion will reduce to some extent 
the light transmission.
Some protection from light was conferred to Vitamin A, Vitamin E and folic 
acid in the CB admixture too. As an example, for Vitamin A in VL and 
exposed to UVA irradiation, Vitamin A could not be detected (Table 6.13), 
however in CB, slight concentrations of between 8 % - 15 % could still be 
detected (Table 6.20). When vitamin A in CB sample is protected from light, it 
was stable throughout the 30 days simulation conditions.
6.5. Conclusions
All vitamins analysed were stable when stored refrigerated for up to 30 days. 
When subjected to administration temperatures of 25°C following the next 24 
hours, the vitamins remained stable provided they were protected from light.
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CHAPTER SEVEN
PHOTOSTABILITY OF VITAMINS - EFFECTS OF 
ULTRAVIOLET LIGHT UPON DIFFERENT DELIVERY
CONDITIONS
7.1. Introduction
Photostability testing in recent years has gained much attention partly due to 
the introduction of the ICH Guideline Q1B, to regulate the registration of 
pharmaceutical products (ICH Steering Committee 1996; Tonnesen 1996). 
Artificial light sources have negligible UV irradiation and only sunlight causes 
photodegradation by absorption of UV light (Allwood 2000). For sunlight, 
influencing factors include the time of day, the weather condition, and the 
season (Allwood 1982; Allwood 2000). The photodegradation of a light 
sensitive product may vary too, depending on a number of factors, such as the 
packaging material, the light source, the intensity of the light, the proximity of 
the infusion to the light source, the infusion time and infusion rate (Allwood 
and Martin 2000).
UV radiation can be divided into three bands, UVC, UVB and UVA. UVC is 
shortwave radiation with wavelengths of between 200 nm -  290 nm. It is also 
called far UV and is absent at the earth surface because of absorption by ozone 
in the upper atmosphere. UVB has wavelengths between 280 nm -  320 nm, 
and is the UV band which causes sunburn and skin cancer. UVA has long 
wavelengths of between 320 nm — 400 nm, is also called near UV, because of 
its close proximity to the visible spectrum. Sunlight also emits radiation in the 
visible region (400 -  800 nm) and infrared region (800 -  3200 nm) (Tonnesen 
2004).
A commercially prepared PN formulation is packaged with a sheet of plastic 
overwrap for protection. This package overwrap is removed so that the PN
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components can be mixed and the addition of the vitamins, trace elements and 
other additives can be made. The degree of photodegradation is difficult to 
predict, therefore during storage and administration of the infusion, photolabile 
products such as the PN formulations, are recommended to be protected from 
light (Allwood 2000). It has also been shown in the earlier chapters that some 
vitamins are degraded by light. For home patients, PN is administered on a 
cyclical basis during the night, however, if infused during the day, it is 
inevitable that some exposure to light occurs, therefore the potential problem of 
photoinstability should be considered (Allwood 1999; Wormleighton and 
Catling 1998).
Penetration of UV radiation depends on the degree of transparency of the 
packaging material, based on their light transmission characteristics. Plastics, 
for example, block UV penetration differently according to their composition 
(Tonnesen 2004). Red plastic bags offer good protection between 190 and 590 
nm (Dahl et al. 1986). Black plastic bags give a good protection against UV 
light (Webber 1979) while aluminium foil is a light-proof material.
Covering the PN formulation totally with aluminium foil has the disadvantage 
of decreasing visibility since it is not possible to check the bag during delivery, 
such as for any sign of precipitates, air inline or creaming. Therefore different 
types of coloured protective covers are used to give some protection from light. 
Red plastic covers are usually supplied by pharmaceutical manufacturers while 
the black plastic cover is usually the improvised cover used in practice by 
nursing staff during PN administration.
In this chapter, the photostability of the vitamin minibag formulations was 
assessed in the presence of different types of protective covers, to examine the 
degree of UVA protection conferred by the covers.
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7.2. Methods
Three different test samples, SV, VL and CB, were evaluated. Test samples SV 
were prepared as in Chapter Four (see 4.2.2), test samples VL were prepared as 
in Chapter Five (see 5.2.1), and test samples CB were prepared as in Chapter 
Six (see 6.2.2).
7.2.1. Experimental Design
The samples were stored at either 25°C or at 40°C in the pharmaceutical
stability chamber for 24 hours. The minibags were, in addition, exposed to
•  •  • 0UVA irradiation of 3.5 W/m intensity, this exposure being equivalent to about
1 0 - 2 0  hours daylight exposure of the samples placed on a sunny window sill 
(Anderson and Byard 2004).
The types of protective covers used for the minibags were as follows:
i) Without any protective covers
ii) With red plastic covers (from Fresenius Kabi)
iii) With black plastic covers (black plastic bin liners)
iv) Wrapped with aluminium foil
Samples wrapped with aluminium foil acted as controls. Another different set 
of samples were prepared and exposed to the same condition for physical 
analysis. The test samples were prepared in triplicate.
7.2.2. Sampling
For physical analysis, samples were taken at 0 hour and at 24 hours after 
exposure in the pharmaceutical stability chamber. For chemical analysis, 
samples were taken at 0 hour, and after 3, 6  and 24 hours of exposure. Peak 
areas of all the 12  samples at 0  hour were averaged and the content analysis 
was regarded as 1 0 0 %.
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The sampling methods and the physical and chemical analyses performed are 
described in Chapter Four for SV and Chapter Five for VL.
The sampling method and the analysis for CB are described in Chapter Six (see 
6.2.3).
7.3. Results
The following abbreviations are used to denote the exposure conditions of the 
minibags:
FF25C /40C 
Red25C /40C 
Black25C/40C 
A125C /40C
Without any protective covers, stored at 25°C or 40°C 
With red FK plastic covers, stored at 25°C or 40°C 
With black plastic covers, stored at 25°C or 40°C 
Wrapped with aluminium foil, stored at 25°C or 40°C
7.3.1. Physical Analysis
7.3.1.1. Water-soluble Vitamin Solutions SV
7.3.1.1.1. Appearance
There was no apparent change in appearance of SV solutions from their initial 
light yellow colour and a light green haze when viewed with the fibreoptic 
light, except those of clear minibags kept at 40°C (FF40C) where the colour 
turned to a dull yellow.
7.3.1.1.2. Turbidity
The results of NTU measurements are tabulated in Table 7.1. All samples 
showed a decrease in NTU units by the end of the study period. The clear 
minibags without any protective cover, kept at 40°C (FF40C) showed the 
highest change in NTU units.
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Table 7.1: NTU measurements of SV solutions with different protective covers
Minibags 0 h (n=12) 24 h
FF25C 4.74 ± 0.07 4.28 ± 0.08
Red25C 4.74 ± 0.07 4.80 ± 0.06
Black25C 4.74 ± 0.07 4.73 ± 0.09
A125C 4.74 ± 0.07 4.74 ±0.21
FF40C 4.75 ±0.13 2.81 ±0.07 *
Red40C 4.75 ±0.13 4.66 ± 0.07
Black40C 4.75 ±0.13 4.65 ± 0.09
A140C 4.75 ±0.13 4.65 ± 0.06
*: values with change in NTU of more than 0.5 units
7.3.1.1.3. Dissolved Oxygen
The results of DO content of SV minibags are tabulated in Table 7.2. Graphical 
illustrations are shown in Figure 7.1 and Figure 7.2. The graphs clearly showed 
that DO content of solutions decreased upon subjection to high temperatures, 
and that the DO content of the clear minibags was lowest.
Table 7.2: DO content in mg/1 of SV minibags with different protective covers
Minibags 0 h (n=12) 24 h
FF25C 4.38 ±0.45 0.87 ± 0.03
Red25C 4.38 ±0.45 1.78 ± 0.17
Black25C 4.38 ± 0.45 2.78 ± 0.40
A125C 4.38 ±0.45 3.41 ±0.09
FF40C 4.54 ±0.38 1.53 ±0.12
Red40C 4.54 ±0.38 2.19 ±0.07
Black40C 4.54 ±0.38 2.17 ±0.26
A140C 4.54 ±0.38 2.26 ± 0.05
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Figure 7.1: DO content of SV minibags with various protective covers at 25°C
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Figure 7.2: DO content of SV minibags with various protective covers at 40°C
7.3.1.1.4. pH
The results of pH measurements o f SV samples are tabulated in Table 7.3. 
Clear samples without any protective covers showed pH changes o f more than 
0.5 units after exposure to UVA. The higher the exposure temperature, the 
greater the pH change.
Table 7.3: pH measurements of SV minibags with different protective covers
Minibags 0 h (n=12) 24 h
FF25C 6.00 ± 0.04 5.31 ±0.06*
Red25C 6.00 ± 0.04 5.59 ±0.06
Black25C 6.00 ± 0.04 5.77 ±0.10
A125C 6.00 ± 0.04 6.00 ±0.04
FF40C 5.95 ± 0.04 4.81 ±0.05 *
Red40C 5.95 ± 0.04 5.34 ±0.02*
Black40C 5.95 ±0.04 5.56 ±0.05
A140C 5.95 ±0.04 5.74 ±0.03
*: change in pH of more than 0.5 units
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7.3.I.2. Fat-soluble vitamins VL
7.3.1.2.1. Appearance
There was no apparent change in appearance of VL emulsions from their initial 
milky white colour.
7.3.1.2.2. Dissolved Oxygen
The results of DO measurement of VL minibags are tabulated in Table 7.4 with 
the graphs shown in Figure 7.3 and Figure 7.4. DO change was not remarkable 
at 25°C as compared to 40°C.
Table 7.4: DO content in mg/1 of VL minibags with different protective covers
Minibags 0 h (n=12) 24 h
FF25C 5.80 ±0.45 4.66 ± 0.09
Red25C 5.80 ±0.45 5.97 ±0 .07
Black25C 5.80 ±0.45 5.98 ±0 .07
A125C 5.80 ±0.45 6.19 ±0 .06
FF40C 6.06 ± 0.26 3.75 ±0.13
Red40C 6.06 ±0.26 4.35 ±0 .17
Black40C 6.06 ± 0.26 4.50 ±0 .04
A140C 6.06 ± 0.26 4.61 ±0 .22
FF25C
Red25C
Black25C
AI25C
0 6 12 18 24
Tim e (h)
Figure 7.3: DO content of VL minibags with various protective covers at 25°C
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Figure 7.4: DO content of VL minibags with various protective covers at 40°C
7.3.1.2.3. pH
The results of pH of VL minibags are shown in Table 7.5. From the table, only 
VL minibags without any protective covers exposed to UVA at 40°C during 
administration produced pH changes o f more than 0.5 units.
Table 7.5: pH measurements of VL minibags with different protective covers
Minibags 0 h (n=12) 24 h ApH
FF25C 6.90 ± 0.20 6.74 ± 0.02 0.16
Red25C 6.90 ± 0.20 6.99 ± 0.02 0.09
Black25C 6.90 ± 0.20 7.05 ± 0.08 0.15
A125C 6.90 ± 0.20 6.99 ± 0.02 0.08
FF40C 7.20 ± 0.04 6.64 ± 0.06 0.56*
Red40C 7.20 ± 0.04 6.93 ± 0.03 0.27
Black40C 7.20 ± 0.04 6.93 ± 0.08 0.27
A140C 7.20 ± 0.04 6.98 ± 0.02 0.21
*: values with change in pH o f more than 0.5 units
7.3.1.2.4. Laser Diffraction
The maximum diameter for all samples was less than 4.3 pm with D[4,3] of 
between 0.33 to 0.36 pm throughout the study durations.
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7.3.1.2.5. Light Microscopy
All samples had lipid globules sizes of less than 5 pm before and after 
exposure to UVA.
7.3.I.3. Combined Fat-soluble and Water-soluble Vitamins (CB)
7.3.1.3.1. Appearance
The CB emulsions were homogenous milky yellow with a milky white 
meniscus. There was no change in appearance upon subjecting the samples to 
the treatment conditions.
7.3.1.3.2. Dissolved Oxygen
The results of DO measurement for CB minibags are tabulated in Table 7.6. 
DO content decreased when minibags were subjected to the treatment 
conditions.
Table 7.6: DO content in mg/1 of CB minibags with different protective covers
Minibags 0 h (n=12) 24 h
FF25C 4.27 ± 0.47 0.61 ±0.05
Red25C 4.27 ± 0.47 2.32 ±0.21
Black25C 4.27 ± 0.47 2.75 ±0.13
A125C 4.27 ± 0.47 2.69 ± 0.24
FF40C 4.30 ±0.38 1.14 ± 0.15
Red40C 4.30 ±0.38 1.84 ±0.38
Black40C 4.30 ±0.38 1.90 ±0.35
A140C 4.30 ±0.38 2.18 ±0.29
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Figure 7.5: DO content of CB minibags with various protective covers at 25°C
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Figure 7.6: DO content of CB minibags with various protective covers at 40°C
73.1.3.3. pH
The results of pH for CB minibags are shown in Table 7.7.
Table 7.7: pH measurements of CB minibags with different overwraps
Minibags 0 h (n=12) 24 h
FF25C 6.31 ± 0 .06 5.37 ± 0 .22  *
Red25C 6.31 ± 0 .06 5.86 ±0.01
Black25C 6.31 ± 0 .06 6.02 ± 0.03
A125C 6.31 ± 0 .06 6.20 ± 0.03
FF40C 6.21 ± 0 .04 4.90 ± 0.01 *
Red40C 6.21 ± 0 .04 5.56 ±0.01 *
Black40C 6.21 ± 0.04 5.63 ± 0.03 *
A140C 6.21 ± 0 .04 5.72 ±0.02
*: change in pH of more than 0.5 units
From the table, CB minibags without any protective covers exposed to UVA at 
25°C and 40°C produced pH changes of more than 0.5 units, the change in pH
165
was greater for the FF40C minibag. Even minibags with red and black plastic 
wraps exposed to UVA at 40°C had pH changes of more than 0.5 units.
7.3.1.3.4. Laser Diffraction
The lipid globule size for all samples was less than 4.30 pm with a value of 
D[4,3] of between 0.32 to 0.36 pm throughout the study durations tested.
7.3.1.3.5. Light Microscopy
The samples had lipid globule sizes of less than 5 pm diameter with an 
occasional one or two 5 pm lipid globule observed.
7.3.2. Chemical Analysis
7.3.2.1. Water-soluble Vitamins SV
The results of pyridoxine, nicotinamide, thiamine, folic acid, and riboflavin 
sodium phosphate in SV solutions are tabulated from Table 7.8 to Table 7.14, 
while the graphs are displayed from Figure 7.7 to Figure 7.14.
7.3.2.1.1. Pyridoxine
Table 7.8: Percentage content of Pyridoxine in SV minibags with different 
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100 ± 0 84.33 ± 0.23 74.54 ± 1.66 56.95 ± 1.00
Red25C 100 ± 0 96.45 ± 1.88 97.88 ± 1.72 94.48 ± 0.66
Black25C 100 ± 0 95.69 ± 0.65 96.93 ± 1.01 95.11 ± 1.23
A125C 100 ± 0 97.25 ± 2.99 97.98 ± 2.12 97.81 ± 2.01
FF40C 100 ± 0 84.90 ± 1.99 76.78 ± 1.07 46.40 ± 3.55
Red40C 100 ± 0 98.18 ± 2.60 95.28 ± 1.26 93.82 ± 1.13
Black40C 100 ± 0 95.82 ± 4.11 95.26 ± 3.98 96.68 ± 0.08
A140C 100 ± 0 97.93 ± 1.84 99.39 ± 0.40 92.67 ± 0.04
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Figure 7.7: Pyridoxine content in SV minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.8: Pyridoxine content in SV minibags with different protective covers, 
exposed to UVA at 40°C
There was significant difference (p<0.001) between clear minibags and all the 
protective covers at both temperatures. There was no significant difference 
between red, black or aluminium foil covers at either temperature.
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7.3.2.1.2. Nicotinamide
Table 7.9: Percentage content of nicotinamide in SV minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 1 0 0 ± 0 100.04 ± 1.58 96.30 ±3.46 98.59 ± 1.54
Red25C 100  ± 0 99.17 ±0.35 99.29 ± 0.65 99.07 ± 0.04
Black25C 100  ± 0 99.35 ± 0.94 99.52 ±0.15 99.23 ± 0.40
A125C 100  ± 0 101.20 ± 2.50 100.01 ± 1.19 99.75 ± 1.35
FF40C 100  ± 0 100.33 ±0 .94 101.06 ± 1.33 9 4 . 4 4  ± 4 .3 5
Red40C 100  ± 0 99.10 ± 1.68 99.75 ± 0.36 99.34 ± 1.61
Black40C 100  ± 0 97.51 ±3.63 99.24 ± 2.80 1 01 .1 2  ± 0 .8 8
A140C 100  ± 0 99.78 ±2.41 100.51 ±0.23 99.68 ± 1.93
—•— FF25C 
-m —  Red25C 
Black25C 
AI25C
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Time (h)
Figure 7.9: Nicotinamide content in SV minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.10: Nicotinamide content in SV minibags with different overwraps, 
exposed to UVA and 40°C
There was no significant difference between the groups tested at either 
temperature.
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7.3.2.1.3. Thiamine
Table 7.10: Percentage content of thiam ine in SV minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 103.74 ± 2 .20 97.61 ±2.56 97.09 ± 1.44
Red25C 100  ± 0 103.67 ± 0 .60 104.19 ± 1.02 105.41 ±2.10
Black25C 100  ± 0 102.10 ± 3.63 105.53 ±0.40 106.95 ± 1.35
A125C 100  ± 0 103.89 ±4.35 107.08 ±2.54 101.15 ± 6.52
FF40C 100  ± 0 97.26 ±2.05 97.75 ± 1.47 86.05 ±4.19
Red40C 100  ± 0 96.35 ± 5 .59 95.30 ±3.29 91.65 ±2.26
Black40C 100  ± 0 96.96 ± 3 .46 97.72 ±2.96 98.67 ±0.15
A140C 100  ± 0 99.47 ± 1.69 100.67 ± 1.65 94.78 ±3.23
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Figure 7.11: Thiamine content in SV minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.12: Thiamine content in SV minibags with different protective covers, 
exposed to UVA at 40°C
There was no significant difference betw een the groups tested at either
tem perature.
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7.3.2.1.4. Folic acid
Table 7.11: Percentage content of folic acid in SV minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100 ± 0 104.37 ± 1.03 99.95 ± 3.43 101.83 ± 1.31
Red25C 100  ± 0 103.22 ±0.85 103.78 ±0.89 103.17 ± 0.39
Black25C 100  ± 0 102.94 ± 1.27 104.01 ±0.62 103.59 ±0.81
A125C 100  ± 0 105.28 ± 2 .84 104.75 ± 1.84 104.17 ± 1.63
FF40C 100  ± 0 101.08 ± 1.66 100.87 ±2.14 90.25 ± 4.07
Red40C 100  ± 0 98.59 ± 1.70 97.77 ±0.66 97.34 ± 1.41
Black40C 100  ± 0 97.52 ± 4 .08 97.64 ±3.37 99.67 ±0.50
A140C 100 ± 0 98.59 ± 2 .02 100.17 ±0.39 96.95 ± 1.17
*  — FF25C
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Figure 7.13: Folic acid content in SV minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.14: Folic acid content in SV minibags with different protective covers, 
exposed to UVA at 40°C
There was no significant d ifference betw een the groups tested at either
tem perature.
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73.2.1.5. Riboflavin Sodium Phosphate
Table 7.12: Percentage content of riboflavin sodium phosphate in SV minibags 
with different protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 84.58 ±0 .92 74.29 ±2.14 54.01 ±0.48
Red25C 100  ± 0 95.93 ± 1.84 97.47 ± 1.30 94.18 ±0.72
Black25C 100  ± 0 95.52 ± 1.32 96.45 ± 1.60 95.10 ± 1.32
A125C 100  ± 0 97.82 ±2.83 98.14 ±2.02 97.71 ±2.11
FF40C 100  ± 0 82.65 ±2.26 71.09 ± 2.28 29.45 ±5.56
Red40C 100  ± 0 98.43 ± 2.29 97.86 ±4.18 92.51 ± 1.20
Black40C 100  ± 0 96.18 ±3 .96 96.05 ±3.94 96.31 ±0.80
A140C 100  ± 0 97.86 ± 1.56 100.05 ±0.66 92.05 ± 1.55
Time (h)
■FF25C 
Red25C 
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Figure 7.15: Riboflavin sodium phosphate content in SV minibags with different 
protective covers, exposed to UVA at 25°C
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Figure 7.16: Riboflavin sodium phosphate content in SV minibags with different 
protective covers, exposed to UVA at 40°C
The mean difference was significant at p<0.001 between the clear minibags 
and all the protective covers at both temperatures. There was no significant 
difference between red, black or aluminium foil covers at either temperature.
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13.2.2. Fat-soluble Vitamins VL
The results of Vitamin A and Vitamin E in VL minibags are tabulated in Table 
7.13 and 7.14 with their corresponding graphs depicted in Figures 7.17 to 7.20.
7.3.2.2.I. Vitamin A
Table 7.13: Percentage content of Vitamin A in VL minibags with different 
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 24.24 ±3.44 4.87 ± 1.20 nd
Red25C 100  ± 0 94.67 ± 1.60 90.50 ±2.07 72.51 ±0.44
Black25C 100  ± 0 98.86 ± 1.87 96.93 ± 2.93 92.08 ± 0.47
A125C 100  ± 0 96.26 ± 4 .27 95.94 ±3.57 91.71 ±2.91
FF40C 100  ± 0 11.97 ±2.75 1.48 ±0.13 nd
Red40C 100  ± 0 97.73 ± 1.46 91.14 ± 1.46 65.83 ± 1.25
Black40C 100  ± 0 97.00 ± 3 .50 91.03 ±2.20 71.06 ± 9.17
A140C 100  ± 0 100.64 ± 2 .14 96.75 ± 1.97 95.14 ± 3.98
nd: not detected
120 
100 
80 
55 60
40 
20 
0
0 6 12 18 24
Time (h)
Figure 7.17: Vitamin A content in VL minibags with different protective covers, 
exposed to UVA at 25C
There was significant difference at p<0.001 between the clear FF25C and the 
red, black or aluminium foil covers, and at p<0.05 between the red and the 
black or aluminium foil covers. There was no significant difference in the 
means between the aluminium foil covers and the black plastic covers.
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Figure 7.18: Vitamin A content in VL minibags with different protective covers, 
exposed to UVA at 40C
The difference between group means was significant at p<0.001 between the 
clear FF40C minibags and the red, black or aluminium foil covers. The 
aluminium foil cover was significantly different from the red and black covers 
at p<0.05. There was no group difference between the black and red protective 
covers.
73.2.2.2. Vitamin E
Table 7.14: Percentage content of Vitamin E in VL minibags with different 
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 89.55 ± 1.74 83.40 ±2.97 68.35 ±0.91
Red25C 100  ± 0 100.36 ± 1.99 99.24 ± 2.23 97.22 ± 1.34
Black25C 100  ± 0 101.76 ± 3.59 101.94 ±2.06 100.79 ± 2 .26
A125C 100  ± 0 98.82 ±3 .10 99.62 ± 4.40 97.95 ±3.64
FF40C 100  ± 0 90.35 ± 1.30 78.24 ± 7.65 51.69 ± 1.10
Red40C 100  ± 0 104.56 ± 1.47 93.01 ± 12.55 95.24 ±4.83
Black40C 100  ± 0 100.48 ± 4 .74 96.02 ± 1.23 90.53 ± 8.47
A140C 100  ± 0 100.22 ±4 .50 91.83 ±4.44 86.77 ±8.26
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Figure 7.19: Vitamin E content in VL minibags with different protective covers, 
exposed to UVA at 25C
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Figure 7.20: Vitamin E content in VL minibags with different protective covers, 
exposed to UVA at 40C
There was significant difference at p<0.001 between the clear minibags and all 
the protective covers. There was no significant difference between red, black or 
aluminium foil covers at either temperature.
1.3.23. Fat-soluble and Water-soluble Vitamin Admixtures CB
The results of pyridoxine, nicotinamide, thiamine, folic acid, and riboflavin 
sodium phosphate, Vitamin A and Vitamin E in CB emulsions are tabulated 
from Table 7.15 to Table 7.21, while the graphs are displayed from Figure 7.21 
to Figure 7.34.
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7.3.2.3.L Pyridoxine
Table 7.15: Percentage content of pyridoxine in CB minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 96.13 ± 3 .52 89.17 ± 1.27 70.25 ±3.78
Red25C 100  ± 0 101.87 ± 0.86 100.39 ± 1.24 98.14 ±0.41
Black25C 100  ± 0 99.62 ±3.95 99.18 ± 1.73 96.00 ± 4.44
A125C 100  ± 0 101.98 ± 0 .59 100.21 ±0.84 98.88 ±2.33
FF40C 100  ± 0 87.19 ±0.46 79.86 ±0.53 57.64 ±2.78
Red40C 100  ± 0 97.51 ±2.01 93.02 ±0.31 91.81 ± 1.92
Black40C 100  ± 0 93.87 ±2.01 93.43 ±0.62 89.88 ±0.74
A140C 100  ± 0 92.94 ± 1.95 91.7 ±  1.76 91.60 ±0.28
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Figure 7.21: Pyridoxine content in CB minibags with different protective covers, 
exposed to UVA at 25C
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Figure 7.22: Pyridoxine content in CB minibags with different overwraps, 
exposed to UVA at 40C
In Figure 7.21 and Figure 7.22, there was significant difference at p<0.001 
between the clear minibags and all the protective covers at both temperatures. 
The group means between red, black and aluminium covers were not 
significantly different.
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7.3.2.3.2. Nicotinamide
Table 7.16: Percentage content of nicotinamide in CB minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 99.92 ± 3 .70 100.87 ± 1.03 99.55 ±3.68
Red25C 100  ± 0 102.15 ±0 .40 100.80 ± 1.26 100.40 ±0.18
Black25C 100  ± 0 99.61 ±3 .88 99.17 ± 1.79 99.65 ± 5.95
A125C 100  ± 0 101.56 ± 1.11 100.79 ±0.72 99.41 ± 1.64
FF40C 100  ± 0 97.54 ± 0 .59 94.52 ± 0.42 93.37 ± 1.49
Red40C 100  ± 0 98.87 ± 1.78 95.00 ±0.18 94.54 ± 1.84
Black40C 100  ± 0 94.84 ± 1.98 94.70 ± 0.23 92.75 ± 0.86
A140C 100  ± 0 94.38 ±2.05 93.37 ± 1.84 94.00 ± 0.23
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Figure 7.23: Nicotinamide content in CB minibags with different overwraps, 
exposed to UVA at 25C
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Figure 7.24: Nicotinamide content in CB minibags with different overwraps, 
exposed to UVA at 40C
There was no significant difference between the protective covers at 25°C and 
40°C for nicotinamide.
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7.3.2.33. Thiamine
Table 7.17: Percentage content of thiamine in CB minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 99.51 ±4.07 103.92 ±2.12 99.61 ±4.40
Red25C 100  ± 0 104.77 ±2.50 106.16 ± 0.81 100.09 ±5.32
Black25C 100 ± 0 101.70 ± 4.27 105.49 ± 1.95 102.04 ±4.69
A125C 100  ± 0 105.26 ±0.60 106.49 ±0.81 104.59 ±4.41
FF40C 100  ± 0 93.64 ±0.28 91.57 ±2.24 86.73 ± 2.26
Red40C 100  ± 0 95.83 ± 1.58 92.91 ±0.67 95.19 ± 1.83
Black40C 100  ± 0 92.70 ±2.39 95.27 ±0.43 92.76 ± 0.95
A140C 100 ± 0 92.40 ± 1.04 94.17 ± 1.84 95.55 ±0.02
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Figure 7.25: Thiamine content in CB minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.26: Thiamine content in CB minibags with different protective covers, 
exposed to UVA at 40°C
There was no significant difference betw een the groups tested at either
tem perature for thiamine.
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7.3.2.3.4. Folic acid
Table 7.18: Percentage content of folic acid in CB minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 98.52 ± 3 .37 99.65 ± 1.13 96.74 ±4.19
Red25C 100  ± 0 103.92 ±0.54 99.02 ± 1.06 98.41 ±0.05
Black25C 100  ± 0 98.04 ±3.63 97.58 ± 1.76 94.28 ±3.33
A125C 100  ± 0 97.08 ±5.84 95.01 ±7.29 97.92 ± 2.23
FF40C 100  ± 0 96.04 ± 0.46 92.59 ± 1.22 86.41 ±3.45
Red40C 100  ± 0 96.07 ± 2.24 92.22 ± 0.43 91.52 ± 3.35
Black40C 100  ± 0 92.61 ±2.19 93.23 ±0.23 89.69 ±0.88
A140C 100  ± 0 92.07 ±2.20 91.52 ± 1.30 91.78 ± 0.31
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Figure 7.27: Folic acid content in CB minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.28: Folic acid content in CB minibags with different protective covers, 
exposed to UVA at 40°C
There was no significant difference between the protective covers at either 
25°C and 40°C for folic acid.
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7.3.2.3.5. Riboflavin Sodium Phosphate
Table 7.19: Percentage content of riboflavin sodium phosphate in CB minibags 
with different protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100  ± 0 90.59 ±3.37 85.15 ± 1.48 57.41 ±2.90
Red25C 100  ± 0 99.71 ±0.83 97.37 ±0.90 97.25 ± 1.69
Black25C 100  ± 0 97.35 ±3.65 96.45 ± 1.75 94.29 ± 4.26
A125C 100  ± 0 99.26 ±0 .66 97.61 ±0.56 96.22 ± 1.61
FF40C 100  ± 0 85.75 ±0.42 74.95 ± 0.94 35.00 ±2.92
Red40C 100  ± 0 96.32 ± 1.50 93.61 ±0.49 91.28 ± 2.11
Black40C 100  ± 0 92.80 ±2.12 93.86 ±0.73 89.88 ± 1.11
A140C 100  ± 0 92.31 ± 1.77 93.19 ± 1.82 91.78 ±0.27
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Figure 7.29: Riboflavin sodium phosphate content in CB minibags with different 
protective covers, exposed to UVA at 25°C
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Figure 7.30: Riboflavin sodium phosphate content in CB minibags with different 
protective covers, exposed to UVA at 40°C
There was significant different at pO.OOl between the clear minibags and all 
the protective covers at both temperatures. There was no significant difference 
between the red, black and aluminium foil covers at either temperature.
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7.3.23.6. Vitamin A
Table 7.20: Percentage content of Vitamin A in CB minibags with different
protective covers
Samples Oh 3 h 6 h 24 h
FF25C 100  ± 0 62.31 ± 1.36 42.30 ±2.05 8.53 ±0.84
Red25C 100  ± 0 95.52 ±4.01 102.90 ±2.90 83.04 ± 1.84
Black25C 100  ± 0 98.00 ± 2 .70 102.90 ± 1.34 91.45 ±3.96
A125C 100  ± 0 100.28 ±7.98 101.76 ± 2.10 99.19 ± 1.88
FF40C 100  ± 0 45.68 ±3.48 21.93 ±2.36 2.62 ± 0 .10
Red40C 100  ± 0 101.84 ± 2 .09 91.71 ±8.72 79.93 ± 5.02
Black40C 100  ± 0 102.35 ± 5 .70 94.59 ±3.68 85.81 ±6.58
A140C 100  ± 0 100.40 ±6.73 102.08 ±4.41 93.53 ± 12.25
Time (h)
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■Red25C 
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Figure 7.31: Vitamin A content in CB minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.32: Vitamin A content in CB minibags with different protective covers, 
exposed to UVA at 40°C
The group mean difference was significant at pO.OOl between the clear 
minibags and all the protective covers at both temperatures. The group means 
between red, black and aluminium covers were not significantly different.
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7.3.2,3.7. Vitamin E
Table 7.21: Percentage content of Vitamin E in CB minibags with different
protective covers
Minibags Oh 3 h 6 h 24 h
FF25C 100 ± 0 94.37 ±0.61 92.48 ±2.16 88.19 ±2.23
Red25C 100 ± 0 97.67 ±4.17 108.18 ±2.40 95.18 ± 1.89
Black25C 100 ± 0 99.15 ±2.78 104.54 ± 1.94 98.04 ±2.14
A125C 100 ± 0 101.51 ±7.78 103.58 ±2.60 103.14 ± 1.52
FF40C 100 ± 0 90.35 ±5.74 82.51 ±7.31 95.17 ±4.05
Red40C 100 ± 0 103.95 ±2.15 97.83 ± 8.96 96.33 ± 5.24
Black40C 100 ± 0 104.92 ±6.05 106.12 ±3.31 100.93 ±4.82
A140C 100 ± 0 100.68 ±0 .06 104.71 ±3.96 97.31 ± 11.30
—♦— FF25C 
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Figure 7.33: Vitamin E content in CB minibags with different protective covers, 
exposed to UVA at 25°C
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Figure 7.34: Vitamin E content in CB minibags with different overwraps, 
exposed to UVA at 40°C
There was significant difference at 25°C (p<0.05) and at 40°C (pO.OOl) 
between the clear minibags and the protective covers. The results between red, 
black and aluminium foil covers were not significantly different at either 
temperature.
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7.3.3. Results Summary
The results of this study is summarised in Table 7.22.
Table 7.22: Summary of the stability duration of vitamin minibags with different 
protective covers exposed to UVA at 25°C and 40°C
Tempera­ Vitamin Minibag Protective covers
ture None Red Black Alfoil
25°C p SV < 3 h 24 h 24 h 24 hr
CB 3 h 24 h 24 h 24 h
N SV 24 h 24 h 24 h 24 hCB 24 h 24 h 24 h 24 h
T SV 24 h 24 h 24 h 24 hCB 24 h 24 h 24 h 24 h
FA SV 24 h 24 h 24 h 24 hCB 24 h 24 h 24 h 24 h
RSP SV < 3 h 24 h 24 h 24 hCB 3 h 24 h 24 h 24 h
Vitamin VL < 3 h 6 h 24 h 24 h
A CB < 3 h 6 h 24 h 24 h
Vitamin VL 3 h 24 h 24 h 24 h
E CB 6 h 24 h 24 h 24 h
40°C P SV < 3 h 24 h 24 h 24 hCB < 3 h 24 h 24 h 24 h
N SV 24 h 24 h 24 h 24 hCB 24 h 24 h 24 h 24 h
T SV 6 h 24 h 24 h 24 hCB 6 h 24 h 24 h 24 h
FA SV
24 h 
(90%) 24 h 24 h 24 h
CB 6 h 24 h 24 h 24 h
RSP SV < 3 h 24 h 24 h 24 hCB < 3 h 24 h 24 h 24 h
Vitamin VL < 3 h 6 h 6 h 24 h
A CB < 3 h 6 h 6 h 24 h
Vitamin VL 3 h 24 h 24 h 24 h
E CB 3 h 24 h 24 h 24 h
S: Stable; U: Unstable
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7.4. Discussion
Visual examination of the samples showed that all samples remained clear for 
SV and homogenous for VL and CB, with lipid globules sizes of less than 5 
pm. NTU measurements of SV solutions showed a decrease in NTU units. As 
for pH, the minibags without the protective covers had pH change of more than 
0.5 units, while the dissolved oxygen contents decreased upon subject to higher 
temperatures. These physical assessments have been discussed in the earlier 
chapters and will not be reiterated in this chapter.
As can be seen from the summary in Table 7.22, at 25°C and 40°C with the 
plastic or aluminium covers, all the water-soluble vitamins examined, and the 
fat-soluble Vitamin E were stable for at least 24 hours in the SV or VL, and the 
CB minibags. When exposed without any protective covers, the stability of 
pyridoxine, riboflavin sodium phosphate, Vitamin A and Vitamin E were 
reduced to 6  hours or less at 25°C, while at 40°C, the stability of thiamine was 
also reduced to 6  hours in SV, VL or CB minibags. Folic acid stability in clear 
minibags was reduced to 6  hours in CB emulsion at 40°C although its 
percentage content at 24 hours was only slightly reduced to 8 6 %.
Wrapping the vitamin minibags during delivery with red or black plastics, or 
with aluminium foil hence gives some protection of the vitamins from 
degradation by UVA, where significant protection at p<0.001 was conferred by 
the protective covers for pyridoxine and riboflavin sodium phosphate in SV 
and CB minibags, and for Vitamin A and Vitamin E in VL and CB minibags. 
There was some UVA protection by the protective covers for thiamine and 
folic acid although this degree o f protection was not shown to be statistically 
significant from the unprotected minibag.
With Vitamin A, it can be seen that it is greatly affected when exposed to UVA 
with its stability reduced to 6  hours even when wrapped with red plastic cover 
at 25°C, while without any protective cover, the stability was reduced to less 
than 3 hours in both formulations VL and CB. These results again confirm the
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results of Chapter Five that Vitamin A is greatly affected by light, in this case 
by UVA. Greatest protection is obtained when the minibag was wrapped with 
aluminium foil. There was insufficient protection of Vitamin A with the black 
or red plastic bags at 40°C, with the stability reduced to 6 hours.
The result is comparable to the study conducted by Drott et al (1991) where 
they found that the use of red plastic bags was inadequate to preserve the 
Vitamin A in solution but sufficient to protect the Vitamin E. Another study by 
Shenai et al (1981) suggested that the amount of Vitamin A delivered to be 
increased by three to fourfold to compensate for the losses or that Vitamin A to 
be administered by an alternative method such as by intramuscular injection. 
Having said this, if a red plastic protective cover was used, it may be sufficient 
to infuse the vitamin minibag formulation for up to 6 hours since its stability 
duration is within this period of time. Alternatively, the infusion may be started 
during the night when UVA radiation is negligible.
As for the CB admixtures, some protection from light was noted for Vitamin 
A. In VL emulsion with FF25C exposure condition (see Table 7.13), Vitamin 
A content was 24% at 3 hours and could not be detected at 24 hours. However, 
in CB emulsion and with the same exposure condition (see Table 7.20), 
Vitamin A content at 3 hours was 62% and there was still about 8% left at 24 
hours. Slight protection was conferred with riboflavin sodium phosphate in CB 
emulsions too. In SV solution at FF40C (see Table 7.12), the riboflavin sodium 
phosphate content was 29% at 24 hours, while in CB emulsion at FF40C (see 
Table 7.19), the content was 35% at 24 hours. As discussed in Chapter Six, 
these are possibly due to emulsification which reduced the light transmission. 
There was no obvious protective effect for the other vitamins in CB emulsion.
In terms of the degree of UVA protection of the vitamins by different types of 
protective covers, it can be seen that different coloured plastic covers have 
different degree of protection. From this study, the red plastic cover seemed to 
have less UVA protective effect when compared to the black plastic cover, as
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shown by the reduced stability of Vitamin A at 25°C. This may be due to the 
limited wavelength range of UV protection provided by the red plastic bag of 
between 190 and 590 nm as compared to black plastic bag which generally 
gives good protection against UV light over a much wider wavelength range. 
The protective effects also depend on the type of dyes used (Weber 1979) and 
the thickness of the plastic bags. Having said this, Vitamin A was also affected 
when covered with the black plastic bag at 40°C, with its stability reduced to 6 
hours too. In determining the choice of protective covers in clinical practice, 
other factors such as the cost, availability, and ease of use by nursing staff, like 
when carrying out visual checks on the minibags during infusion to patients, 
will all ultimately have to be considered.
7.5. Conclusions
All the vitamins analysed were stable for 24 hours, provided they were light 
protected. Aluminium foil provided the best protection from UVA for all the 
vitamins, while the red and black plastic bags provided partial protection of 
Vitamin A from UVA.
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CHAPTER EIGHT
CONCLUSIONS
8.1. Conclusions
Long shelf life macronutrient PN bags are available commercially as triple 
chamber bags in which the seals of the amino acids, glucose and lipid 
components can be opened and the components mixed as an all-in-one 
admixture. For complete nutrition support of parenterally fed patients however, 
these still require the addition of micronutrients into the final bag just before 
administration because o f stability issues with the vitamins and incompatibility 
and precipitation issues with the trace elements.
The problems associated with the provision of micronutrients to PN patients in 
regards to stability issues and differing stability data have been outlined in 
Chapter One. The recent NICE guidelines (NICE 2006a) recommended that 
micronutrients should be added to PN just before administration. For a ward 
based inpatient requiring PN in the hospital, the micronutrient additions are 
carried out by the pharmacy aseptic compounding unit, although these 
additions are possibly omitted for the weekend supply as any additions are only 
made aseptically by the pharmacy. For home PN patients, either the patient or 
their care provider is taught to do these micronutrient additions. There is a 
possibility that the micronutrients are inadvertently omitted due to additional 
task involved. In a national audit carried out by the British Pharmaceutical 
Nutrition Group in 2003, the audit revealed that for hospitals with a PN 
service, 33% of the patients did not receive vitamins or trace elements in 
accordance with recommendations (Sizer 2004). Problems of personnel 
handling of sterile preparations arise here too as in relation to the Audit 
Commission’s ‘A Spoonful of Sugar’ report (Audit Commission 2001), which 
recommends that aseptic manipulations should be carried out by the pharmacy
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as part of improvement in the quality of care. This is also in line with the NICE 
guidelines that the micronutrients additions into PN bag be made under a 
pharmaceutically controlled environmental condition (NICE 2006a). Therefore 
there was an opportunity to develop a micronutrient formulation with a longer 
shelf life and a stability profile that need not require reconstitution and/or any 
further handling.
In considering the micronutrient formulation, in theory, it would be most 
practical to have a single micronutrient formulation consisting of both the 
vitamins and trace elements. Knowing the fact that both the vitamins and trace 
elements are multi-components by their own category, having a complete 
micronutrient formulation would require an extensive length of study, due to 
many other influencing factors such as interaction problems between the 
vitamins and trace elements (Harraki et al. 1995). Hence it was decided that 
either the vitamins or the trace elements could be investigated at any one time. 
The vitamin formulation was decided upon because the equipment needed to 
investigate its stability, such as the HPLC, was already available in the present 
laboratory and the readily available multivitamin injections on the market such 
as Solivito® N Adult and Vitlipid® N Adult injections would be a good start 
point since end-users would be familiar with their composition and some 
stability data would be available for comparison.
Another point of consideration was that the base vehicle used should be an 
aqueous 0.9% sodium chloride intravenous solution. Presently, no stability 
studies have been carried out with fat-soluble vitamins in aqueous systems or 
combined water-soluble and fat-soluble vitamins in such aqueous admixtures.
The development of validated stability indicating HPLC methods in this thesis 
enables only the investigation of the vitamins that could be determined in a 
single run as described in Chapter Two. Thus, the stability of five water- 
soluble B vitamins, namely, pyridoxine, nicotinamide, thiamine, folic acid and 
riboflavin sodium phosphate contained in Solivito® N Injection, and the fat-
187
soluble vitamins, Vitamin A and Vitamin E, contained in Vitlipid® N Adult 
Injection in 100 ml 0.9% sodium chloride was investigated. A test run in 
glucose 5% intravenous solution was also tested with the same peaks obtained. 
The five water-soluble vitamins were identified by separating Solivito® N 
Adult solution by reversed phase HPLC and gradient run method while the two 
fat-soluble vitamins were identified from an assay method developed by the 
changing of detection wavelength in a single run. Forced degradation of the 
samples showed no interference of the degradation products with the peaks of 
interest and the methods developed were found to be repeatable and stability 
indicating.
Henceforth, their basic stability profile upon different storage conditions at 4, 
25, 30 and 40°C was investigated as described in Chapter Four for the water- 
soluble vitamins and Chapter Five for the fat-soluble vitamins, as well as upon 
subjection to simulation conditions encountered in clinical practice as 
described in Chapter Six. Stability studies assessed included delivery 
conditions with different protective covers at 25°C and 40°C as described in 
Chapter Seven. A preliminary study also investigated the vitamins stability in 
glass containers as background data in the initial phase of the project work and 
as comparison but was phased out in view of the fact that the most used 
packaging nowadays is plastic bags as discussed in Chapter Three.
Initial assessment of the five water-soluble vitamins upon different storage 
conditions showed that the vitamins were stable for 168 hours at 4°C, with 
more than 90% remaining. For solutions stored at 25°C, they remained stable 
for 168 hours if they were light-protected, in this case from artificial 
fluorescent light having an illuminance equivalent to general ward lighting 
condition. Interestingly, for the fat-soluble vitamins examined, they were also 
found to be stable for 168 hours at 4°C and at 25°C, provided the emulsions 
were protected from the artificial light.
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It has been implicated that only the UV light affects the photostability of 
vitamins (Allwood 1982a; Allwood and Kearney 1998; Dahl et al. 1986) and 
not fluorescent light as it emits insignificant UV radiation. However, this study 
has shown that extended exposure to artificial light affects the vitamin stability. 
Therefore, the precautionary measure of light protection for the vitamins is still 
required.
In Chapter Six, when the vitamins were investigated simulating clinical 
conditions, they were found to be stable for up to 30 days storage at 4°C, and 
remained stable when the solutions were then subjected to 25°C for the next 24 
hours, provided they were light-protected. Because it would be most 
convenient to administer the water-soluble and the fat-soluble vitamins 
together at the same time, an assessment of the combined admixture of the 
water-soluble and fat-soluble vitamins simulating clinical conditions were also 
carried out. The results were promising with all vitamins examined remaining 
stable for up to 30 days in the refrigerator, followed by 25°C for the next 24 
hours, provided they were light protected. These stability data could be 
practically useful for pharmacy aseptic compounding unit preparing 
multivitamin infusion for both hospital ward inpatients and home PN patients.
The photostability study during delivery of the vitamin minibags with the 
different protective covers in Chapter Seven showed that different coloured 
plastic protective covers have varying protection against UVA radiation, 
depending among others, on their degree of light penetration and the type of 
coloured dye used (Webber 1979). The study showed that the protective covers 
provide protection from UVA for 24 hours for most of the vitamins 
investigated except for Vitamin A when the stability was reduced to 6 hours 
with the red plastic cover. One way of minimising photodegradation during 
delivery is by infusing the vitamin minibag at night as an alternative time of 
delivery or to infuse the vitamin minibag for up to 6 hours when using a red 
plastic cover which may provide sufficient protection.
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In conclusion, a simple ready-to-use micronutrient minibag formulation 
containing water-soluble and/or fat-soluble vitamins in an aqueous normal 
saline solution was studied for its possible development, with baseline physical 
and chemical data gathered. Extensive data on the vitamins investigated in 
different storage and clinical condition of administration showed promising 
results with the vitamins being stable during its application in simulated 
clinical practice if light protected. This longer shelf life vitamin minibag 
developed would be useful and of benefit when made available in the market, 
for its application to PN patients in the hospital especially for the weekend 
supply and for home PN patients where a ready-to-use vitamin minibag frees 
the patient or their care provider from additional reconstitution and dilution of 
sterile preparations.
8.2. Limitations
There are a number of limitations to this study. Firstly, not all the vitamins in 
the formulation, such as ascorbic acid, Vitamin B12, Vitamin D and Vitamin K 
have been assayed, as in the time available, suitable stability indicating assay 
methods that could be used alongside those developed for the majority of 
vitamins could not be found and validated.
The studies carried out were not controlled for oxygen as these studies 
investigated the real clinical set-up when prepared in the aseptic compounding 
unit. For commercial purposes, the effect of oxygen on the stability of the 
vitamins in the minibags requires further investigation.
When investigating the vitamins’ stability in the minibag, its use in clinical 
practice was simulated from its storage right through to its administration to the 
patient. However, when investigating the protective covers in the delivery 
study in Chapter Seven, it needs to be pointed out that investigation of the 
vitamins stability does not mimic delivery through the infusion tubing set.
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In terms of time and workable scope, because there was only one 
pharmaceutical stability chamber to test for the different temperatures, studies 
were not run concurrently, therefore analyses such as HPLC assays were 
carried out according to temperature settings, thus this prolonged the duration 
of the project study.
8.3. Future Work
Future work would investigate the stability of the other component vitamins in 
this multivitamin infusion minibag which are ascorbic acid, biotin, pantothenic 
acid, Vitamin B 12, Vitamin D and Vitamin K. For the stability study of ascorbic 
acid, the total ascorbic acid concentration which includes dehydroascorbic acid 
would require investigation too as dehydroascorbic acid is also a biologically 
active component of Vitamin C.
Another area would be to investigate the vitamins’ photostability through the 
infusion set during administration to patients. This study would include 
investigation of the protective effects of different coloured tubings during 
infusion.
For commercial production, the stability of these vitamins in multilayered or 
gas impermeable bags, together with the overwraps to exclude the permeation 
of oxygen would possibly need to be carried out. A controlled stability study 
with oxygen degassed from the minibag by using an inert gas such as helium or 
nitrogen could be investigated. The control for this study would also need to be 
light-protected.
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APPENDIX 1
Some known nutritional functions of selenium as selenoproteins (adapted 
from Rayman 2000)
Selenoprotein Function
Glutathione peroxidises Antioxidant enzymes; remove hydrogen peroxide, and 
lipid and phospholipid hydroperoxides (thereby 
maintaining membrane integrity, modulating 
eicosanoid synthesis, modifying inflammation and 
likelihood of ropagation of further oxidative damage to 
biomolecules such as lipids, lipoproteins, and DNA.
(Sperm) mitochondrial 
capsule selenoprotein
Form of glutathione peroxidise (GPx4); shields 
developing sperm cells from oxidative damage and 
later polymerises into structural protein required for 
stability / motility of mature sperm.
Iodothyronine deiodinases Production and regulation of level of active thyroid 
hormone, T3, from thyroxine, T4.
Thioredoxin reductase Reduction of nucleotides in DNA synthesis; 
regeneration of antioxidant systems; maintenance of 
intracellular redox state, critical for cell viability and 
proliferation; regulation of gene expression by redox 
control of binding of transcription factors to DNA.
Selenophosphate
synthetase
Required for synthesis of selenophosphate, the 
precursor of selenocysteine, and therefore for 
selenoprotein synthesis.
Selenoprotein P Found in plasma and associated with endothelial cells. 
Appears to protect endothelial cells against damage 
from peroxynitrite.
Selenoprotein W 
Prostate epithelial 
selenoprotein (15kDa)
Needed for muscle function.
Found in epithelial cels of ventral prostate. Seems to 
have redox function (resembles GPx4), perhaps 
protecting secretory cells against development of 
carcinoma.
DNA bound spermatid 
selenoprotein (34 kDa)
Glutathione peroxidise-like activity. Found in stomach 
and spermatozoa. May protect developing sperm.
18 kDa selenoprotein Important selenoprotein, found in kidney and large 
number of other tissues. Preserved in selenium 
deficiency.
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APPENDIX 2
Stability characteristics o f vitamins (adapted from DeRitter 1982)
Vitamin A Sensitive to atmospheric oxygen (retinol less stable than its 
esters); trace metals catalyse decomposition; inactivated by 
UV light; isomerises at acid pH; stable in alkali; in aqueous 
dispersions palmitate esters more stable to heat than 
retinol<pH 5.5; palmitate most stable ester under moisture 
stress; stabilise by antioxidants and protective coatings.
Cholecalciferol 
(Vitamin D)
Sensitive to atmospheric oxygen; trace metals and carriers 
with acid surface activity catalyse isomerisation or 
decomposiyion; generally more stable than vitamin A; 
stabilised by antioxidants and protective clothings.
Vitamin E Tocopherol sensitive to atmospheric oxygen, especially to 
alkali and sensitive to UV light; esters very stable.
Vitamin K Fairly stable to heat; decomposed to sunlight and alkali.
Ascorbic acid 
(Vitamin C)
Stable when dry; readily oxidised in solution; decomposition 
catalysed by metal ions (copper and iron); greatest instability 
at about pH 4.
Biotin Stable to air and acid and at neutral pH; slightly unstable in 
alkali.
Cyanocobalamin 
(Vitamin B]2)
Decomposed by oxidising and reducing agents; slightly 
unstable in acid and alkaline solution; ascorbic acid and 
thiamine-niacinamide combination accelerate the 
decomposition; sensitive to light in very dilute solutions for 
assay.
Folic acid Unstable <pH 5; decomposed by sunlight and riboflavin; 
decomposed by reducing agents.
Niacin and 
niacinamide
Very stable.
Calcium
pantothenate
Unstable in acid (<pH 5) and alkali; maximum stability at pH 
6-7.
Panthenol More stable than calcium pantothenate at < pH 5.
Pyridoxine 
(Vitamin B6)
Normally very stable; metal ions can catalyse decomposition; 
dilute solutions for assay are very sensitive to light.
Riboflavin 
(Vitamin B2)
Stable in acid solution; unstable in alkaline solution; sensitive 
to light, especially in alkaline solution or in very dilute acid 
solutions for assay; decomposed by reducing agents.
Thiamine 
(Vitamin Bi)
Increasingly unstable in solution as pH rises; decomposed by 
oxidising or reducing agents; cleaved by sulphite veiy rapidly 
at high pH; hydrochloride more hygroscopic than 
mononitrate.
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